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ABSTRACT OF THE DISSERTATION 
 
Mechanisms of Copper-Dependent Notochord Formation in Zebrafish 
 
by 
 
John Michael Gansner 
 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Molecular Cell Biology) 
 
Washington University in St. Louis, 2010 
 
Professor Jonathan D. Gitlin, Chair 
 
 
The interplay of genes and nutrition during early development profoundly impacts fetal 
outcome. Copper is an essential nutrient required for the redox activity of many enzymes, 
and recent work in our laboratory has elucidated the phenotype of copper deficiency in 
zebrafish, which includes a strikingly distorted notochord. The studies described here 
establish the specific genetic etiology of this distortion and reveal a number of gene-gene 
and gene-nutrient interactions critical to notochord morphogenesis. 
 We first demonstrate that the notochord distortion observed in copper-deficient 
zebrafish results from lysyl oxidase cuproenzyme inhibition. Four lysyl oxidase family 
members are expressed throughout the developing zebrafish notochord, including loxl1 
and loxl5b. Morpholino antisense experiments reveal that knockdown of loxl1 results in 
notochord distortion and also demonstrate overlapping roles for loxl1 and loxl5b in 
notochord formation. Furthermore, partial knockdown of either loxl1 or loxl5b sensitizes 
embryos to notochord distortion when combined with reduced copper availability, and 
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any of these treatments alone sensitizes embryos to notochord distortion after partial 
disruption of the gene encoding a lysyl oxidase substrate, col2a1. 
 To elucidate additional gene-nutrient interactions involved in notochord 
formation, we conducted a forward genetic screen for mutants that exhibit increased 
notochord distortion after partial lysyl oxidase inhibition. This screen was facilitated by 
the identification of a novel, highly potent lysyl oxidase inhibitor, 2-mercaptopyridine-N-
oxide, and yielded a mutant with defects in notochord and vascular morphogenesis, puff 
daddy
gw1
. Subsequent work demonstrated that the puff daddy
gw1
 phenotype results from 
loss of zebrafish fibrillin-2. Importantly, the notochords of puff daddy
gw1 
mutants are 
strikingly sensitized to distortion under conditions of suboptimal copper nutrition that do 
not affect wild-type embryos. This sensitization is also observed in a published notochord 
mutant, gulliver
m208
, and we demonstrate that the gulliver
m208
 phenotype arises from a 
missense mutation in the alpha 1 chain of type VIII collagen. 
 
 Taken together, these studies demonstrate essential roles for copper and multiple 
extracellular matrix components in late notochord formation and suggest that nutritional 
status should be interpreted within the polymorphic genetic context of the developing 
embryo. 
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Gene-nutrient interactions in early development 
Adequate nutrition during embryogenesis is critical for preventing adverse developmental 
outcomes, and what is “adequate” is determined partly by genetic context. In the agouti 
mouse strain, dietary supplementation of female mice with vitamin B12 or other methyl-
donors during pregnancy permanently alters gene expression and results in fewer 
offspring with obesity and an abnormal yellow coat color (1). Furthermore, different 
genetic breeds of ewes grazed on the same copper-deficient pasture give birth to 
offspring with strikingly dissimilar incidences of enzootic ataxia, a disease resulting from 
copper deficiency (2). In humans, a role for genetic susceptibility loci in the pathogenesis 
of fetal iodine deficiency disorder – the leading cause of preventable mental retardation 
in newborns – was likewise suggested by observations that not everyone born to an 
iodine-deficient mother is affected (3-5). A few of these genetic susceptibility loci have 
recently been identified (4, 6), and perinatal iodine supplementation should be 
particularly advantageous for mothers with these or other undiscovered genetic risk 
factors for iodine deficiency. Similarly, genetic susceptibility loci may determine the 
need for folate supplementation in the prevention of neural tube defects. Indeed, perinatal 
folate supplementation has been shown epidemiologically to reduce the risk of fetal 
neural tube defects by 50-70% and genetic risk factors have been described (7). 
A great deal of evidence from animal models and epidemiologic studies supports 
the importance of diverse gene-nutrient interactions in determining developmental 
outcome (2, 8, 9). In essence, nutrient deprivation provides a stress that can result in the 
expression of congenital birth defects or other adverse fetal outcomes depending on 
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genetic background. The elucidation of gene-nutrient interactions during development is 
thus of particular relevance, since it can provide insight into the molecular pathways of 
organogenesis and may also allow for targeted therapeutic interventions designed to 
prevent disease.  
Cuproenzymes in development 
Copper is an essential nutrient required by many proteins as a cofactor for catalyzing 
electron transfer reactions (10). Cuproenzymes perform a number of functions critical to 
normal human development (Table 1), and these functions appear to be substantially 
conserved across species (10). Copper deficiency can result from insufficient dietary 
intake or from genetic factors (2). In humans, Menkes disease results from loss of 
function mutations in the intracellular copper transporter ATP7A, which delivers copper 
to the secretory pathway for incorporation into cuproenzymes or export from the cell 
(11). Children with Menkes disease appear normal at birth but soon exhibit many features 
attributable to loss of cuproenzyme activity, including skin hypopigmentation, kinky hair, 
cerebral and cerebellar degenerative symptoms such as hypotonia and seizures, lax skin, 
arterial tortuosity, emphysema, osteoporosis, and bladder diverticuli (11, 12). 
Subcutaneous copper injections fail to clinically reverse disease progression unless a 
small amount of residual ATP7A activity remains (12), as would be expected from a 
defect in copper delivery to the secretory pathway. Death generally occurs by three years 
of age, although survival is better in an allelic form of the disease known as Occipital 
Horn Syndrome where a greater degree of ATP7A activity is present (12, 13). In patients 
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with Occipital Horn Syndrome, scoliosis or kyphosis of the vertebral column are 
common and developmental delay is less profound (10).    
Our laboratory has recently delineated the phenotype of copper deficiency in the 
zebrafish embryo, which can be induced either pharmacologically through incubation in 
copper chelators such as neocuproine or through genetic disruption of atp7a, as in the 
mutant calamity (14). Copper deficiency in zebrafish results in a pleiotropic phenotype 
including loss of melanin pigmentation, midbrain/hindbrain degeneration, and striking 
notochord distortion. The role for copper in notochord formation was previously 
unappreciated, and notochord distortion thus provides a new, highly visible phenotype 
that can be utilized for further study of copper homeostasis during embryonic 
development.  
 
Enzyme Function 
Lysyl oxidase Chemical crosslinking of collagens and elastin 
Tyrosinase Melanin pigment biogenesis 
Ceruloplasmin Ferroxidase 
Peptidylglycine -amidating 
monooxygenase 
Peptide hormone activation 
Cytochrome c oxidase Electron transport and cellular respiration 
Copper-zinc superoxide 
dismutase 
Antioxidant defense 
Sulfhydryl oxidase Chemical cross-linking of keratin 
Table 1. Select human cuproenzymes and functions. 
 
Notochord formation 
The notochord is a midline axial organ that specifies left-right asymmetry and provides 
structural support to the growing embryo. It also plays a critical role in patterning nearby 
ectodermal, mesodermal, and endodermal tissues including the neural tube, somites, 
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pancreas, heart, and dorsal aorta (15, 16). The notochord facilitates locomotion in lower 
chordates and is required for vertebral column formation. Indeed, defects in notochord 
formation have been linked to abnormalities in vertebral bone structure and other 
congenital birth defects in humans (15).  
 The notochord is specified early in embryogenesis and originates from the dorsal 
organizer. Notochord progenitors in this anatomic structure differentiate first into 
chordamesoderm and then into mature notochord. The transition from chordamesoderm 
to mature notochord involves the formation of an extracellular matrix sheath that 
constrains a single row of notochord vacuolar cells as their vacuoles inflate. This 
transition also correlates with the extinction of an embryonic gene program expressed by 
chordamesoderm (16). In zebrafish, a number of mutants with defects in different stages 
of notochord morphogenesis have been described (17-19). Of interest, defects in late 
notochord formation can arise from extracellular matrix abnormalities that impair the 
integrity of the notochord sheath (20). 
Zebrafish as a model for studying gene-nutrient interactions in early development 
Zebrafish provide a useful model for interrogating the relationship between genes and 
nutrition during early development. This vertebrate is genetically tractable and completes 
embryogenesis rapidly ex utero where organogenesis can be directly observed; 
furthermore, nutrient concentrations can be precisely controlled in the zebrafish 
embryonic milieu via pharmacologic manipulation.  
Many phenotypes relevant to human development can be studied in zebrafish, and 
a number of zebrafish mutants identified in forward genetic screens have already 
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increased our understanding of the cell biologic mechanisms underlying human disease 
(21-23). Zebrafish are amenable to chemical mutagenesis, and phenotypic screening of 
mutant carriers can be conducted using haploid offspring, which complete the first few 
days of embryonic development relatively normally despite having half the normal 
complement of chromosomes (24). A major advantage of the haploid method is that F1 
females (derived by fertilizing wild-type clutches with sperm from mutagenized males) 
can be utilized, eliminating the need to generate and maintain large families of F2 fish, 
which requires time and space (24). Once a mutant is identified, polymorphic strains of 
fish and large clutch sizes permit meiotic mapping of the lesion to a limited region of the 
genome for subsequent cloning of the affected gene (25, 26). Morpholino antisense 
oligonucleotides can be used to recapitulate the mutant phenotype in wild-type fish by 
altering splicing or inhibiting translation, resulting in transient knockdown of specific 
gene expression (27). Conversely, microinjection of wild-type mRNA into one-cell 
embryos will usually rescue the mutant phenotype. Importantly, forward genetic screens 
in zebrafish can be carried out in the presence of pharmacologic agents at doses just 
below what is required to elicit a phenotype in wild-type embryos. This permits the 
identification of hypomorphic alleles that might go undetected without pharmacologic 
stress, and focuses the screen on a biologic pathway of interest. When the pharmacologic 
agent alters nutrient metabolism, gene-nutrient interactions can be detected. 
Summary 
At present, zebrafish are the vertebrates most closely related to humans that are amenable 
to the application of powerful genetic techniques and also allow embryogenesis to be 
 7 
observed in real-time. The studies in this thesis describe several gene-gene and gene-
nutrient interactions critical to normal notochord morphogenesis. Chapter 2 demonstrates 
that the notochord distortion observed in copper-deficient zebrafish embryos results from 
inhibition of specific lysyl oxidase cuproenzymes. Chapter 3 describes the identification 
and characterization of 2-mercaptopyridine-N-oxide, a novel, highly potent lysyl oxidase 
inhibitor. Chapter 4 reports the use of this inhibitor in a forward genetic screen for 
mutants that exhibit increased notochord distortion after partial lysyl oxidase inhibition, 
and discusses the characterization of a mutant identified in the screen. Chapter 5 
demonstrates that the phenotype of a published notochord mutant, gulliver, results from a 
missense mutation in the gene encoding the alpha 1 chain of type VIII collagen. Taken 
together, the data in this thesis contribute to an understanding of notochord formation and 
lysyl oxidase function, and elucidate some of the complex gene-nutrient interactions that 
shape development. 
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Abstract 
Recent studies reveal a critical role for copper in the development of the zebrafish 
notochord, suggesting that specific cuproenzymes are required for the structural integrity 
of the notochord sheath. We now demonstrate that β-aminopropionitrile, a known 
inhibitor of the copper-dependent lysyl oxidases, causes notochord distortion in the 
zebrafish embryo identical to that seen in copper deficiency. Characterization of the 
zebrafish lysyl oxidase genes reveals eight unique sequences, several of which are 
expressed in the developing notochord. Specific gene knockdown demonstrates that loss 
of loxl1 results in notochord distortion, and that loxl1 and loxl5b have overlapping roles 
in notochord formation. Interestingly, while notochord abnormalities are not observed 
following partial knockdown of loxl1 or loxl5b alone, in each case this markedly 
sensitizes developing embryos to notochord distortion if copper availability is 
diminished. Likewise, partial knockdown of the lysyl oxidase substrate col2a1 results in 
notochord distortion when combined with reduced copper availability or partial 
knockdown of loxl1 or loxl5b. These data reveal a complex interplay of gene expression 
and nutrient availability critical to notochord development. They also provide insight into 
specific genetic and nutritional factors that may play a role in the pathogenesis of 
structural birth defects of the axial skeleton. 
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Introduction 
Structural birth defects are a leading cause of morbidity and mortality in humans. Despite 
recent advances identifying the molecular genetic basis of several such disorders, the 
genetic and environmental determinants of most structural birth defects remain unknown 
(28). One of the most important environmental factors influencing the outcome of fetal 
development is nutrition, and epidemiologic data, twin studies, and phenotype-genotype 
correlations all suggest that specific nutritional influences in combination with genetic 
susceptibility at multiple loci have profound long-term effects on pregnancy outcome 
(29). While in utero development severely limits experimental elucidation of the 
mechanisms and timing of critical events affected by nutrition during early embryonic 
development, recent studies suggest that the zebrafish may be an informative, genetically 
tractable model organism for such analysis (14, 22, 30).  
 The notochord is a useful structure for examining the complex interplay of genes 
and nutrition in early vertebrate development. This organ is readily visible throughout 
early zebrafish development, is the first to fully differentiate during embryogenesis, and 
is essential for the patterning of surrounding ectodermal, mesodermal, and endodermal 
tissues (31). The notochord is also a critical midline structure required for locomotion in 
some chordates, and for axial skeletal formation in vertebrates (31). Furthermore, the cell 
biological mechanisms underlying notochord maturation, involving cell vacuolation, 
matrix biosynthesis, and sheath formation, have begun to be elucidated through a series 
of elegant genetic experiments (17-20). Given the critical role of the notochord in 
chondrogenesis and fate determination of surrounding tissues including neural tube, 
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heart, and skeleton (16), as well as the large number of human structural birth defects 
arising from these tissues, elucidation of the nutritional and genetic mechanisms of 
notochord formation may be of direct relevance to our understanding of the etiology of 
congenital malformations. 
 During studies examining the role of copper in embryonic development, we 
discovered a critical role for this nutrient in late notochord formation (14). These findings 
suggested that specific cuproenzymes may be required for the structural integrity of the 
zebrafish notochord sheath, a concept supported by recent studies in Xenopus laevis (32). 
In this current study we have determined a role for two specific lysyl oxidase genes in 
notochord formation, and defined a complex biological pathway modulated by copper 
nutrition that underlies this process. Our data suggest that copper status during embryonic 
development should be interpreted in the context of environmental and genetic 
modulators of cuproenzyme activity. Indeed, the results raise the intriguing possibility 
that suboptimal copper availability, due either to nutritional or genetic variation during 
embryonic development, contributes to human birth defects of the axial skeleton. 
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Materials and methods 
Zebrafish strains and maintenance 
Zebrafish were reared under standard conditions at 28.5°C (33) and staged as described 
(34). Synchronous, in vitro fertilized embryos were obtained from AB or AB/WIK stocks 
for all experiments.  
Pharmacologic treatment 
Pharmacologic compounds were purchased from Sigma (St. Louis, MO).-
aminopropionitrile (A3134) and neocuproine (N1501) were prepared as 100 mM stocks 
in egg water and dimethyl sulfoxide, respectively, and diluted in egg water. Embryos 
were incubated in compound starting at 3 hpf and examined with an Olympus SZX12 
zoom stereomicroscope at 24, 30, 48, and 72 hpf. Images of representative fish mounted 
in 2% methylcellulose were acquired with an Olympus DP70 camera. 
Identification and annotation of zebrafish lysyl oxidase genes 
Exons encoding conserved regions of the lysyl oxidase catalytic domain (35) were 
detected by TBLASTN search of the Ensembl zebrafish genome (Zv5). A clone of lox 
was commercially available (Open Biosystems #6971279); full-length cDNA sequences 
of all other family members were obtained using 5‟ and 3‟ rapid amplification of cDNA 
ends (RACE) and RT-PCR based on sequence homology to human, mouse, and frog 
lysyl oxidase sequences. Primers were as follows: loxl1 forward primer 5‟-
CGCCTTCTTTTATTAGTCTTCTGG-3‟ and reverse primer 5‟-
ACAGCGACGTCAGGAATTCC-3‟; loxl2a – forward primer 5‟-
ATGGCGGTGTCTTCTGCATTGTGC-3‟ and reverse primer 5‟-
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CTATCTGAGGTGGTTCAGCTGGTTGC-3‟; loxl2b – forward primer 5‟-
GCCATACAATCTGAGCCTCTGTC-3‟ and reverse primer 5‟-
CTTTACCTGTGGGTCACCTGG-3‟; loxl3a – forward primer 5‟-
ATGGGACAGTTTGCTAACAGC-3‟ and reverse primer 5‟-
TTATGAGATCTTGTTGTTGAGCTGCC-3‟; loxl3b – forward primer 5‟- 
GTGTTTGTGTCCTTTGATGC-3‟ and reverse primer 5‟-
GCTGTACATGAAGAGTGATCT-3‟; loxl5a – nested 5‟RACE primers 5‟- 
CACTCGAGCTGTACGCTGAACTGGAAAGGC-3‟ (first reaction) and 5‟- 
GCACAGGGCTTGAACGCACCACATGCCC-3‟ (second reaction), and 3‟ PCR 
amplification with forward primer 5‟-CATTAAGATGTGCCGCAGAGG-3‟and reverse 
primer 5‟-CTCACCCGGTGATCCTACAGTTG-3‟; loxl5b – forward primer 5‟-
CCCACATCCAGAGGAGCGAA-3‟ and reverse primer 5‟-
TCCTCACCCAGTTATGATGCAG-3‟. GenBank accession numbers are: lox – 
EF030479; loxl1 – EF030480; loxl2a – EF030481; loxl2b – EF030482; loxl3a – 
EF030483; loxl3b – EF030484; loxl5a – EF030485; loxl5b – EF030486. An alignment 
of the C-terminal portion of zebrafish and human lysyl oxidases was created in ClustalW 
with human CD163 as outgroup (36, 37), and phylogenetic analysis carried out according 
to the parsimony method (38). Bootstrap values over 100 replicates are noted. Signal 
peptides and scavenger-receptor, cysteine rich domains were predicted using SignalP 3.0 
and Motif scan (39, 40). Copper binding domains, Bone Morphogenetic Protein-1 (BMP-
1) cleavage sites, and lysyl-tyrosyl quinone cofactor residues were identified based on 
homology to known lysyl oxidase sequences (41-43).  
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Whole mount in situ hybridization and frozen sections 
Lysyl oxidase and col2a1 (44) probe constructs were generated as partial clones by RT-
PCR and ligated into pCRII (Invitrogen). DIG-labeled antisense RNA probes were 
synthesized from these constructs using a DIG-labeling kit (Roche), and whole mount in 
situ hybridization performed as previously described (14, 45). Embryos for frozen 
sections were subsequently embedded in PBS containing 1.5% agarose/5% sucrose. 
Blocks were equilibrated in 30% sucrose at 4C, mounted with O.C.T. (Tissue-Tek), and 
cut on a Leica Cryostat after freezing with liquid nitrogen. 14 M sections were collected 
on Superfrost slides (Fisher) and mounted in 50% glycerol-PBS for visualization on an 
Olympus BX60 microscope.  
Morpholino and mRNA injections 
Morpholino oligonucleotides (27) targeting splice sites of exons encoding the lysyl 
oxidase copper binding domain (43) were resuspended in Danieau buffer, diluted to 
include 0.05% phenol red, and injected into one- to four-cell embryos. Morpholinos 
targeting the start sites of loxl1 and loxl5b, the 5‟ splice acceptor site of an exon 
corresponding to exon 48 of the human col2a1 orthologue, and standard control 
morpholino (Gene Tools, LLC) were likewise prepared and injected. Morpholino 
sequences are as follows: loxl1 (splice) – 5‟- GTGTAGATGTGGACTCACTGATGGC-
3‟; loxl1 (splice) – 5‟- GTAATGCCTGATGGAGACAAGAGAC-3‟ (Fig. 7 and Fig. 8); 
loxl1 (start) – 5‟-AGTACATGCAGCATATTGAGAAGAC-3‟; loxl2b – 5‟-
GATCTGGAGCAGCTAGAAAAAACAA-3‟; loxl3b – 5‟-
CAGCTGCGGACATAAACAAACAAAT-3‟; 
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loxl5b (splice) – 5‟-GCCTGTGGAATAAACACCAGCCTCA-3‟; loxl5b (start) – 5‟- 
TAAAGCTGTATGATTCGCTCCTCTG-3‟; col2a1 – 5‟-
CCTGAAGGTCCCTATTATAAATAAC-3‟. Capped, polyadenylated mRNA for rescue 
experiments was generated from full-length clones of loxl1, loxl5b, and control 
transposase (46) using the mMESSAGE mMACHINE kit (Ambion), with 300 pg of 
mRNA injected per embryo. Rescue was calculated by taking the difference between the 
percentages of embryos with distorted notochords injected with lysyl oxidase and control 
mRNA, and then dividing this number by the percentage of embryos with distorted 
notochords injected with control mRNA. Statistical analysis was conducted using one-
way ANOVA for independent samples based on the percentages of embryos with the 
distorted notochord phenotype from at least three separate experiments. In all cases, 
abnormal splicing was detected by RT-PCR of RNA from 15 embryos injected with 
control or lysyl oxidase morpholino using primers to exons flanking the putative splice 
site. Nucleotide sequencing of putative splice products identified on agarose or 
polyacrylamide gels confirmed the presence of a premature stop codon in the splice 
variants. The intensity of wild-type PCR products was quantified using non-saturated gel 
pictures and ImageJ 1.37v software (47), and the percentage of wild-type splice form 
remaining after morpholino knockdown calculated.  
Transmission Electron Microscopy 
Dechorionated embryos were fixed in 2.5% glutaraldehyde/0.1 M sodium cacodylate and 
sequentially stained with osmium tetroxide and uranyl acetate. They were then 
dehydrated, embedded in PolyBed 812, and thin sectioned on a Reichert-Jung Ultra-Cut. 
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Slices were post-stained in 4% uranyl acetate and lead citrate, and viewed on a Zeiss 902 
electron microscope. Photographs were recorded with Kodak EM film. 
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Results 
-aminopropionitrile recapitulates the notochord phenotype of copper deficiency 
Copper deficiency, induced by either chemical (neocuproine) or genetic (calamity
vu69
) 
means, results in a pleiotropic phenotype that includes a distorted, wavy notochord (14). 
Lysyl oxidases are copper-dependent enzymes that stabilize extracellular matrix by 
crosslinking elastin and collagens (35, 43), a process thought to be important for 
maintaining notochord sheath integrity during notochord vacuolation. -
aminopropionitrile irreversibly inhibits lysyl oxidases by binding the active site of the 
catalytic domain (48, 49), and incubation of 3 hpf zebrafish embryos with β-
aminopropionitrile resulted in striking notochord distortion and blunted somites, similar 
to what is observed with the copper chelator neocuproine (Fig. 1 and S. Fig. 1). 
Equivalent results were also obtained after incubation with semicarbazide, another known 
inhibitor of lysyl oxidases (data not shown), suggesting that these enzymes play a central 
role in notochord formation. β-aminopropionitrile treatment does not result in the 
pleiotropic phenotype of copper deficiency, including absence of melanin pigmentation, 
midbrain-hindbrain degeneration, and loss of red blood cells (Fig. 1B vs. 1C), reflecting 
the broader scope of cuproenzyme inhibition achieved with neocuproine. Furthermore, 
the effect of -aminopropionitrile on notochord morphology was not due to copper 
chelation as this phenotype was not reversible with CuCl2 (data not shown). Although the 
notochord distortion observed with -aminopropionitrile in Figure 1 is less than that with 
neocuproine, the mechanisms resulting in this process are likely the same because ten-
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fold higher doses of -aminopropionitrile result in a degree of distortion identical to that 
seen with neocuproine (S. Fig. 1).  
The zebrafish genome encodes eight lysyl oxidases 
These data suggested a requirement for lysyl oxidase activity in zebrafish notochord 
development. The human genome encodes five lysyl oxidase family members 
characterized by the presence of a conserved copper binding domain and residues for a 
lysyl-tyrosyl quinone cofactor. Although experimental evidence suggests a role for two of 
these lysyl oxidases in elastin and collagen crosslinking (50-54), the precise role of each 
family member in extracellular matrix formation, cancer biology, and intracellular 
signaling remains undetermined. Using a bioinformatic approach, we identified and 
cloned eight unique zebrafish lysyl oxidase genes, revealing that each human lysyl 
oxidase has a zebrafish orthologue except LOXL4 (Fig. 2 and S. Fig. 2). While lysyl 
oxidase genes are well conserved between humans and zebrafish based on nucleotide 
sequence alignment, Loxl3a and Loxl3b lack a signal peptide and the full complement of 
scavenger receptor domains found in human LOXL3 (Fig. 2A and S. Fig. 2). Our analysis 
also revealed two novel zebrafish lysyl oxidases, Loxl5a and its paralogue Loxl5b, that 
are closely related to LOX and LOXL1 by phylogenetic analysis but have not been 
previously described in other species (Fig. 2B and S. Fig. 2A). The presence of 
paralogues for some zebrafish lysyl oxidases likely reflects a genome duplication event 
and subsequent partitioning of gene function (55, 56).  
Four lysyl oxidases are expressed throughout the developing notochord 
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To elucidate the role of specific lysyl oxidases in notochord formation, we assessed lysyl 
oxidase mRNA expression in zebrafish embryos by whole-mount in situ hybridization. 
Four lysyl oxidase family members – loxl1, loxl2b, loxl3b, and loxl5b – were readily 
detected throughout the notochord during early zebrafish development (Fig. 3), and were 
specifically expressed within the vacuolar cells, as seen in frozen sections of 15 somite 
embryos (Fig. 4). Lysyl oxidase expression was observed as early as the 5 somite stage 
(Fig. 3A,M), well before notochord vacuolation begins, and was extinguished after 
vacuolation is complete, between 24 hpf and 48 hpf (data not shown). While loxl1 and 
loxl5b were robustly expressed at the caudal tip (Fig. 3D,P, arrowheads), loxl2b and 
loxl3b were not (Fig. 3H,L), possibly reflecting a differential requirement for their 
activity during notochord elongation. Closer inspection revealed that loxl5b is expressed 
anterior to the notochord, in the prechordal plate region (Fig. 3O, asterix), and that loxl1 
is expressed in the hypochord (Fig. 4A, arrows), providing a new marker for this 
structure and suggesting a role for loxl1 in crosslinking extracellular matrix near the 
developing aorta (57, 58). lox, loxl3a, and loxl5a were not expressed in or near the 
notochord between the 5 somite stage and 48 hpf, but could be detected by 5 dpf, while 
loxl2a was faintly and transiently expressed in a limited region of the anterior notochord 
before 24 hpf and was not studied further (data not shown). 
Morpholino knockdown of loxl1 or loxl1 and loxl5b together results in a distorted 
notochord 
To determine the precise developmental functions of individual lysyl oxidases expressed 
throughout the notochord, we conducted knockdown experiments using morpholino 
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antisense oligonucleotides (Fig. 5 and Table 1). Whereas control morpholino had no 
observable effect on developing zebrafish embryos (Fig. 5A and Table 1), a splice 
morpholino to loxl1 recapitulated the notochord distortion and blunted somites observed 
with -aminopropionitrile and neocuproine (Fig. 5B and Table 1), revealing that this 
family member is necessary for late notochord formation in zebrafish. Morpholino 
knockdown of loxl2b, loxl3b, and loxl5b induced minor changes to notochord 
architecture, including occasional notochord kinks (Fig. 5C-E and Table 1), and the 
loxl5b morpholino also caused caudal vein edema (Fig. 5E, arrows). In all cases, a 
specific effect of these splice morpholinos on lysyl oxidase gene transcription was 
confirmed by demonstrating abnormal splicing and generation of a premature stop codon 
(S. Fig. 3 and data not shown). Since very few embryos injected with morpholinos to 
loxl2b, loxl3b, and loxl5b alone developed the distorted notochord phenotype at high 
morpholino doses (Fig. 5C-E and Table 1), we tested all possible combinations of lysyl 
oxidase morpholinos. Morpholino doses of loxl1 and loxl5b that did not result in 
notochord distortion when used alone, together recapitulated the notochord phenotype 
and blunted somites observed with -aminopropionitrile and neocuproine (Fig. 5F and 
Table 1). This was the only morpholino combination resulting in a notochord phenotype 
(Table 1 and S. Table 1), and was similarly recapitulated with morpholinos targeting the 
start sites of loxl1 and loxl5b (Table 1 and S. Fig. 1). Taken together, these observations 
indicate that these two lysyl oxidases have specific overlapping functions in notochord 
development. The notochord distortion elicited by combined knockdown of loxl1 and 
loxl5b (Fig. 5F and Table 1) was specifically rescued with co-injection of either loxl1 or 
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loxl5b mRNA (Fig. 5H,I and Table 2), but not control mRNA (Fig. 5G and Table 2). 
Importantly, each of the lysyl oxidase splice morpholinos also resulted in head necrosis 
(Fig. 5B-E) that was not rescued with specific mRNA injection (data not shown), 
suggesting that this phenotype results from a non-specific morpholino effect. Consistent 
with this concept, head necrosis is not observed following treatment with either -
aminopropionitrile or neocuproine (S. Fig. 1).  
Nutrient, gene interactions in notochord distortion 
Since the notochord phenotype observed with combined loxl1 and loxl5b knockdown is 
identical to that seen with -aminopropionitrile and neocuproine, we next examined the 
interaction of copper availability and lysyl oxidase gene expression in notochord 
formation (Fig. 6). For these experiments, doses of loxl5b morpholino and neocuproine 
were determined such that they did not cause notochord distortion when used alone (Fig. 
6B,C and Table 3). In striking contrast, embryos subjected to combined treatment with 
these same doses of loxl5b morpholino and neocuproine developed distorted notochords 
(Fig. 6D and Table 3). Experiments using loxl1 morpholino and neocuproine yielded 
similar results (Table 3), supporting the model that specific inhibition of two lysyl 
oxidases accounts for the notochord abnormalities observed with -aminopropionitrile 
and neocuproine. Most significantly, these data also reveal that copper availability 
influences the phenotypic outcome of notochord development according to the genetic 
content of the embryo.  
 In this context, we also examined the role of collagen II, a structural component 
of the notochord sheath, in notochord formation. Collagen II is a lysyl oxidase substrate 
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whose spatio-temporal pattern of expression corresponds with that of the notochord-
expressed lysyl oxidases during early zebrafish development (44). We determined the 
highest dose of col2a1 morpholino that could be injected without phenotypic 
abnormalities (Fig. 6E), and incubated these injected embryos in a dose of neocuproine (2 
M) that was also without effect. This combined treatment resulted in notochord 
distortion (data not shown), revealing the importance of copper nutrition in the context of 
collagen II disruption and predicting a genetic interaction between collagen II and the 
notochord-expressed lysyl oxidases. Consistent with this prediction, about half of the 
embryos injected with loxl5b and col2a1 morpholinos together revealed a conspicuously 
distorted notochord (Fig. 6F and Table 4), demonstrating that decreased expression of 
loxl5b sensitizes embryos to col2a1 disruption. A comparable result was also obtained 
using the loxl1 and col2a1 morpholinos (Table 4). The specificity of this effect was 
confirmed by detection of a splicing defect resulting from the col2a1 morpholino that 
causes a premature stop codon (S. Fig. 3 and data not shown). The observation that in 
each case only about 50% of the embryos displayed the abnormal notochord phenotype 
may be due either to additional lysyl oxidase substrates that play a role in notochord 
formation or to submaximal disruption of col2a1 gene expression at this morpholino dose 
(S. Fig. 3). Taken together, these data illustrate the complex interplay of multigenic 
expression and nutrition required for notochord formation in developing zebrafish 
embryos.  
col2a1 expression persists in notochord vacuolar cells after lysyl oxidase inhibition 
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The foregoing experiments suggest that collagen II is a substrate for both Loxl1 and 
Loxl5b in zebrafish. As recently demonstrated (59), col2a1 expression persists in the 
vacuolar cells of the notochord at 24 hpf when embryos are treated with a dose of 
neocuproine that causes notochord distortion (Fig. 7B). One possible explanation for this 
phenomenon is impairment of a feedback mechanism that normally downregulates 
production of col2a1 upon collagen crosslinking in the notochord sheath. Consistent with 
this idea, embryos treated with -aminopropionitrile (Fig. 7C) or injected with 
morpholinos to loxl1 and loxl5b (Fig. 7D) continued to express col2a1 in the vacuolar 
cells of the notochord at 24 hpf, whereas control embryos did not (Fig. 7A). The 
persistent expression of col2a1 was not due to developmental delay, as embryos added 
somites at the same rate under all experimental conditions (data not shown).  
 We next considered whether the persistent col2a1 expression was specific to a 
reduction in crosslinking or was a generalized response to mechanical distortion of the 
notochord. To explore this idea, we incubated embryos in a dose of neocuproine (2 M) 
that did not cause notochord distortion but that partially disrupted crosslinking, as 
revealed by the combined neocuproine and loxl5b studies. Persistent col2a1 expression 
was observed within the notochord vacuolar cells at 24 hpf under these conditions (S. 
Fig. 4), similar to what is observed in neocuproine-treated embryos incubated with 
anesthetic to prevent notochord distortion (59). These data are consistent with a feedback 
mechanism originating from the products of the crosslinking process.  
 The col2a1 expression data suggest a model where lysyl oxidase inhibition affects 
the final stages of notochord development at a time when the extracellular matrix 
 24 
components, including collagen II, are already in place in the notochord sheath. The 
notochord sheath in zebrafish is composed of three distinct layers: an internal basal 
lamina, a middle fibrillar layer, and an external granular layer (Fig. 8A) (16, 60). 
Inspection of the notochord sheath by electron microscopy revealed that inhibition of 
lysyl oxidase activity by neocuproine, -aminopropionitrile, or combined loxl1 and 
loxl5b knockdown was without effect on these layers (Fig. 8B-D). This observation is 
consistent with the idea that lysyl oxidase inhibition alters the final stages of notochord 
sheath formation. 
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Discussion 
These studies reveal an essential role for two specific lysyl oxidase genes, loxl1 and 
loxl5b, in notochord formation, and demonstrate a complex interplay of gene expression 
and nutrient availability that is relevant to the pathogenesis of human structural birth 
defects (Fig. 9A,B). A role for lysyl oxidases in notochord formation was hypothesized 
from previous work using small molecules (14, 32), and our current data establish a 
genetic basis for this pharmacologic notochord distortion. Various lysyl oxidases have 
been implicated in tumor metastasis, wound healing, cardiac fibrosis and elastin fiber 
homeostasis (50, 54, 61, 62). However, the precise function of individual lysyl oxidase 
family members in development has been difficult to discern given the lack of inhibitors 
unique to any given enzyme. This study is the first to demonstrate that genetic deficiency 
of specific lysyl oxidases results in notochord distortion, and elucidates a specific and 
novel interaction between gene function (lysyl oxidases) and nutrition (copper) during 
development. While it is logical that copper-dependent enzymes such as lysyl oxidases 
would be inactive in the complete absence of copper, it is more difficult to predict the 
effect of mild copper deficiency on enzyme activity, and more importantly, to determine 
what components of the developing notochord would become essential in the setting of 
impaired – but not absent – lysyl oxidase function. The specific role for loxl1 and loxl5b 
in notochord formation is supported by sensitization experiments using neocuproine (Fig. 
6 and Table 3), and these genes may be candidates for late notochord mutants identified 
in previous forward genetic screens (17, 18) or for human disorders of the axial skeleton. 
Though we cannot completely rule out the possibility that the low penetrance of a 
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distorted notochord phenotype using splice morpholinos to loxl2b, loxl3b, or loxl5b alone 
(Table 1) results from incomplete disruption of gene expression (S. Fig. 3), combinations 
involving these morpholinos did not convincingly demonstrate a role for loxl2b or loxl3b 
in notochord formation (Table 1 and S. Table 1).  
 Our data also demonstrate a genetic interaction between two lysyl oxidases (loxl1 
and loxl5b) and the collagen substrate col2a1 (Fig. 6). This could reflect either direct 
crosslinking of this collagen substrate or crosslinking of additional extracellular matrix 
proteins that interact with collagen II for proper notochord formation. The latter 
possibility has been proposed in recent morphological studies on the notochord sheath of 
teleosts (63) and could account for observations in coatomer I protein complex mutants 
(19), where defects in the secretion of lysyl oxidases or additional such extracellular 
matrix components would give rise to the notochord sheath abnormalities. In all cases, 
reduced crosslinking of collagen fibrils from impaired lysyl oxidase activity would 
prevent the feedback inhibition of col2a1 produced by notochord vacuolar cells, resulting 
in prolonged col2a1 expression (Fig. 7). Alternatively, persistent col2a1 expression could 
result indirectly from a general loss of notochord sheath integrity.   
 The observed lysyl oxidase expression patterns and phenotypes (Fig. 3, Fig. 4, 
Fig. 5 and data not shown) suggest that the zebrafish will be a useful model organism for 
elucidating the complex and specific roles of lysyl oxidases in development. In addition, 
the phylogenetic analysis (Fig. 2B) may prove helpful. The lack of a zebrafish orthologue 
to LOXL4 is consistent with a BLAST search revealing such orthologues only in 
mammals (data not shown), and the markedly different expression patterns of this gene in 
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human and mouse (64-66) may indicate that it has divergent, specialized roles in these 
organisms. Moreover, it is now apparent that scavenger receptor, cysteine-rich domains 
are a more variable feature of lysyl oxidase structure than previously anticipated. 
LOXL2, LOXL3, and LOXL4 are considered related because they all possess four 
scavenger receptor, cysteine-rich domains, which are completely absent in LOX and 
LOXL1. However, zebrafish loxl3a and loxl3b encode only a single scavenger receptor, 
cysteine-rich domain that is truncated (Fig. 2A), as does a Xenopus clone of loxl3 
previously assumed to be partial (S. Fig. 2C) (32). While the function of these domains 
remains unknown, a splice variant of LOXL3 that excludes some scavenger-receptor, 
cysteine-rich domains has recently been described, and appears to have altered substrate 
specificity (67).  
 Definitive demonstration of a role for specific lysyl oxidases in notochord 
formation is of direct relevance to embryonic environmental exposures to nitrile 
compounds in plasticizers and carbamates in pesticides. Recent toxicological studies 
demonstrate that such pesticides induce notochord distortion in developing zebrafish 
embryos (59, 68) as well as persistent expression of col2a1 by vacuolar cells of the 
notochord (59). These findings are identical to our observations with loxl1, loxl5b, and 
col2a1 morpholino knockdown combined with neocuproine treatment (Fig. 5B,F, Fig. 6 
and Fig. 7), suggesting that the pesticides act through direct or indirect inhibition of these 
lysyl oxidase family members. Importantly, these data raise the distinct possibility that 
embryonic exposure to such toxins in specific genetic contexts may predispose to the 
later development of structural birth defects (Fig. 9B), where the inheritance of this 
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genetic variation would not be reflected in Mendelian ratios of the observable 
phenotypes. 
 The notochord is a critical structure required for vertebral column patterning in 
vertebrates (69) and its distortion in zebrafish phenotypically mimics a number of axial 
skeletal defects in humans including idiopathic scoliosis. Of note, while -
aminopropionitrile causes notochord distortion in zebrafish (Fig. 1B and S. Fig. 1), it is 
also well known to cause scoliosis in rats and other mammals (70). Interestingly, 
disruptions in extracellular matrix components involved in notochord formation have 
been identified in clinical syndromes that include scoliosis. Two different mutations in 
exon 48 of the COL2A1 gene cause spondyloepiphyseal dysplasia with scoliosis in 
humans (71, 72). Furthermore, the kyphoscoliosis type of Ehler-Danlos syndrome (EDS 
VI) (73) results from loss of function mutations in the gene encoding lysyl hydroxylase 
type 1, which catalyzes the conversion of lysine to hydroxylysine in collagen prior to 
oxidization by lysyl oxidases. Taken together with the nutritional (copper) and toxicology 
findings noted above, these data raise the intriguing possibility that polymorphisms at 
multiple extracellular matrix component loci, including the lysyl oxidase genes identified 
here, may predispose to axial skeletal malformations in situations where nutrition or 
environment might otherwise be considered adequate (Fig. 9B). This concept is 
supported by our previous findings revealing a hierarchy of nutrient distribution to the 
developing embryo under limiting conditions (14) and as such is of broad relevance to 
our understanding of the pathogenesis of structural birth defects. The data reported here 
provide a testable model for these ideas with regards to common defects of the axial 
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skeleton and reveal that zebrafish permit unique insights into the complex interplay of 
genes, environment and nutrition in development and disease.  
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Figure legends 
Fig. 1. β-aminopropionitrile recapitulates the notochord phenotype of copper 
deficiency. Wild-type embryos were incubated in vehicle (A), 10 M neocuproine (B), or 
10 mM -aminopropionitrile supplemented with 10 M CuCl2 (C). At 48 hpf, the 
notochord (arrowheads) is distorted in embryos treated with neocuproine (B) and -
aminopropionitrile (C); however, melanocytes (arrows) are present after -
aminopropionitrile (C) but not neocuproine treatment (B), demonstrating that-
aminopropionitrile does not act through copper chelation. 
Fig. 2. Lysyl oxidase family members in zebrafish. (A) The zebrafish genome encodes 
eight distinct lysyl oxidases, all of which contain a conserved copper binding domain 
depicted in yellow. Scavenger receptor, cysteine-rich domains (SRCR) of unknown 
function are in blue and are truncated in Loxl3a and Loxl3b (SR with strikethrough). (B) 
Phylogenetic tree depicting the evolutionary relationship between human and zebrafish 
lysyl oxidases. HsCD163 is used as an outgroup, and bootstrap values over 100 replicates 
are noted. Loxl5a and Loxl5b (green) represent new additions to the lysyl oxidase family 
that closely resemble LOX and LOXL1 in structure. Zebrafish encode orthologues to all 
human lysyl oxidase genes except LOXL4. 
Fig. 3. Four lysyl oxidases are expressed throughout the developing zebrafish 
notochord by in situ hybridization. (A-D) loxl1; (E-H) loxl2b; (I-L) loxl3b; and (M-P) 
loxl5b. Stages of development are 5 somites (A,E,I,M); 10 somites (B,F,J,N); 15 somites 
(C,G,K,O); and 20 somites (D,H,L,P). loxl1 and loxl5b are robustly expressed at the 
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caudal notochord tip (arrowheads) while loxl5b is also expressed anterior to the 
notochord (asterix). 
Fig. 4. Lysyl oxidases are expressed by notochord vacuolar cells. (A-D) Frozen cross-
sections of 15 somite embryos were obtained after in situ hybridization with the 
following probes: (A) loxl1; (B) loxl2b; (C) loxl3b; and (D) loxl5b. The notochord is 
indicated (arrowheads). Hypochord staining of loxl1 (arrows) suggests a role for this 
family member in extracellular matrix crosslinking near the developing aorta. (E) 
Cartoon demonstrating the location of the hypochord (h) and floorplate (f), which are 
closely apposed to the notochord (n). Lysyl oxidases are not expressed in the floorplate. 
Fig. 5. Morpholino knockdown of loxl1 or loxl1 and loxl5b together results in 
notochord distortion. Wild-type embryos were injected with morpholinos (MO) to 
notochord-expressed lysyl oxidases and photographed at 24 hpf. (A) 12 ng standard 
control; (B) 6 ng loxl1; (C) 3.7 ng loxl2b; (D) 12 ng loxl3b; (E) 7.4 ng loxl5b; (F) 2.4 ng 
loxl1 and 5 ng loxl5b. The notochord (arrowheads) is strikingly distorted after 
knockdown of loxl1 (B), and caudal vein edema develops with the loxl5b morpholino (E, 
arrows). Combining doses of loxl1 and loxl5b morpholino that do not cause notochord 
distortion alone also recapitulates the notochord phenotype seen with neocuproine and -
aminopropionitrile treatment (F). This distortion is specifically rescued by co-injection of 
mRNA encoding either loxl1 (H) or loxl5b (I), but not control sequence (G).  
Fig. 6. Partial knockdown of loxl5b sensitizes embryos to notochord distortion in the 
presence of suboptimal copper nutrition (A-D) or disruption of col2a1 (E,F). Wild-
type embryos were injected with 5 ng of control morpholino (A,C) or loxl5b morpholino 
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(B,D), and incubated with (C,D) or without (A,B) 2 M neocuproine starting at 3 hpf. 
Embryos injected with loxl5b morpholino develop notochord distortion (arrowhead) in 
the context of diminished copper availability (D). Embryos injected with 7.4 ng of col2a1 
morpholino (E) are sensitized to develop notochord distortion (arrowhead) upon co-
injection of 5 ng of loxl5b morpholino (F), demonstrating a genetic interaction between 
col2a1 and loxl5b. Photographs were obtained at 30 hpf (A-D) and 24 hpf (E,F).  
Fig. 7. Expression of col2a1 mRNA by notochord vacuolar cells persists late 
following lysyl oxidase inhibition. Wild-type embryos were injected with 7.4 ng control 
morpholino (A), incubated in 10 M neocuproine (B), incubated in 10 mM -
aminopropionitrile supplemented with 10 M CuCl2 (C), or injected with 3.7 ng each of 
loxl1 and loxl5b morpholino (D). In situ hybridization was carried out at 24 hpf, and 
frozen sections confirmed persistent col2a1 expression following lysyl oxidase inhibition 
(B-D, arrowhead), as well as floorplate and hypochord staining (A-D, arrows). 
Fig. 8. Electron micrographs of the notochord sheath from cross-sections of 30 hpf 
embryos: (A) 7.4 ng control morpholino; (B) 10 M neocuproine; (C) 10 mM -
aminopropionitrile; (D) 3.7 ng each of loxl1 and loxl5b morpholino. Sheath components 
include a basal lamina (I), fibrillar layer (II), and granular layer (III). All three layers are 
preserved after lysyl oxidase inhibition. 
Fig. 9. Model of pathways involved in notochord formation. (A) The cuproenzymes 
Loxl1 and Loxl5b crosslink collagen II in the notochord sheath, which suppresses 
vacuolar cell expression of col2a1 as the notochord differentiates. (B) Polymorphisms at 
multiple genetic loci interact with environmental factors to cause disease. As a result, 
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what is normally considered adequate nutrition may in fact be suboptimal during a 
specific developmental window. The gene atp7a encodes a transporter required for 
copper uptake (14). 
Table 1. loxl1 is necessary for notochord formation in developing zebrafish 
embryos, and overlaps in function with loxl5b. Wild-type embryos were injected with 
morpholinos to notochord-expressed lysyl oxidases and examined at 24 hpf. The number 
and percentage of embryos with and without a distorted notochord phenotype is noted. 
Injection of 6 ng of loxl1 splice morpholino causes notochord distortion in 88% of 
embryos, an effect not seen with morpholinos to loxl2b, loxl3b, or loxl5b alone. However, 
injection of 2.4 ng of loxl1 morpholino and 5 ng of loxl5b morpholino together causes 
notochord distortion in 94% of embryos, demonstrating that loxl1 and loxl5b have 
overlapping roles in notochord formation. This finding was recapitulated in separate 
experiments with start site (ATG) morpholinos to loxl1 and loxl5b. The number of 
embryos examined includes dead embryos that could not be scored for notochord 
phenotype; the loxl2b morpholino causes significant embryo death at higher doses. Data 
shown are the pooled results of three independent experiments. 
Table 2. The distorted notochord phenotype resulting from combined loxl1 and 
loxl5b knockdown is specific and can be rescued by co-injection of mRNA encoding 
either loxl1 or loxl5b. Wild-type embryos injected with control or loxl1 and loxl5b 
morpholinos together were co-injected with control or lysyl oxidase mRNA, as indicated. 
The number and percentage of embryos with and without a distorted notochord 
phenotype at 24 hpf is noted, as well as the percentage rescue attributable to each mRNA. 
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Exogenously-supplied loxl1 or loxl5b mRNA produces a marked improvement in 
notochord morphology, substantially decreasing the proportion of embryos with 
notochord distortion. Injection of lysyl oxidase mRNA alone did not result in any 
overexpression phenotype. The number of embryos examined includes dead embryos that 
could not be scored for notochord phenotype. Data shown are the pooled results of three 
independent experiments. 
Table 3. Partial knockdown of loxl1 or loxl5b sensitizes embryos to notochord 
distortion in the presence of suboptimal copper nutrition. Wild-type embryos were 
injected with control or lysyl oxidase-specific morpholino, as indicated, and incubated 
with or without neocuproine at doses that were determined not to cause notochord 
distortion alone. Embryos injected with lysyl oxidase-specific morpholino and incubated 
in 2 M neocuproine were sensitized to develop notochord distortion. The number of 
embryos examined includes dead embryos that could not be scored for notochord 
phenotype. Each result is pooled from three independent experiments, which were scored 
at 24 hpf.  
Table 4. Genetic interaction of loxl1 and loxl5b with col2a1. Wild-type embryos were 
injected with the indicated morpholino combinations and scored for notochord distortion 
at 24 hpf. Partial knockdown of loxl1 and col2a1 together, but not alone, causes the 
distorted notochord phenotype. An identical result is obtained with morpholinos to loxl5b 
and col2a1, suggesting that diminished activity of these lysyl oxidases sensitizes embryos 
to notochord distortion in the presence of col2a1 disruption. Importantly, collagen II is a 
lysyl oxidase substrate produced by the notochord vacuolar cells and present in the 
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notochord sheath. The number of embryos examined includes dead embryos that could 
not be scored for notochord phenotype. Each result is pooled from three independent 
experiments. 
 S. Fig. 1. Comparison of the notochord distortion obtained in zebrafish using three 
distinct methods of lysyl oxidase inhibition at 24 hpf. Wild-type embryos were 
incubated in 10 M neocuproine (A), 10 mM -aminopropionitrile supplemented with 10 
M CuCl2 (B), 100 mM -aminopropionitrile supplemented with 10 M CuCl2 (C), or 
injected with 6 ng each of loxl1 and loxl5b start (ATG) morpholino (D). 10 M 
neocuproine (A) causes greater notochord distortion than 10 mM -aminopropionitrile 
(B), but an identical phenotype is obtained with 100 mM -aminopropionitrile (A vs. C). 
Melanin pigmentation has not yet developed in the embryos pictured, but is not affected 
by -aminopropionitrile treatment or by the morpholino injection. 
S. Fig. 2. Protein sequence alignment of zebrafish lysyl oxidase family members with 
human orthologues. (A) lox, loxl1, loxl5a, and loxl5b; (B) loxl2a and loxl2b; (C) loxl3a 
and loxl3b with Xenopus laevis clone XL051k10 included for comparison. A number of 
conserved elements are indicated including predicted signal peptides (bold, underlined), 
BMP-1 cleavage sequences (bold, italicized), scavenger receptor cysteine-rich domains 
(gray, underlined), copper binding domains (gray), and lysyl-tyrosyl quinone cofactor 
residues (bold). 
S. Fig. 3. Lysyl oxidase and collagen II splice morpholinos decrease the abundance 
of wild-type splice forms and cause specific changes in splice site usage. (A) loxl1 (B) 
loxl2b (C) loxl3b (D) loxl5b and (E) col2a1. Wild-type embryos injected with the 
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indicated doses of morpholino were harvested at 20 hpf and cDNA prepared from equal 
amounts of RNA. The intensity of the wild-type (WT) product obtained by PCR was 
quantified and the percentage of wild-type splice form remaining after morpholino 
knockdown determined, as noted. This measure is independent of processes that may 
depress levels of the mutant (Mut) splice products, including degradation through 
nonsense-mediated decay. The primer set used to amplify loxl1 does not amplify the 
mutant band. 
S. Fig. 4. Persistent expression of col2a1 by notochord vacuolar cells after lysyl 
oxidase inhibition is not due to mechanical distortion of the notochord. Wild-type 
embryos incubated with (B) or without (A) 2 M neocuproine were probed for col2a1 
expression at 24 hpf. col2a1 expression persists in the notochord vacuolar cells after 
treatment with 2 M neocuproine, which affects crosslinking but does not cause 
mechanical distortion. This suggests that the signal to downregulate col2a1 expression in 
the vacuolar cells of the notochord originates from the products of the crosslinking 
reaction. 
S. Table 1. Morpholinos to combinations of lysyl oxidase family members other than 
loxl1 and loxl5b do not result in notochord distortion. Wild-type embryos were 
injected with the indicated morpholino doses and examined at 24 hpf for notochord 
distortion. The number of embryos examined includes dead embryos that could not be 
scored for notochord phenotype. Each result is pooled from three independent 
experiments.  
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Specific Morpholino Dose of 
morpholino (ng)  
# of embryos 
examined 
Phenotype of notochord distortion 
- + 
Ctrl 12 302 278 (100%) 0 (0%) 
loxl1 6 271 30 (12%) 217 (88%*) 
loxl2b 2.4 212 122 (98%) 3 (2%) 
loxl3b 12 190 128 (96%) 6 (4%) 
loxl5b  5 263 237 (98%) 6 (2%) 
loxl1 2.4 297 272 (99%) 2 (1%) 
loxl1/loxl5b  2.4/5 292 17 (6%) 254 (94%*) 
Ctrl 12 173 138 (100%) 0 (0%) 
loxl1 ATG 12 158 145 (100%) 0 (0%) 
loxl5b ATG 12 159 140 (92%) 12 (8%) 
loxl1 ATG/loxl5b ATG 6/6 188 33 (19%) 145 (81%*) 
*p < 0.01 versus controls by ANOVA  
 
 
Table 1 
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Specific 
Morpholino 
Dose of 
morpholino 
(ng) 
Specific 
mRNA 
# of embryos 
examined 
Phenotype of notochord 
distortion 
Rescue of 
notochord 
phenotype - + 
Ctrl 7.4 Ctrl 240 226 
(100%) 
0 (0%) NA 
loxl1/loxl5b  2.4/5 Ctrl 223 8 (4%) 195 (96%) NA 
loxl1/loxl5b  2.4/5 loxl1 238 137 (63%) 80 (37%*) 62% 
loxl1/loxl5b  2.4/5 loxl5b 251 197 (86%) 33 (14%*) 85% 
*p < 0.01 versus loxl1/loxl5b MO with Ctrl mRNA by ANOVA  
 
 
Table 2 
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Specific 
Morpholino 
Dose of 
morpholino 
(ng) 
Pharmacologic 
treatment 
# of embryos 
examined 
Phenotype of notochord 
distortion 
- + 
Ctrl 2.4 None 104 104 (100%) 0 (0%) 
Ctrl  2.4 2 M neocuproine  113 111 (98%) 2 (2%) 
loxl1 2.4 None 143 127 (100%) 0 (0%) 
loxl1 2.4 2 M neocuproine 132 49 (39%) 77 (61%*) 
Ctrl 5 None 139 136 (100%) 0 (0%) 
Ctrl 5 2 M neocuproine 138 132 (99%) 2 (1%) 
loxl5b 5 None 147 126 (95%) 7 (5%) 
loxl5b 5 2 M neocuproine 147 1 (1%) 140 (99%*) 
*p < 0.01 versus controls by ANOVA  
 
 
Table 3 
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Specific Morpholino Dose of 
morpholino (ng)  
# of embryos 
examined 
Phenotype of notochord distortion 
- + 
loxl1/ctrl 2.4 /7.4 202 146 (99%) 1 (1%) 
col2a1/ctrl 7.4 /2.4 206 161 (98%) 4 (2%) 
col2a1/loxl1 7.4/2.4 258 118 (58%) 84 (42%*) 
loxl5b/ctrl 5/7.4 151 137 (93%) 10 (7%) 
col2a1/ctrl 7.4/5 122 116 (99%) 1 (1%) 
col2a1/loxl5b 7.4/5 217 111 (54%) 96 (46%*) 
*p < 0.01 versus controls by ANOVA 
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A 
 
HsLOX           MRFAWTVLLLGPLQLCALVHCAPPAAGQQQPPREPPAAPGAWRQQIQWENNGQVFSLLSL 60 
DrLox           MSMSLIDTFIYAFAHVCLLSCIAQTG---QTQRQGNTGAAALRQTIQWQHNGKLFSILSQ 57 
HsLOXL1         MALARGSRQLGALVWGACLCVLVHGQ---QAQPGQGSDPARWRQLIQWENNGQVYSLLNS 57 
DrLoxl1         --------MLHVLLMSLWVLGSVTGQ---SQS--QPDDTNPWRQMIQWENNGRVYSLLNS 47 
DrLoxl5a        --MTKYSFIFCLSIHLCVLVFLNTAQ-----------NHGAWQHKVKWETNGQVYSLLSA 47 
DrLoxl5b        MFFTISNFIFFLYL-LQGLNNLTSAQ-----------SSAQWRNRVRWVNNGQVFSLMST 48 
                         :        :                       :: ::*  **:::*::.  
 
HsLOX           GSQYQPQ--RRRDP----------GAAVPGAANASAQQPRTPILLIRDNRTA------AA 102 
DrLox           GSEYQPP--LKRD-----------GNKEQAQARPVAIVRNDDAATRTDSSAP------SR 98 
HsLOXL1         GSEYVPAGPQRSES----------SSRVLLAGAPQAQQRRSHGSPRRRQAPSLPLPGRVG 107 
DrLoxl1         GAEYVPARNQERDR----------NHRVLLADAP---NRRSQGGNVRRQAPS-----RGS 89 
DrLoxl5a        SSQYHAPASGKQHARFLLRRQIIPSFTGRIFMGQFAKTRMHTAGHVVRSSPVPGHIGLNA 107 
DrLoxl5b        GSEFHAPVPSRRQSRVYQ------SSRTDAVPGRSMQIRLEAMDRPANSAPDSALLGPDR 102 
                .::: .    . .           .                       . .          
 
HsLOX           RTRTAGSSGVTAGR-PRPTARHWFQAGYSTSRARERGASRAENQTAPGEVPALSNLRPPS 161 
DrLox           ASQSRGSVRVPSGTGARGGASRWLSG----DGARTRGVHGRRNHTDP-LRSINGTDRPAG 153 
HsLOXL1         SDTVRGQARHPFGFGQVPDNWREVAVGDSTGMARARTSVSQQRHGG--SASSVSASAFAS 165 
DrLoxl1         SETVRGQARHPFGFGQVPENWRQQQG----AVGRSETSRFQSQTGSRYRPSSGASSSASS 145 
DrLoxl5a        KHMISGHIRNNNQLPLHAKKVAFSSD----ETLRTQTWPYRTSPTGTTTHGPVKNSEISR 163 
DrLoxl5b        AQYIMANSRAPGARQMQVMQRHRAPP----ASRNNSTVPSEYSGGGGRTG------ENTR 152 
                     .                           .                        .  
 
HsLOX           RV--------------------------------------------DGMVG--------- 168 
DrLox           DD--------------------------------------------EVMVG--------- 160 
HsLOXL1         TYRQQPSYPQQFPYPQAPFVSQYENYDPASRTYDQGFV---YYRPAGGGVGAGAAAVASA 222 
DrLoxl1         SYPQYP-IPQ-----QPPFGAPYDQVS--DRSYEPPFLGTGYSAGTGGGFGGGSYGGYST 197 
DrLoxl5a        APKQHK--------------------------------------ITSQPVAKQPSPATGK 185 
DrLoxl5b        R---------------------------------------------GQAVAN-------- 159 
                                                                 ..          
 
HsLOX           ------------------------------------------------DDPYNPYKYSD- 179 
DrLox           ------------------------------------------------DDPYNPYKSTDP 172 
HsLOXL1         GVIYPYQPRARYEEYGGGEELPEYPPQGFYPAPERPYVPPPPPPPDGLDRRYSHSLYSEG 282 
DrLoxl1         GSFGGGNP-ANDDRYR------FYPPFG-QQYQAVPAQPAQPPFSDGLDHRYTHSLFNED 249 
DrLoxl5a        PPTPEEKQHAKPQPIS-----------NATNKSKLSPSLDAPSASGNVRNVRNPLVQVEA 234 
DrLoxl5b        -----FQQIAAPTDNS-----------NTVN-------------SDNENEARTPNVPAEQ 190 
                                                                    .     :  
 
HsLOX           --------------------DNPYYNYYDTYERPRP------------------------ 195 
DrLox           --------------------DNPYYNYYDTYERPRP------------------------ 188 
HsLOXL1         TPGFEQAYPDPGPEAAQAHGGDPRLGWYPPYANPPPEAYGPPRALEPPYLPVRSSDTPPP 342 
DrLoxl1         NPAVPNGASSNTGSSFQPAVQSPQYEQFPPYGRPQP---------QPPFLQPAPRNPLVS 300 
DrLoxl5a        RG-GESMIDDEPTN--HQANRNSFYNLLPYGNTNRS------------------------ 267 
DrLoxl5b        GATSETMPGDDPRN--RNT---VFYNIYPPGGRTII------------------------ 221 
                                                                             
 
HsLOX           ------GGRYRPGYGTGYFQYG----LPDLVADPYYIQASTYVQKMSMYNLRCAAEENCL 245 
DrLox           ------AQ--RPGYGTGYFQNG----LPDLVGDPYYIQASTYVQRVPMYNLRCAAEENCL 236 
HsLOXL1         GGERNGAQQGRLSVGSVYRPNQNGRGLPDLVPDPNYVQASTYVQRAHLYSLRCAAEEKCL 402 
DrLoxl1         ----NTAENPNINVGSVYRPQQ--RGLPDLVPDPNYVQASTYVQRAHMYSLRCAAEEKCL 354 
DrLoxl5a        ----PQRE---TGHGTRYFLNG----LPDLIPDPYYIQAASYIQRVQMYTLRCAAEENCL 316 
DrLoxl5b        ----PRRPPPGTGYGTRFFQNG----LPDLVPDPYSIQAGSYIQRVQMYALRCAAEENCL 273 
                            . *: :        ****: **  :**.:*:*:  :* *******:** 
 
HsLOX           ASTAYRADVRDYDHRVLLRFPQRVKNQGTSDFLPSRPRYSWEWHSCHQHYHSMDEFSHYD 305 
DrLox           ASSAYRSSVRDYDMRMLLRFPQRVKNQGTSDFLPSRPRYTWEWHSCHQHYHSMDEFSHYD 296 
HsLOXL1         ASTAYAPEATDYDVRVLLRFPQRVKNQGTADFLPNRPRHTWEWHSCHQHYHSMDEFSHYD 462 
DrLoxl1         ASSAYNAETTDYSVRVLLRFPQRVKNQGTADFMPNRPRHTWEWHSCHQHYHSMDEFSHYD 414 
DrLoxl5a        SSSAYSSSVRDLDYRVLLRFPQRVKNQGTADFLPVKPHYDWEWHSCHQHYHSMDAFSNYD 376 
DrLoxl5b        ARTAYRPTVRDLDYRVLLRFPQKVRNMGTADFLPVKPRHQWEWHSCHQHYHSMDAFSHYD 333 
                : :** . . * . *:******:*:* **:**:* :*:: ************** **:** 
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HsLOX           LLDANTQRRVAEGHKASFCLEDTSCDYGYHRRFACTAHTQGLSPGCYDTYGADIDCQWID 365 
DrLox           LLDATTHRRVAEGHKASFCLEDTSCDYGYYRRYACTSHTQGLSPGCYDTYNADIDCQWID 356 
HsLOXL1         LLDAATGKKVAEGHKASFCLEDSTCDFGNLKRYACTSHTQGLSPGCYDTYNADIDCQWID 522 
DrLoxl1         LLEVSSGRKVAEGHKASFCLEDTTCDFGHLKRYACTAHTQGLSPGCFDTYNADIDCQWID 474 
DrLoxl5a        LLDAATGRKVAEGHKASFCLEDTSCDPGVRRRYACTAHTQGLGPGCYDTYHANIDCQWID 436 
DrLoxl5b        LLDISTGRKVAEGHKASFCLEDTGCDPGFHRRYACTAHTQGLSPGCHDTYAANIDCQWID 393 
                **:  : ::*************: ** *  :*:***:*****.***.*** *:******* 
 
HsLOX           ITDVKPGNYILKVSVNPSYLVPESDYTNNVVRCDIRYTGHHAYASGCTISPY 417 
DrLox           ITDVKPGNYILKVSVNPSYQVPESDYSNNVVRCDVRYTGNYAYVSGCHISQY 408 
HsLOXL1         ITDVQPGNYILKVHVNPKYIVLESDFTNNVVRCNIHYTGRYVSATNCKIVQS 574 
DrLoxl1         ITDVQPGNYILKLQVNPKYLVLESDFTNNIVRCNIHYTGRYAKTTNCKISQS 526 
DrLoxl5a        ITDVSPGDYILKVTVNPGFQVQGSDFSNNIVRCDIRYTGLYVQTNNCRITG- 487 
DrLoxl5b        ITDVPPGNYILKVTVNPDFLVAESDFSNNVVRCEVIYTGIYIQTRNCIITG- 444 
                **** **:****: *** : *  **::**:***:: *** :  . .* *    
 
B 
 
HsLOXL2         MERPLCSHLCSCLAMLALLSPLSLAQYDSWPHYPEYFQQPAPEYHQPQAPANVAKIQLRL 60 
DrLoxl2a        ------MAVSSA----LCVFGL-------LVLVQAQSELQQ------------PKIELRL 31 
DrLoxl2b        -----MLALWSISFVLLCSWRLSYAQYEHLGFAIAYQEPEQDLYTPPELPADTPRIQLRL 55 
                        : *          *               :               .:*:*** 
 
HsLOXL2         AGQKRKHSEGRVEVYYDGQWGTVCDDDFSIHAAHVVCRELGYVEAKSWTASSSYGKGEGP 120 
DrLoxl2a        AGDKRKHYEGRLEVFYNNEWGTVCDDDFSIEAAHVACRQLGFLGAVAWSPSAKFGQGEGR 91 
DrLoxl2b        AGEKRKHNEGRVEVFYEGEWGTVCDDDFTIHAAQVICRELGYFEAISWSPSSKYGKGEGR 115 
                **:**** ***:**:*:.:*********:*.**:* **:**:. * :*:.*:.:*:***  
 
HsLOXL2         IWLDNLHCTGNEATLAACTSNGWGVTDCKHTEDVGVVCSDKRIPGFKFDNSLINQIENLN 180 
DrLoxl2a        IWLDNVHCTGRENSLAACPSNGFGVSDCRHSEDVGVICNQKRIPGHRFINIMNNNIETLE 151 
DrLoxl2b        IWFDNVHCKGKEKSLAQCESNGIGVSDCKHSEDVGVVCSDKRIPGFKFVNTLTNNINSLN 175 
                **:**:**.*.* :** * *** **:**:*:*****:*.:*****.:* * : *:*:.*: 
 
HsLOXL2         IQVEDIRIRAILSTYRKRTPVMEGYVEVKEGKTWKQICDKHWTAKNSRVVCGMFGFPGER 240 
DrLoxl2a        ERVEEIRIRPISS-HLKRIPITEGYVEVKEWGKWRQICDEEWTPLNSRVVCGMYGFPGEK 210 
DrLoxl2b        IQVEDVRIRPILASYRKRIPVTEGYVEVKDGGKWKQICDDEWTQMNSRVICGMFSFPGQK 235 
                 :**::***.* : : ** *: *******:  .*:****..**  ****:***:.***:: 
 
HsLOXL2         TYNTKVYKMFASRRKQRYWPFSMDCTGTEAHISSCKLGPQVSLDPMKNVTCENGLPAVVS 300 
DrLoxl2a        NYNNKVYRSLSMRKKKNYWGFLVNCTGNEAHMSSCRLG--KALEPKRNGTCGRGLPVVVS 268 
DrLoxl2b        RYNTRVYKMFARRRKPSYWDYTINCTGKEAHLSSCTLG--HTLS---NSTCEEGTPVVVS 290 
                 **.:**: :: *:*  ** : ::***.***:*** **   :*.   * ** .* *.*** 
 
HsLOXL2         CVPGQVFSPDGPSRFRKAYKPEQPLVRLRGGAYIGEGRVEVLKNGEWGTVCDDKWDLVSA 360 
DrLoxl2a        CVPGRAFAPSSSIGFRKAYRPEQPLVRLRGGANVGEGRVEVLKNGVWGTVCDDNWNLKAA 328 
DrLoxl2b        CIPGRAFAPTPMTGYKKAFRQEQPLVRLRGGAVVGEGRVEVLKNGEWGTICDDNWNLLAA 350 
                *:**:.*:*     ::**:: *********** :*********** ***:***:*:* :* 
 
HsLOXL2         SVVCRELGFGSAKEAVTGSRLGQGIGPIHLNEIQCTGNEKSIIDCKFNA--ESQGCNHEE 418 
DrLoxl2a        TVVCRELGFGSAKEALTGAKLGQGMGPVHMNEVECSGFEKSLTDCYFNN--DALGCSHEE 386 
DrLoxl2b        TVVCRELGFGSAKEALSGGQLGQGMGPVHMNEVQCSGFEKSVTECSFNMEKDSEGCSHEE 410 
                :**************::*.:****:**:*:**::*:* ***: :* **   :: **.*** 
 
HsLOXL2         DAGVRCNTPAMGLQKKLRLNGGRNPYEGRVEVLVERNGSLVWGMVCGQNWGIVEAMVVCR 478 
DrLoxl2a        DAAVRCNVPAMGFQKRIRLSGGRNPFEGRVEVLAEKNGSLVWGTVCSENWGIIEAMVVCR 446 
DrLoxl2b        DAGVKCNVPAMGFQQRLRLSGGRNPFEGRVEVLVERNGSLVWGTVCGEGWTTMEAMVVCR 470 
                **.*:**.****:*:::**.*****:*******.*:******* **.:.*  :******* 
 
HsLOXL2         QLGLGFASNAFQETWYWHGDVNSNKVVMSGVKCSGTELSLAHCRHDGEDVACPQGGVQYG 538 
DrLoxl2a        QLGLGFASHAFQETWYWAGDANADNVVMSGVRCSGTEMSLPQCLHHGKHINCPKGGGRFA 506 
DrLoxl2b        QLGLGFASNAFQETWYWPGAVNADAVVMSGVRCAGTEMSLSHCLHHGEYLSCPKGGGRFA 530 
                ********:******** * .*:: ******:*:***:**.:* *.*: : **:** ::. 
 
HsLOXL2         AGVACSETAPDLVLNAEMVQQTTYLEDRPMFMLQCAMEENCLSASAAQTDPTTGYRRLLR 598 
DrLoxl2a        AGVSCSDTAPDLVLNAQLVEQTTYLEDRPMYALQCALEENCLSSTARKNDHSS-YRRLLR 565 
DrLoxl2b        AGVSCSETAPDLVLNPQVVEQTTYLEDRPMFMLQCAYEENCLASTSSATPANS-PRRLLR 589 
                ***:**:********.::*:**********: **** *****::::  .  .:  ***** 
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HsLOXL2         FSSQIHNNGQSDFRPKNGRHAWIWHDCHRHYHSMEVFTHYDLLNLNGTKVAEGHKASFCL 658 
DrLoxl2a        FSSQIHNVGQSDFRPKLGYHAWTWHECHRHYHSMEVFTHYDLLSLNGTKVAEGHKASFCL 625 
DrLoxl2b        FSSQIHNNGQSDFRPKISRENWVWHDCHRHYHSMEVFTHYDLLSTNGTKVAEGHKASFCL 649 
                ******* ******** . . * **:*****************. *************** 
 
HsLOXL2         EDTECEGDIQKNYECANFGDQGITMGCWDMYRHDIDCQWVDITDVPPGDYLFQVVINPNF 718 
DrLoxl2a        EDTHCDEGISKRYHCANFGEQGITVGCWDTYRHDIDCQWIDVTDVKPGDYIFQVVINPNY 685 
DrLoxl2b        EDSECDEGIEKRYECANFGEQGITVGCWDTYRHDIDCQWVDITDVKPGDYIFQIVINPNY 709 
                **:.*: .*.*.*.*****:****:**** *********:*:*** ****:**:*****: 
 
HsLOXL2         EVAESDYSNNIMKCRSRYDGHRIWMYNCHIGGSFSEETEKKFEHFSGLLNNQLSPQ 774 
DrLoxl2a        DVAESDYTNNVMKCKCRYDGYRIWTYSCHIGGSRSSD-MDEYS---GMSNQLNHLR 737 
DrLoxl2b        EVAESDYTNNIVKCRCRYDGHRIWMYNCHIGGSFSAETEDTFP---GLINNQVTHR 762 
                :******:**::**:.****:*** *.****** * :  . :    *: *:    : 
 
C 
 
HsLOXL3         MRPVSVWQWSPWGLLLCLLCSSCLGSPSPSTGPEKKAGSQGLRFRLAGFPRKPYEGRVEI 60 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
HsLOXL3         QRAGEWGTICDDDFTLQAAHILCRELGFTEATGWTHSAKYGPGTGRIWLDNLSCSGTEQS 120 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
HsLOXL3         VTECASRGWGNSDCTHDEDAGVICKDQRLPGFSDSNVIEVEHHLQVEEVRIRPAVGWGRR 180 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
HsLOXL3         PLPVTEGLVEVRLPDGWSQVCDKGWSAHNSHVVCGMLGFPSEKRVNAAFYRLLAQRQQHS 240 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
HsLOXL3         FGLHGVACVGTEAHLSLCSLEFYRANDTARCPGGGPAVVSCVPGPVYAASSGQKKQQQSK 300 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
HsLOXL3         PQGEARVRLKGGAHPGEGRVEVLKASTWGTVCDRKWDLHAASVVCRELGFGSAREALSGA 360 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
HsLOXL3         RMGQGMGAIHLSEVRCSGQELSLWKCPHKNITAEDCSHSQDAGVRCNLPYTGAETRIRLS 420 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
HsLOXL3         GGRSQHEGRVEVQIGGPGPLRWGLICGDDWGTLEAMVACRQLGLGYANHGLQETWYWDSG 480 
DrLoxl3a        ------------------------------------------------------------ 
DrLoxl3b        ------------------------------------------------------------ 
XlLoxl3         ------------------------------------------------------------ 
                                                                             
 
 
 55 
HsLOXL3         NITEVVMSGVRCTGTELSLDQCAHHGTHITCKRTGTRFTAGVICSETASDLLLHSALVQE 540 
DrLoxl3a        ----MVMSGVKCKGDEMTLTDCQHH-SVVSCKRAGAQFSAGVICSDMASDLVLNAPLVEQ 55 
DrLoxl3b        ----MVMSGVKCTGDEMSISQCQHH-RTVNCQKAAARFAAGVICSETASDLVLNAPLVQQ 55 
XlLoxl3         ----MVLSGVRCTGREMSLEQCSHH-SSVSCKNTGTRHAAGVICSETASDLVLHSSLVQE 55 
                    :*:***:*.* *::: :* **   :.*:.:.::.:******: ****:*::.**:: 
 
HsLOXL3         TAYIEDRPLHMLYCAAEENCLASSARSANWPYGHRRLLRFSSQIHNLGRADFRPKAGRHS 600 
DrLoxl3a        TVYIEDRPLHLLYCAAEENCLAKSAAQASWPYGHRRLLRFSSEIHNIGKADFRPRLGRHS 115 
DrLoxl3b        TTYIEDRPLHMLYCAAEEDCLSKSAASANWPYGHRRLLRFSSQIHNIGRADFRPKAGRHS 115 
XlLoxl3         TAYIEDRPLHMLYCAAEENCLSSSARHANWPYGHRRLLRFSSQIHNNGRADFRPKAGRHS 115 
                *.********:*******:**:.**  *.*************:*** *:*****: **** 
 
HsLOXL3         WVWHECHGHYHSMDIFTHYDILTPNGTKVAEGHKASFCLEDTECQEDVSKRYECANFGEQ 660 
DrLoxl3a        WVWHECHRHYHSMDIFTYYDLLSLNGTKVADGHKASFCLEDTECHEGVSKRYECANFGEQ 175 
DrLoxl3b        WVWHACHGHYHSMDIFTHYDLMSANGTKVAEGHKASFCLEDTDCDEGVSKRYECANFGEQ 175 
XlLoxl3         WVWHECHGHYHSMDIFTHYDMLTPNGTKVAEGHKASFCLEDSECQELVSKRYECANFGEQ 175 
                **** ** *********:**::: ******:**********::*.* ************* 
 
HsLOXL3         GITVGCWDLYRHDIDCQWIDITDVKPGNYILQVVINPNFEVAESDFTNNAMKCNCKYDGH 720 
DrLoxl3a        GITVGCWDLYRHDIDCQWIDITDVSPGNYILQVIINPNFEVAESDFTNNAMRCNCKYDGH 235 
DrLoxl3b        GITVGCWDLYRHDIDCQWIDITDVKPGNYILQVVINPNYEVSESDFTNNAMKCNCKYDGH 235 
XlLoxl3         GITVGCWDLYRHDIDCQWIDITDVKPGNYILQVVINPNFEVAESDFTNNAMKCNCKYDGH 235 
                ************************.********:****:**:*********:******** 
 
HsLOXL3         RIWVHNCHIGDAFSEEANRRFERYPGQTSNQII--------------------- 753 
DrLoxl3a        RVWLHKCHLGDSFSEEAEKEFEHYPGQLNNKIS--------------------- 268 
DrLoxl3b        RIWVHNCHIGDAFSEEAEKKFEKYPGQLNNQIS--------------------- 268 
XlLoxl3         RIWIHNCHLGDAFSEEANKRFEHTGENLTTRYFDAWFSTGLKTPSFFATRNKLE 289 
                *:*:*:**:**:*****::.**:   : ..:                        
 
 
Supplementary Figure 2 
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Supplementary Figure 3 
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Specific Morpholino Dose of 
morpholino (ng)  
# of embryos 
examined 
Phenotype of notochord distortion 
- + 
loxl1/loxl2b 2.4/1.6 53 49 (100%) 0 (0%) 
loxl1/loxl3b 2.4/5 49 32 (78%) 9 (22%) 
loxl2b/loxl3b 1.6/5 44 18 (100%) 0 (0%) 
loxl2b/loxl5b 1.6/5 45 26 (90%) 3 (10%) 
loxl3b/loxl5b 5/5 42 32 (86%) 5 (14%) 
 
 
Supplementary Table 1 
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Supplementary Figure 4 
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Abstract 
2-Mercaptopyridine-N-oxide causes notochord distortion in zebrafish embryos similar to 
what is observed after lysyl oxidase cuproenzyme inhibition with -aminopropionitrile. 
We demonstrate in vitro that 2-mercaptopyridine-N-oxide potently inhibits amine oxidase 
activity in adult zebrafish extracts. We also demonstrate that 2-mercaptopyridine-N-oxide 
causes notochord distortion in haploid embryos at nanomolar concentrations, making it 
practical to conduct forward genetic sensitivity screens using a sub-threshold dose of this 
compound. 
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Introduction 
The notochord is one of the most conspicuous organs visible during zebrafish 
embryogenesis, allowing pharmacologic compounds that affect notochord formation to 
be easily identified. 2-Mercaptopyridine-N-oxide was noted to recapitulate the notochord 
distortion observed in copper-deficient zebrafish embryos without diminishing melanin 
pigmentation except at very high concentrations (74). Based on the known hierarchy of 
copper metabolism (14), this suggested that copper chelation is not the principal mode of 
action of 2-mercaptopyridine-N-oxide and that this compound directly inhibits the lysyl 
oxidases required for notochord formation. We demonstrate by biochemical assay that 2-
mercaptopyridine-N-oxide potently diminishes amine oxidase activity in adult zebrafish 
extracts and that it causes notochord distortion in gynogenetic haploid embryos. 
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Materials and methods 
Zebrafish maintenance 
Zebrafish were reared under standard conditions at 28.5C (33) and staged as described 
(34). All experiments were carried out in accordance with Washington University‟s 
Division of Comparative Medicine guidelines.  
Pharmacologic treatment 
Pharmacologic compounds were purchased from Sigma-Aldrich (St. Louis, MO). β-
Aminopropionitrile (A3134) and 2-mercaptopyridine-N-oxide (188549) were prepared as 
100 mM stocks in water and dimethyl sulfoxide, respectively, and diluted in water. For 
experiments with haploid embryos, egg water (33) was used instead of water and 
embryos were placed in compound between 3 and 6 hpf.  
Lysyl oxidase assay (75) 
Fish were euthanized and pulverized in liquid nitrogen with a mortar and pestle. The 
powder was collected in PBS and rocked for 1 h at 4 °C before centrifuging at 10 000 g 
for 30 min to obtain an insoluble fraction, which was mechanically homogenized and 
extracted overnight in 6 M urea–50 mM sodium borate pH 8.2 with agitation at 4 °C. The 
supernatant was isolated after a second centrifugation at 30 000 g for 30 min and diluted 
to 1.2 M urea with 50 mM sodium borate, pH 8.2. Lysates were then concentrated using 
Amicon YM-10 columns and the flow-through saved. 
 Assays were carried out in triplicate at 37 °C using 150 µL of lysate or flow-
through and 50 µL of a 4x reaction buffer containing 4 U mL
–1
 type II horseradish 
peroxidase, 40 mM cadaverine, and 40 µM Amplex UltraRed in 1.2 M urea–50 mM 
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sodium borate, pH 8.2. Amplex UltraRed fluorescence was measured at defined intervals 
using an excitation of 560 nm and an emission of 590 nm. For each sample, the 
background fluorescence of the corresponding flow-through with or without drug was 
subtracted to generate a corrected fluorescence, reported in relative fluorescent units 
(RFU). 
Haploid embryo generation 
Gynogenetic haploid embryos were generated as described (33). Briefly, sperm from 
multiple adult male fish was pooled in 300 L of Hank‟s buffer (“Final”), deposited on a 
chilled watch glass, and subjected to UV irradiation for 7 seconds at maximum power in 
a UV Stratalinker 1800 (Stratagene). It was then collected with a new tip and stored on 
ice. 10 L aliquots were used to fertilize individual clutches from female fish. 
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Results 
2-Mercaptopyridine-N-oxide inhibits zebrafish amine oxidase activity in vitro 
Work performed by our collaborators demonstrated that wild-type diploid embryos 
exposed to nanomolar concentrations of 2-mercaptopyridine-N-oxide develop a 
phenotype of notochord distortion similar to the one obtained with lysyl oxidase 
inhibition. To determine whether 2-mercaptopyridine-N-oxide inhibits zebrafish amine 
oxidase activity in vitro, we performed a biochemical assay (75) using extracts from adult 
fish. In this assay, addition of 500 μM β-aminopropionitrile inhibited amine oxidase 
activity almost 80%, while addition of 5 μM 2-mercaptopyridine-N-oxide reduced 
activity by almost 30% (Fig. 1). Interestingly, addition of both compounds resulted in an 
additive effect, suggesting that the mechanisms of action of β-aminopropionitrile and 2-
mercaptopyridine-N-oxide are different. Approximately the same amount of inhibition is 
obtained with 100 μM β-aminopropionitrile as with 5 μM 2-mercaptopyridine-N-oxide 
(data not shown), reflecting the greater potency of β-aminopropionitrile as a lysyl oxidase 
inhibitor in vitro. Importantly, β-aminopropionitrile causes notochord distortion in wild-
type zebrafish embryos at millimolar concentrations (see Chapter 2), confirming that 2-
mercaptopyridine-N-oxide also has superior potency in vivo. Concentrations of 2-
mercaptopyridine-N-oxide higher than 5 μM could not be used in the assay because they 
diminished fluorescence non-specifically. 
2-mercaptopyridine-N-oxide causes notochord distortion in haploid embryos 
We next tested the effect of 2-mercaptopyridine-N-oxide on wild-type gynogenetic 
haploid embryos to determine if this compound would be useful in a forward genetic 
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sensitivity screen. Titration experiments revealed consistent notochord distortion at 
concentrations of 200 nM and no distortion at 50 nM (Table 1). This was of particular 
interest because -aminopropionitrile lacks the potency to induce notochord distortion in 
gynogenetic haploid embryos at concentrations as high as 1 mM(Table 2). 
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Discussion 
Taken together with detailed studies conducted by our collaborators, the phenotypic and 
biochemical data presented here demonstrate that lysyl oxidases are direct targets of 2-
mercaptopyridine-N-oxide. In addition, the titration experiments (Table 1) reveal that this 
compound induces notochord distortion in gynogenetic haploid embryos, a finding that 
now permits forward genetic sensitivity screens where notochord formation is examined 
in the context of impaired lysyl oxidase function.  
The in vitro inhibition of amine oxidase activity observed with -
aminopropionitrile provides biochemical evidence for the evolutionary conservation of 
lysyl oxidase enzymatic activity between zebrafish and mammals. While 1 mM -
aminopropionitrile does not cause notochord distortion in gynogenetic haploids, higher 
concentrations of this inhibitor may result in the anticipated phenotype. 
These studies suggest that high-throughput screening of pharmacologic 
compounds could be used to identify additional lysyl oxidase inhibitors by examining 
embryos for the phenotype of notochord distortion in the context of normal melanin 
pigmentation. Inhibitors of specific lysyl oxidase family members would help elucidate 
the individual roles of these proteins in development and could be useful in preventing 
hypoxia-induced cancer metastasis (54).  
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Figure legends  
Fig. 1. 2-Mercaptopyridine-N-oxide inhibits lysyl oxidase activity. Lysyl oxidase 
activity in crude fish extracts was measured in the absence and presence of a known lysyl 
oxidase inhibitor β-aminopropionitrile (βAPN) or 2-mercaptopyridine-N-oxide (MCP) or 
both combined. Data shown is representative of three separate experiments and activity is 
presented in relative fluorescent units with each data point as the mean of three triplicate 
measurements, error bars indicate standard deviation. 
Table 1. 2-Mercaptopyridine-N-oxide causes notochord distortion in haploid 
embryos. Gynogenetic haploid embryos were incubated in increasing concentrations of 
2-mercaptopyridine-N-oxide and examined for notochord distortion at 24 hpf. Some but 
not all embryos in 75 nM 2-mercaptopyridine-N-oxide exhibited notochord distortion. All 
embryos in 200 nM 2-mercaptopyridine-N-oxide exhibited notochord distortion.  
Table 2. Effect of -aminopropionitrile on notochord formation in haploid embryos. 
Gynogenetic haploid embryos were incubated in increasing concentrations of -
aminopropionitrile and examined for notochord distortion at 24 hpf. Notochord distortion 
was not observed at concentrations of -aminopropionitrile ranging from 50 M to 1 
mM.  
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Abstract 
Recent studies demonstrate that lysyl oxidase cuproenzymes are critical for zebrafish 
notochord formation, but the molecular mechanisms of copper-dependent notochord 
morphogenesis are incompletely understood. We therefore conducted a forward genetic 
screen for zebrafish mutants that exhibit notochord sensitivity to lysyl oxidase inhibition, 
yielding a mutant with defects in notochord and vascular morphogenesis, puff daddy
gw1
 
(pfd
gw1
). Meiotic mapping and cloning reveal that the pfd
gw1
 phenotype results from 
disruption of the gene encoding the extracellular matrix protein fibrillin-2, and the spatio-
temporal expression of fibrillin-2 is consistent with the pfd
gw1
 phenotype. Furthermore, 
each aspect of the pfd
gw1
 phenotype is recapitulated by morpholino knockdown of 
fibrillin-2. Taken together, the data reveal a genetic interaction between fibrillin-2 and the 
lysyl oxidases in notochord formation and demonstrate the importance of fibrillin-2 in 
specific early developmental processes in zebrafish.  
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Introduction 
Structural birth defects are a significant cause of morbidity and mortality in humans and 
result from both genetic and environmental factors (76-78). Nutrition is a critical 
environmental factor affecting early development (29), and deficiencies in several 
nutrients during pregnancy are known to cause structural birth defects (77, 79). As 
nutritional status can now be increasingly interpreted within a specific genetic context, 
identification of alleles that confer susceptibility to nutritional or metabolic abnormalities 
may allow for therapeutic intervention or prevention of birth defects. Zebrafish provide a 
genetically tractable model to examine gene-nutrient interactions during early vertebrate 
development as early morphogenesis can be directly observed and levels of specific 
nutrients precisely controlled in the embryonic milieu via pharmacologic manipulation 
(14, 30, 80). 
The zebrafish notochord is well suited to the study of gene-nutrient interactions 
during development. This prominent organ is easily visualized, consisting of a series of 
notochord vacuolar cells that exert turgor pressure on an extracellular matrix sheath (31). 
The notochord provides axial support to the growing embryo, is essential for subsequent 
vertebral column formation, and secretes signaling molecules required for neural 
patterning, muscle differentiation, and cardiac formation (16). Furthermore, defects in 
extracellular matrix formation lead to compromised notochord sheath function and 
notochord abnormalities and therefore can be readily detected. Indeed, large forward 
genetic screens (17, 18) have established the importance of laminins and coatomer 
proteins in notochord differentiation and sheath formation (19, 20).  
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The fibrillins are a family of extracellular matrix proteins that form 10 nm-
diameter microfibrils around the notochord and in other tissues during development (81-
84). The human genome encodes three fibrillins which are numbered sequentially, have a 
highly modular and conserved domain organization, and exhibit about 68% amino acid 
identity with each other (85). Because of this similarity, fibrillin family members have 
historically been distinguished by a few salient features, including a single internal 
unique region which is proline-rich in fibrillin-1, glycine-rich in fibrillin-2, and 
proline/glycine-rich in fibrillin-3 (84). The composition of this domain, which may act as 
a hinge region (86), is thought to contribute to functional differences between individual 
family members (84). In addition, the number and location of integrin-binding RGD-
motifs and N-glycosylation sites differ between family members (84). While little is 
known about fibrillin-3, the other fibrillins have a long history and were first studied in 
avian development using monoclonal antibodies to fibrillin-1 (clone 201) (87) and 
fibrillin-2 (the JB3 antibody) (82). In particular, the role of fibrillin-2 in embryo 
patterning and axis formation has been extensively studied in avians (88-90).   
Our laboratory has recently delineated the phenotype of copper deficiency in a 
zebrafish model of Menkes disease, which includes a strikingly distorted notochord (14). 
This notochord distortion is due to the inhibition of two specific copper-dependent lysyl 
oxidases that normally crosslink collagens and other extracellular matrix proteins in the 
notochord sheath (80). Partial disruption of collagen II, a lysyl oxidase substrate and 
notochord sheath protein, sensitizes embryos to notochord distortion after suboptimal 
copper nutrition or partial lysyl oxidase inhibition, demonstrating a complex interplay of 
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gene dosage and nutrient availability critical to notochord formation (80). To understand 
the molecular mechanisms of notochord formation in relation to copper nutrition, we 
conducted a forward genetic screen for mutants exhibiting notochord sensitivity to lysyl 
oxidase inhibition. In this current study, we report the identification and characterization 
of one such mutant with defects in notochord and vascular morphogenesis, puff daddy 
(pfd
gw1
).   
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Materials and methods 
Zebrafish maintenance 
Zebrafish were reared under standard conditions at 28.5C (33) and staged as described 
(34). Synchronous, in vitro fertilized embryos were obtained for all experiments, which 
were carried out in accordance with Washington University‟s Division of Comparative 
Medicine guidelines. AB stocks were used except when pfd
gw1 
was crossed to WIK for 
mapping and to Tg(fli1a:EGFP)
y1
 (91) for visualization of vascular defects. In Figs. 1, 2, 
3A-D, 4, 5, 7A-J, and 8, “wild-type” refers to either +/+ or +/- embryos, which could not 
be phenotypically distinguished. 
Chemical mutagenesis and forward genetic screening 
Mutagenesis was carried out with N-ethyl-N-nitrosourea according to standard methods 
(92). Briefly, male zebrafish were incubated for 1 hour in 3 mM N-ethyl-N-nitrosourea at 
weekly intervals for five consecutive weeks and outcrossed to generate F1 carriers 
(AB*/AB) after a rest period. Gynogenetic haploid offspring from F1 females were 
screened using a dose (50 nM) of the lysyl oxidase inhibitor 2-mercaptopyridine-N-oxide 
(74) that is slightly lower than the dose required to cause notochord distortion in 
haploids. In addition, frank notochord mutants detected in concurrent screens were also 
interrogated for notochord sensitivity to partial lysyl oxidase inhibition by this method. 
Random intercrosses of F2 progeny confirmed transmission of the mutation. 
Microscopy 
Live embryos were anesthetized in tricaine, mounted in 2% methylcellulose, and imaged 
using either Olympus SZX12 (bright-field) or Olympus MVX10 (fluorescent) 
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microscopes fitted with Olympus DP70 cameras. Frozen sections mounted on slides were 
imaged using an Olympus BX60 microscope fitted with a Zeiss AxioCam. Electron 
microscopy was carried out as previously described (80). 
Pharmacologic treatment 
All pharmacologic compounds were purchased from Sigma-Aldrich (St. Louis, MO) 
except losartan, which was purchased from AK Scientific, Inc. (Mountain View, CA). β-
Aminopropionitrile (A3134) was prepared as a 100 mM stock in egg water (33) and 
diluted in egg water; neocuproine (N1501) and 2-mercaptopyridine-N-oxide (188549) 
were prepared as 100 mM stocks in dimethyl sulfoxide and diluted in egg water. Losartan 
(I497) was prepared as a 50 mM stock in dimethyl sulfoxide, diluted in water, and used at 
final concentrations of 5 and 50 M. Embryos were incubated in each compound starting 
at 3-6 hpf. Statistical analysis was performed as previously described (80).  
Meiotic mapping 
F2 carriers were mapcrossed to the polymorphic WIK strain and the progeny (AB*/WIK) 
raised to adulthood. The pfd
gw1
 mutation was assigned to chromosome 22 by centromeric 
linkage analysis (26, 93) using simple sequence length polymorphism (SSLP) markers 
(94) and DNA from early pressure gynogenetic diploids. For fine mapping, 597 mutant 
embryos from AB*/WIK females crossed to AB*/AB males were collected and assessed 
for recombination along chromosome 22 by SSLP analysis. Embryos were incubated in 2 
M neocuproine to accentuate the mutant phenotype and facilitate rapid mutant 
identification. When necessary, candidate marker primer pairs for BAC sequences were 
generated using the Zebrafish SSR search website of the Massachusetts General Hospital 
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(http://danio.mgh.harvard.edu/markers/ssr.html). Primers for the BAC markers used in 
Fig. 6A are: zC124A3 – forward 5‟-GAGTGTTGCAAGTGTAACTTGCCC-3‟ and 
reverse 5‟-ATGGGAAACTAGTTATTTGGCACAG-3‟; zC239M17 – forward 5‟-
GAGTCTAATCAGTGGAGACTTGG-3‟ and reverse 5‟-
CGTACAGATGCTGATCTGGG-3‟; zK49M19 – forward 5‟-
GCATCGTTGCAACTTGCTT-3‟ and reverse 5‟-
TGATGGCAGAATAGTTTCACACA-3‟; bZ36A1 – forward 5‟-
GGCAATAGATTTCAAAGGTGTTTT-3‟ and reverse 5‟-
AATCCAAGGCAATGCAGAAA-3‟. DNA from wild-type and heterozygote embryos as 
well as WIK and AB grandparents was used to ensure polymorphism between AB and 
WIK. Based on available genetic maps of the zebrafish genome (94, 95), the pfd
gw1
 
mutation was localized to a telomeric region of chromosome 22.   
Cloning and protein annotation 
Zebrafish fibrillin-2 was cloned first in pieces and then in its entirety using Superscript III 
reverse transcriptase (Invitrogen) and Phusion DNA polymerase with high-fidelity buffer 
(Finnzymes). The pfd
gw1
 mutation was initially detected by cloning the 5‟ end of fibrillin-
2 from mutant embryo and wild-type adult fin cDNA into pCRII (Invitrogen) using 
forward primer 5‟-AGGGTGAGGCACATTTACCG-3‟ and reverse primer 5‟-
GTGTCTTCACACTCGTCGATG-3‟. Full-length wild-type fibrillin-2 was subsequently 
cloned into pCR-XL-TOPO (Invitrogen) after amplification from 52 hpf embryo cDNA 
using forward primer 5‟-AGGGTGAGGCACATTTACCG-3‟ and reverse primer 5‟-
CTGCAGTGAAGGGCATAGGG-3‟. Full-length clones from 3 separate PCR reactions 
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were sequenced and compared, allowing mutations introduced during PCR to be 
identified. No alternative splice forms were detected. The start site of fibrillin-2 was 
confirmed by 5‟ rapid amplification of cDNA ends (RACE) using wild-type RACE-ready 
cDNA from 15-somite embryos and the primer 5‟-
GACCCTCTGCTGCACCTCCCCCTCAG-3‟. The full-length zebrafish fbn2 sequence is 
available at Genbank (accession number EU449516). The 5‟ portion of zebrafish 
fibrillin-4 (accession number EU854565) was cloned in two overlapping pieces using the 
following primer sets: A) forward primer 5‟-GCAGTCCTTCTGTTGTCCAGG-3‟ and 
reverse primer 5‟-CAGACAGATGATGACCAGGCGG-3‟ and B) forward primer 5‟- 
CCTTTCACTGTGCAATGGAGGC-3‟ and reverse primer 5‟- 
CCACATTATTGACACACCGACC-3‟. The start site was inferred from an EST 
(EE319589). The 3‟ portion of zebrafish fibrillin-4 (accession number EU854566) was 
cloned in multiple overlapping pieces using the following primer sets: A) forward primer 
5‟-CGAATGTGGTCAGAATCCTC-3‟ and reverse primer 5‟- 
CCCATGACCTCCATTACAGC-3‟ B) forward primer 5‟-
GTGAATGTGGTGTTGGGTTC-3‟ and reverse primer 5‟-
GGTGTTGTGTGTAACCCTGTGG-3‟ C) forward primer 5‟-
CCTGGGATATGTGCTCCTGG-3‟ and reverse primer 5‟-
CCCATGACCTCCATTACAGC-3‟ D) forward primer 5‟-
CGTTTAACACCACCAAAGCC-3‟ and reverse primer 5‟-
GCAGTGGCATCTGTAAGAGC-3‟. An 86 bp sequence connecting the 5‟ and 3‟ 
portions was inferred from Zv7_Scaffold988 based on the modular nature of fibrillins. A 
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253 bp extension to the 3‟ end was also inferred in this manner. The far 3‟ end and stop 
codon could not be determined. For both fibrillins, conserved protein domains were 
identified using Motif Scan (40) and by comparison with annotated orthologues (84). The 
NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/) was used to predict N-
glycosylation sites with a potential greater than 0.32. 
Phylogenetic analysis 
DNA coding sequences were aligned using ClustalW2 (96) and a phylogenetic tree was 
constructed in TOPALi v2.5 by the maximum likelihood method (PhyML) using HKY 
substitution and gamma rate models (97-99). 100 bootstrap runs were performed. Similar 
trees were obtained with MEGA4.0 using maximum parsimony or minimum evolution 
methods (100), except that pDrfbn4 diverged before all other fibrillins to form its own 
one-member group. Accession numbers for the non-zebrafish sequences used were: 
HsFBN1 – NM_000138; HsFBN2 – NM_001999; HsFBN3 – NM_032447; MmFbn1 – 
NM_007993; MmFbn2 – NM_010181; RnFbn1 – NM_031825; RnFbn2 – NM_031826; 
BtFbn1 – NM_174053; pXlfbn – DQ310728; and HsLTBP1 – NM_000627.  
Whole-mount in situ hybridization and frozen sections 
Embryos from pfd
gw1
/+ intercrosses were manually dechorionated at the indicated 
developmental stages, fixed in 4% paraformaldehyde-PBS, and dehydrated by methanol 
series. Three fibrillin-2 probe constructs were generated by cloning nonoverlapping 
fragments of the cDNA into pCRII (Invitrogen). DIG-labeled antisense RNA probes were 
synthesized from these constructs using a DIG-labeling kit (Roche), and whole-mount in 
situ hybridization performed as previously described (14, 45). All embryos of the same 
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developmental stage were processed in a single well to ensure identical reaction 
conditions. Frozen sections were prepared as described (80). 
Genotyping 
DNA was extracted from embryos or caudal fin tissue and PCR amplified using primers 
flanking the mutation: forward primer 5‟-GCGGTGTGCGAGAGCGGATG-3‟ and 
reverse primer 5‟-GCATTCTTGAAGGAGCCCCG-3‟. The resulting product was then 
digested with the restriction enzyme AvaII (New England Biolabs) for 5 hrs at 37C and 
a small aliquot run on a 10% TBE polyacrylamide gel for visualization. PCR product 
derived from the mutant allele is not cut by AvaII. For genotyping after whole-mount in 
situ hybridization, embryos were first rehydrated to PBS and incubated in 300 mM NaCl 
for 4 hours at 65°C to reverse crosslinking. They were then placed in DNA extraction 
buffer (80 mM KCl, 10 mM Tris pH 8, 1 mM EDTA, 0.3% Tween 20, 0.3% Igepal), 
boiled 10 minutes, and the DNA phenol-chloroform extracted. Genotyping was 
performed by restriction digest, as described above. 
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
RNA was obtained from pooled wild-type embryos or unfertilized eggs using Trizol 
reagent (Invitrogen) and RT-PCR performed with the SuperScript III One-Step RT-PCR 
Platinum Taq HiFi kit (Invitrogen). Half a microgram of total RNA was used per 25 L 
reaction. The primer annealing temperature was 57C and 30 cycles of PCR were 
performed. Fibrillin-2 primers were: forward primer 5‟- 
CACCTGTAAATGCCCCTCGG-3‟ and reverse primer 5‟- 
GAAGCCCACCCCATTGATGC-3‟. Spadetail primers were: forward primer 5‟-
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GAAGATGTTTACTGACCACTCAG-3‟ and reverse primer 5‟-
GCCTGTTTGTTTAAGACATT-3‟.  
Morpholino and mRNA injections  
Morpholino oligonucleotides (27) targeting start and splice sites in fibrillin-2 were 
resuspended in Danieau buffer (start MO) or water (splice MO), diluted to include 0.05% 
phenol red, and injected into 1-cell embryos. Standard control morpholino (Gene Tools, 
LLC) was resuspended in Danieau buffer and likewise injected. Morpholino sequences 
were: 5‟-GCGACTCCTGAAGCGCCGGTAAATG-3‟ (start MO) and 5‟-
GGGATACTTACGAACTATACACTGG-3‟ (splice MO). The splice MO was used at a 
dose of 1.7 ng. The loxl5b splice morpholino (5‟-
GCCTGTGGAATAAACACCAGCCTCA-3‟) was prepared as previously described (80) 
and was used at a dose of 5 ng. Capped, polyadenylated mRNA for rescue experiments 
was generated from a full-length clone of zebrafish fibrillin-2 using the mMESSAGE 
mMACHINE kit (Ambion). Individual embryos from pfd
gw1
/+ intercrosses were injected 
with between 100 and 1000 pg of mRNA in multiple separate experiments. Statistical 
analysis was performed as previously described (80). 
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Results 
The pfd
gw1
 mutation disrupts notochord and vascular development  
To elucidate the role of copper homeostasis in development, we performed a screen that 
couples N-ethyl-N-nitrosourea mutagenesis to pharmacologic sensitization using a sub-
threshold dose of the lysyl oxidase inhibitor 2-mercaptopyridine-N-oxide (74). A mutant, 
puff daddy (pfd
gw1
), was identified with notochord abnormalities (Fig. 1B, black arrow) 
and normal melanin pigmentation (Fig. 1B, white arrowhead) characteristic of the 
previously identified phenotype of impaired lysyl oxidase function. pfd
gw1
 mutants also 
display a cavernous caudal vein (Figs. 1B, D, white arrows) and fin fold attenuation 
(Figs. 1B, D, black arrowheads) not present in wild-type (+/+ and +/-) embryos at 30 hpf 
(Figs. 1A, C). Skin distention secondary to edema occurs in the lateral truncal region near 
the yolk-sac extension of pfd
gw1
 mutants by 30 hpf (Fig. 1F vs. Fig. 1E, arrowheads), and 
blood cell extravasation is visible in this space (Fig. 1F, arrow). 
The pfd
gw1
 mutation disrupts venous plexus and axial vessel formation 
To examine vascular development in pfd
gw1
 fish, pfd
gw1
 was crossed to a transgenic line 
that expresses enhanced green fluorescent protein in vascular endothelial cells (91). In 
wild-type embryos, the caudal vein forms a venous plexus with a characteristic reticular 
pattern (Fig. 2A, arrowheads), and the dorsal aorta and cardinal vein are appropriately 
lumenized (Fig. 2C, circles). In pfd
gw1
 mutants, endothelial cells are disorganized around 
a cavernous caudal vein (Fig. 2B, arrowheads), and the diameters of the large axial 
vessels are reduced to a variable degree (Fig. 2D, circles). Blood cells do not circulate in 
mutants with particularly small-diameter axial vessels despite a pumping heart (data not 
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shown), and increased vascular resistance due to reduced vessel diameter may contribute 
to the observed impaired heart contractility in pfd
gw1
 mutants (data not shown). The 
distended area in the lateral truncal region of pfd
gw1
 mutants (Fig. 1F, arrowheads) is not 
lined by fli1-expressing cells (data not shown), a finding consistent with edema. While 
the notochord, fin fold, and vascular abnormalities are consistently penetrant in clutches 
from pfd
gw1
 fish, by 3 dpf, the truncal edema resolves and blood flow occurs through the 
caudal vein in most pfd
gw1
 mutants. However, the swim bladder does not inflate, resulting 
in embryonic lethality (data not shown). 
The outer layer of the notochord sheath is disrupted in pfd
gw1
 mutants 
The phenotype of pfd
gw1
 mutants suggested a defect in notochord sheath formation, and 
we therefore imaged this organ in pfd
gw1
 mutants and wild-type embryos by transmission 
electron microscopy (Figs. 3A-D). Ultrastructurally, the notochord sheath consists of 
inner, medial, and outer layers, all of which are clearly visible in a cross-section from a 
wild-type embryo at 30 hpf (Figs. 3A, C). While the inner and medial sheath layers are 
present in pfd
gw1
 mutants, the outer layer is strikingly diminished in size at the region of 
notochord folding (Figs. 3B, D).  
pfd
gw1
 mutants are sensitized to lysyl oxidase inhibition 
Interestingly, lysyl oxidase inhibition results in impaired notochord formation without an 
effect on the outer sheath layer (Figs. 3E, F and Gansner et al., 2007), suggesting that the 
product of the pfd
gw1
 locus has roles in addition to those related to lysyl oxidase 
crosslinking. To examine this, we first incubated clutches from pfd
gw1
/+ intercrosses in 
vehicle (Figs. 4A, B and Table 1) or a dose of the copper chelator neocuproine that does 
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not cause notochord distortion in wild-type embryos (Fig. 4C, Table 1, and Gansner et 
al., 2007). Consistent with the results of our original screen, pfd
gw1
 mutants were 
sensitized to increased notochord distortion under copper-limiting conditions (Fig. 4D vs. 
Fig. 4B and Table 1), presumably due to partial inhibition of lysyl oxidase activity (80). 
To confirm this finding, we incubated clutches from pfd
gw1
/+ intercrosses in a dose of the 
irreversible lysyl oxidase inhibitor -aminopropionitrile that causes very mild notochord 
herniation in wild-type embryos (Fig. 4E, white arrowhead). Under these conditions, 
notochord sensitization in pfd
gw1
 mutants was again observed (Fig. 4F vs. Fig. 4B and 
Table 1). Importantly, pfd
gw1 
mutants could be distinguished from heterozygote and wild-
type siblings in these experiments by the cavernous caudal vein and truncal edema 
present in the mutants. These additional phenotypes are never observed after lysyl 
oxidase inhibition with neocuproine or -aminopropionitrile, even when higher doses of 
these compounds are used (80).   
 We next tested for a genetic interaction between the lysyl oxidases involved in 
late notochord formation (80) and the pfd
gw1
 product by injecting clutches from pfd
gw1
/+ 
intercrosses with control morpholino (Figs. 5A, B and Table 2) or morpholino targeting 
loxl5b (Figs. 5C, D and Table 2). The specificity of this lysyl oxidase morpholino has 
been demonstrated previously (80), and partial morpholino knockdown of loxl5b that 
does not cause notochord distortion in wild-type embryos (Fig. 5C and Gansner et al., 
2007) exacerbates the notochord phenotype of pfd
gw1
 mutants compared to control 
morpholino (Fig. 5D vs. Fig. 5B and Table 2). Once the pfd
gw1
 lesion was identified (see 
below), we genotyped a subset of 32 embryos from these experiments to confirm the 
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genotype assignments in Table 2. Each directly-determined genotype matched the one 
assigned in Table 2 (data not shown), and testing of 17 phenotypically wild-type embryos 
that appeared worse after loxl5b morpholino injection (Table 2) revealed that 15 were 
heterozygous for the pfd
gw1
 lesion (data not shown), possibly due to a slight increase in 
the sensitivity of heterozygote embryos to lysyl oxidase inhibition. 
 The consistent worsening of the notochord phenotype in pfd
gw1
 mutants after 
partial lysyl oxidase inhibition demonstrates an interaction between the pfd
gw1
 product 
and the lysyl oxidases. However, the notochord distortion observed in pfd
gw1
 mutants in 
these sensitization experiments does not adopt the characteristic sine-wave pattern seen in 
wild-type embryos treated with high-dose neocuproine (Fig. 5E), and at this dose of 
neocuproine, the notochords of pfd
gw1
 mutants never develop this classic shape (Fig. 5F 
vs. Fig. 5E). These observations, taken together with the electron microscopy studies 
(Fig. 3), suggest that the pfd
gw1
 product and the lysyl oxidases have overlapping but also 
distinct roles in late notochord formation.   
The pfd
gw1
 mutation disrupts the zebrafish fibrillin-2 gene 
To determine the molecular basis for the notochord sensitivity to lysyl oxidase inhibition 
and other phenotypes observed in pfd
gw1
 mutants, we identified the locus mutated in 
pfd
gw1
 fish (Fig. 6). Meiotic mapping localized the pfd
gw1
 lesion to a telomeric region of 
chromosome 22, and inspection of the physical genome assembly (Zv6) for candidate 
genes in this region revealed sequence coding for an extracellular matrix protein 
of the fibrillin family (Fig. 6A). A fragment of this gene is annotated as fibrillin-3 in the 
current zebrafish genome assembly (Zv7), and human orthologues to the flanking genes 
 87 
timm44 and trh1 (Fig. 6A) flank human fibrillin-3. However, BLAST searches using the 
translated fibrillin EST sequences (Fig. 6A) demonstrated better hits in both cases with 
human fibrillin-1 and fibrillin-2 than with fibrillin-3 (data not shown), suggesting that the 
zebrafish gene might exhibit greater amino acid identity to a fibrillin besides fibrillin-3. 
Sequencing of a 5‟ segment of the zebrafish fibrillin on chromosome 22 revealed 
a nonsense mutation in pfd
gw1
 mutant embryos that was absent in adult, wild-type fish 
(Fig. 6B). This mutation abrogates an AvaII restriction enzyme site, allowing wild-type 
and heterozygote embryos to be distinguished (Fig. 6C) and permitting genotyping of fish 
stocks. Genotyping of stored DNA samples confirmed that the original pfd
gw1
 mutant 
identified in our screen was heterozygous for the nonsense mutation indicated in Fig. 6B, 
and that this mutation was absent in both the WIK grandparent used for the mapcross (see 
Experimental Procedures) and the AB fish used for the outcross (data not shown). Since 
all 7 recombinants at the flanking markers shown in Fig. 6A were homozygous for the 
mutation (data not shown), the recombination rate at this location is 0% (0 out of 597 
meiotic events), consistent with the hypothesis that the nonsense mutation causes the 
pfd
gw1
 phenotype.  
 Cloning of the full-length zebrafish fibrillin on chromosome 22 revealed that it 
encodes a 2868 amino acid protein highly similar to human, mouse, and rat fibrillin-2 
(Figs. 6D, E and S. Fig. 1). In particular, the glycine-rich domain and location of the 
RGD motifs are characteristic of fibrillin-2 but not fibrillin-1 or fibrillin-3 (Figs. 6D, E 
and S. Fig. 1) (84, 85). In addition, 11 of 12 potential N-glycosylation site are conserved 
(S. Fig. 1) and two calcium-binding EGF-like domains are encoded before the first TGF-
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 binding (TB) domain (Fig. 6D and S. Fig. 1), a sequence arrangement that is observed 
in human fibrillin-2 but not in human fibrillin-3 (Fig. 6E) (85). Overall, the zebrafish 
fibrillin on chromosome 22 exhibits 75% amino acid identity with human fibrillin-2 but 
only 67% and 68% identity with human fibrillin-1 and fibrillin-3, respectively (Fig. 6E). 
In view of the high amino acid sequence identity with human fibrillin-2 and the presence 
of functional domains that have historically been used to distinguish fibrillin-2 from other 
fibrillins (the glycine-rich domain, RGD motifs, and N-glycosylation sites), we name this 
gene fibrillin-2 (fbn2). The premature stop codon identified in pfd
gw1
 mutants is predicted 
to result in a severely truncated protein product of only 161 amino acids (Fig. 6D). 
 Since the current zebrafish genome assembly (Zv7) contains a gene fragment 
annotated as fibrillin-2 on chromosome 10 (data not shown), we cloned the majority of 
this gene to determine whether it is a paralogue of zebrafish fbn2 (S. Fig. 2). Surprisingly, 
the fibrillin gene on chromosome 10 encodes a protein without RGD motifs and with a 
novel proline/glutamine-rich domain not found in any fibrillin reported to date (Fig. 6E 
and S. Fig. 3). Consistent with previous nomenclature that differentiates fibrillins based 
on these attributes (84), we name this gene fibrillin-4 (fbn4) (Fig. 6E). Compared to the 
three human fibrillins, zebrafish fibrillin-4 exhibits highest amino acid identity with 
human fibrillin-2 (Fig. 6E). However, this identity (68%) is relatively low, since it is 
comparable to the identity between individual human fibrillin family members (85). 
Importantly, zebrafish fibrillin-2 exhibits greater amino acid identity with human 
fibrillin-2 than does zebrafish fibrillin-4 (Fig. 6E). In addition, zebrafish fibrillin-2 and 
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fibrillin-4 are only 66% identical, suggesting that these zebrafish fibrillins are not 
paralogues created by a genome duplication event in teleosts (55). 
 In order to determine the evolutionary relationship of zebrafish fibrillin-2 and 
fibrillin-4 to fibrillins in other species, we performed a phylogenetic analysis based on 
nucleotide coding sequences (Fig. 6F). This revealed that zebrafish fibrillin-2 is 
evolutionarily related to human fibrillin-3, and that zebrafish fibrillin-4 is distantly 
related to human fibrillin-2 (Fig. 6F). These findings were corroborated by examining the 
exon structure of the zebrafish fibrillins. In zebrafish fbn2, a single exon encodes both the 
sixth calcium-binding EGF-like motif and the first half of the second TB domain (data 
not shown), analogous to what is observed in human fibrillin-3 but not in other human 
fibrillins (85). By contrast, the exon structure of zebrafish fbn4 at this location is identical 
to that of human fibrillin-2 (data not shown). Importantly, a putative orthologue of 
fibrillin-2 in Xenopus laevis (101, 102) clusters with zebrafish fbn2 and human FBN3 in 
the phylogenetic tree (Fig. 6F, arrow). This suggests that in fish and amphibians, a 
fibrillin with highest amino acid identity to human fibrillin-2 has evolved at the fibrillin-3 
locus.  
fbn2 expression is consistent with the pfd
gw1
 phenotype and dramatically reduced in 
pfd
gw1
 mutants 
To determine the developmental expression of zebrafish fbn2, whole-mount in situ 
hybridization was performed on embryos from pfd
gw1
/+ intercrosses (Fig. 7). fbn2 
expression is first visible during gastrulation in the hypoblast (mesendoderm) of embryos 
at 9 hpf (Fig. 7A). In 3-somite embryos, fbn2 expression occurs in the paraxial mesoderm 
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(Fig. 7B, arrowheads) and notochord (Fig. 7B, arrow), consistent with a role for zebrafish 
fibrillin-2 in notochord morphogenesis. In 7-somite embryos, fbn2 is expressed in the 
somites and notochord (Fig. 7C, arrow), with foci of increased staining present near 
notochord-somite boundaries (Fig. 7C, arrowheads). By the 20-somite stage, fbn2 is also 
expressed in the developing venous plexus (Fig. 7D, arrowhead), which forms 
abnormally in pfd
gw1
 mutants, and in the eye (Fig. 7D, arrow). Frozen sections of 20-
somite embryos revealed that this eye expression is restricted to the lens placode (Fig. 
8A, arrowheads) and demonstrated fbn2 expression in the notochord, hypochord, 
floorplate, and paraxial mesoderm (Fig. 8B). At 24 hpf, fbn2 is expressed in the 
hypochord (Fig. 7E and Fig. 8C, arrows), which plays a critical role in axial vascular 
development (57, 58), and in the fin fold epidermis (Fig. 7E and Fig. 8C, arrowheads), 
where fbn2-expressing cells form two parallel lines on either side of the midline (Figs. 
8C, D, arrowheads). Despite expression of fbn2 in the lens placode (Fig. 8A), no 
differences in lens morphology were observed by electron microscopy between pfd
gw1
 
mutants and wild-type embryos at 30 hpf (data not shown). 
 Expression of fbn2 was almost completely absent in a quarter of embryos from 
pfd
gw1
/+ intercrosses at each developmental stage (Figs. 7F-J and data not shown). At 24 
hpf, the mutant phenotype correlated with loss of fbn2 expression, and genotyping of 
embryos after in situ hybridization demonstrated an exact concordance between the 
homozygous mutant genotype and abrogation of fbn2 expression at three different stages 
of development examined (data not shown). Furthermore, heterozygote embryos 
exhibited an intermediate level of fbn2 expression (Fig. 9), revealing that compensatory 
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up-regulation of the wild-type allele does not occur in heterozygous mutant embryos. The 
reduced amount of staining in heterozygous and homozygous mutant embryos supports 
the specificity of the in situ hybridization reactions. Given the distribution of the in situ 
probes across the entire length of the zebrafish cDNA (see Experimental Procedures), 
these findings mitigate against the presence of alternative splice products and suggest 
nonsense-mediated decay of the fbn2 transcript (103). 
 We also examined the developmental onset of fbn2 expression by reverse 
transcriptase-polymerase chain reaction (RT-PCR), which is more sensitive than in situ 
hybridization (Fig. 7K). This revealed that fibrillin-2 mRNA is expressed at very low 
levels in wild-type embryos maternally and until 6-7 hpf, when it is upregulated but is not 
yet detectable by in situ hybridization (Fig. 7K and data not shown). At 9 hpf and the 3-
somite stage, more robust fbn2 expression is apparent (Fig. 7K), and this correlates with 
the detection of fbn2 by in situ hybridization (Figs. 7A, B). As a control, RT-PCR was 
performed in parallel with primers to the gene spadetail (spt) (Fig. 7K). spt expression is 
relatively constant over the time period examined except that it is not present maternally 
(Fig. 7K) (104). Importantly, an RT-PCR product was not obtained if the reactions were 
performed in the absence of RNA (Fig. 7K). 
fbn2 knockdown recapitulates the pfd
gw1
 phenotype  
To confirm that the pfd
gw1
 phenotype directly results from loss of fibrillin-2, we designed 
morpholinos to abrogate zebrafish fbn2 expression (Fig. 10). Whereas wild-type embryos 
injected with control morpholino demonstrated normal formation of the notochord, 
caudal vein, and fin folds (Figs. 10A, C), embryos injected with a fbn2 start morpholino 
 92 
exhibited notochord kinks (Fig. 10B, black arrows), a cavernous caudal vein without 
venous plexus formation (Figs. 10B, D, white arrows), and fin fold attenuation (Figs. 
10B, D, arrowheads). The fbn2 start morpholino also caused truncal skin distention 
characteristic of pfd
gw1
 mutants (Fig. 10F, arrowheads) that was not observed with control 
morpholino (Fig. 10E, arrowheads). These findings were consistent and were dose 
dependent (Table 3). The fbn2 start morpholino had no visible effect on embryos at a 
dose of 0.12 ng (Table 3), and at an intermediate dose of 0.48 ng, only a cavernous 
caudal vein with truncal edema was observed (data not shown), possibly reflecting 
differences in transcript abundance between notochord and caudal vein. At a dose of 7.2 
ng, embryos developed non-specific findings suggestive of morpholino toxicity, such as 
reduced melanin pigmentation and mild necrosis (data not shown). Injection of fbn2 start 
morpholino into pfd
gw1
 mutant embryos did not alter their phenotype (Fig. 10H vs. Fig. 
10G), indicating that the pfd
gw1
 mutation results in a null phenotype, consistent with the 
early location of the premature stop codon and the in situ hybridization findings (Fig. 6D 
and Figs. 7F-J). Importantly, it also did not result in the reduced melanin pigmentation or 
necrosis observed with high dose (7.2 ng) fbn2 start morpholino, providing evidence that 
these phenotypes are non-specific. Injection of a morpholino targeting a splice site in 
fbn2 also recapitulated the pfd
gw1
 phenotype (data not shown), further confirming the 
specificity of the fbn2 knockdown.  
 Injection of mRNA encoding full-length (9 kb) fbn2 into clutches from pfd
gw1
/+ 
intercrosses did not rescue the pfd
gw1
 phenotype, but expression of zebrafish fibrillin-2 in 
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mutant embryos could not be confirmed by western immunoblotting since none of the 
available antibodies cross-reacted with zebrafish fibrillin-2 (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
Discussion 
These data reveal a previously unappreciated role for fibrillin-2 in zebrafish notochord 
and vascular morphogenesis. Fibrillins are large glycoproteins that polymerize to form 
microfibrils in a wide variety of elastic and non-elastic connective tissues (84). 
Microfibrils associate with many different extracellular matrix proteins, bind cell-surface 
integrins, and have recently been shown to modulate the activity of soluble signaling 
factors (105). The demonstration in this current work that the notochords of pfd
gw1
 
mutants are sensitized to lysyl oxidase inhibition (Fig. 4 and Fig. 5) is consistent with the 
recent realization that microfibril structural elements are part of larger, more complex 
networks associated with impaired morphogenesis (106). Indeed, our data reveal gene-
gene and gene-nutrient interactions between fibrillin-2 and the copper-dependent lysyl 
oxidases in notochord formation that were not previously apparent. Interestingly, our 
findings are consistent with the recent discovery in yeast that whereas only ~20% of gene 
deletions have an obvious phenotypic consequence, 97% exhibit a measurable growth 
phenotype under situations of specific chemical or environmental stress (107). In 
addition, the findings add to previous elegant genetic studies that elucidated novel 
molecular pathways required for notochord sheath formation in zebrafish (16, 19, 20).  
Fibrillin gene nomenclature in zebrafish 
The zebrafish genome appears to encode three fibrillins, similar to what is observed in 
human and other vertebrate genomes (data not shown). In the current work, we present 
sequences for two of these fibrillins, which we name fibrillin-2 (fbn2) and fibrillin-4 
(fbn4) (Figs. 6D, E). The third fibrillin, a putative orthologue of fibrillin-1 (fbn1), has not 
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been cloned but has been targeted using morpholinos (108), and we have independently 
confirmed its embryonic expression (data not shown).  
 The two cloned zebrafish fibrillins are named based on amino acid identity to 
human fibrillins and on the presence of unique domains that are thought to modulate 
fibrillin function. Zebrafish fibrillin-2 exhibits the highest amino acid identity with 
human fibrillin-2 (Fig. 6E) and encodes a glycine-rich internal unique region 
characteristic of fibrillin-2 in other species (S. Fig. 1). It also possesses two RGD motifs 
located in the same relative positions as human fibrillin-2 (Figs. 6D, E, and S. Fig. 1). 
Fibrillin RGD motifs mediate interactions with specific cell-surface integrins, and 
increasing data suggest that these interactions are determined in part by the surrounding 
amino acid sequence (109-112). It is therefore not surprising that the two RGD motifs in 
fibrillin-2 have different receptor specificities (111), and the spacing of the RGD motifs, 
which differs between human fibrillin-2 and fibrillin-3, may thus affect integrin binding 
and protein function.  
In contrast to zebrafish fibrillin-2, zebrafish fibrillin-4 exhibits relatively low 
amino acid identity to human fibrillins, with only 68% identity to human fibrillin-2 (Fig. 
6E). Furthermore, zebrafish fibrillin-4 contains a novel proline/glutamine-rich internal 
unique region not found in other fibrillins and also completely lacks RGD motifs. 
Zebrafish fbn4 is thus unlikely to function as a fibrillin-2 orthologue, although it appears 
to be a distant evolutionary relative of human fibrillin-2 by phylogenetic analysis (Fig. 
6F) and is flanked by the zebrafish orthologue of SLC27A6 that flanks human fibrillin-2 
(data not shown). 
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 The zebrafish fibrillin nomenclature presented here has been informed by studies 
in amphibians (101, 102). Xenopus laevis fibrillin contains an antigenic determinant 
recognized by the JB3 antibody to fibrillin-2, and the cloned 3‟ fragment of this fibrillin 
exhibits 77% amino acid identity with human fibrillin-2 but only 68% and 71% identity 
with fibrillin-1 and fibrillin-3, respectively (101). Although the 5‟ sequence of Xenopus 
fibrillin is unknown, it seems likely based on the published expression and functional 
data that this fibrillin is an orthologue of human fibrillin-2 (101, 102). Importantly, the 
amino acid sequences of Xenopus fibrillin and zebrafish fbn2 are 75% identical over the 
region cloned, and their expression patterns are similar (see below). Since both genes 
cluster phylogenetically with human fibrillin-3 (Fig. 6F), the data suggest that Xenopus 
fibrillin and zebrafish fbn2 are functional orthologues of fibrillin-2 that have evolved at 
the human fibrillin-3 locus. The fact that fibrillin family members are already fairly 
similar (~68% amino acid identity in humans), may help to explain how this could have 
occurred.  
Conservation of fibrillin-2 gene expression 
The spatiotemporal expression of zebrafish fbn2 is similar to that of fibrillin-2 in other 
vertebrates. In chick and quail, fibrillin-2 protein localization has been directly and 
extensively studied using the JB3 monoclonal antibody (82, 90, 113, 114). In chick, the 
earliest fibrillin-2 immunostaining is detected in the primitive streak, which gives rise to 
notochord and mesodermal structures that exhibit persistent fibrillin-2 staining 
throughout development (82, 114). In particular, fibrillin-2 containing microfibrils are 
detected extracellularly around the notochord and somites (compare Figs. 7B, C), and 
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also in splanchnic mesoderm and segmental plate mesoderm, which is equivalent to 
paraxial mesoderm in zebrafish (Fig. 7B) (82, 114). In quail, immunostaining using the 
JB3 antibody revealed prominent fibrillin-2 deposition around the notochord and somites, 
as well as fibrillin-2 immunoreactivity in the primitive mesocardium and segmental plate 
mesoderm (90). Of note, fibrillin-2 appeared to physically integrate somites and 
notochord (90), which may explain the increased fbn2 expression at notochord-somite 
boundaries observed in zebrafish (Fig. 7C, arrowheads). Overall, the findings in avian 
species using the JB3 antibody are consistent with the zebrafish RT-PCR and in situ 
hybridization results reported above (Fig. 7 and Fig. 8), both in terms of time of onset 
(pre-gastrulation) and tissue distribution (compare Fig. 7B with Fig. 3 of Rongish et al., 
1998).  
Zebrafish fbn2 expression is also similar to that of Xenopus fibrillin, a putative 
orthologue of fibrillin-2 (101, 102). RNase protection assays demonstrate that Xenopus 
fibrillin is markedly upregulated in mid-gastrula embryos (101), which correlates well 
with the initial increase in zebrafish fbn2 transcript at 6-7 hpf observed by RT-PCR (Fig. 
7K). In addition, fibrillin-2 expression is first detectable by in situ hybridization during 
gastrulation in both organisms (Fig. 7A) (101). Exact comparison of fibrillin-2 expression 
between Xenopus and zebrafish at post-gastrula stages is difficult because Xenopus has a 
distinct neurulation period before segmentation whereas these stages overlap in zebrafish 
and a distinct neurulation period is absent (34). Nevertheless, Xenopus fibrillin is 
expressed in the notochord, somites, floorplate, hypochord, and eye by in situ 
hybridization (101), analogous to what is observed in zebrafish (Figs. 7B-D and Figs. 8A, 
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B). At later stages, Xenopus fibrillin is also expressed in tail fins (101), mimicking 
zebrafish fin fold expression (Fig. 7E and Figs. 8C, D). Interestingly, while notochord 
staining is stronger than somite staining in Xenopus (101), the opposite is true in 
zebrafish (Figs. 7B, C and Fig. 8B), possibly due to a differential requirement for 
fibrillin-2 in axial extension. Future studies using antibodies to zebrafish fibrillin-2 will 
be required to determine the exact timing of zebrafish fibrillin-2 protein deposition in the 
notochord-somite boundary during gastrulation, but this may occur later in zebrafish than 
in Xenopus, as is the case in chick (101).  
Fibrillin-2 expression has also been studied during human and mouse embryonic 
development. In humans, immunostaining demonstrates that fibrillin-2 has a wide tissue 
distribution and is present in fetal eye  as well as in the notochordal sheath and 
perinotochordal mesenchyme (83, 115). In mouse, a wide tissue distribution with 
prominent mesenchyme staining has been noted (116). The overall conserved expression 
pattern of fibrillin-2 argues for conservation of function among these different species. 
Functions of microfibrils 
The functions of specific microfibrillar proteins in various tissues during development are 
incompletely characterized (105). Fibrillin-2 binds multiple other microfibrillar proteins 
in vitro, including microfibril-associated glycoprotein-1 and fibrillin-1 (117-119), and 
morpholino knockdown of zebrafish microfibril-associated glycoprotein-1 or the 
predicted zebrafish fibrillin-1 results in caudal vein dilation and altered plexus formation 
(108) similar to what is observed in pfd
gw1
 mutants (Fig. 2B). A specialized type of 
heterofibril composed of fibrillin-1, fibrillin-2, and microfibril-associated glycoprotein-1 
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may thus be required for venous plexus formation in zebrafish. By contrast, tissue-
specific roles unique to fibrillin-2 are indicated by the notochord kinks, reduced axial 
vessel diameters, fin fold attenuation, and truncal edema observed in pfd
gw1
 mutants but 
not fibrillin-1 or microfibril-associated glycoprotein-1 morphants (Fig. 1 and Fig. 2 vs. 
Chen et al., 2006).  
The precise role of microfibrils in notochord formation is unclear, but our results 
suggest that microfibrils contribute to the strength of the sheath that envelops the 
notochord, at least in zebrafish. The sensitivity of the notochord phenotype in pfd
gw1
 
mutants to lysyl oxidase inhibition (Fig. 4 and Fig. 5) may result in part from an impaired 
ability to recruit or correctly position lysyl oxidases at their site of action in the notochord 
sheath, a hypothesis supported by studies demonstrating a role for microfibril-associated 
proteins in this process (50, 120). This model is also consistent with the observation that 
the heterozygote pfd
gw1
 mutants are largely unaffected by lysyl oxidase inhibition (Fig. 4 
and Fig. 5), provided that enough fibrillin-2 is present in these fish to allow for proper 
targeting of lysyl oxidase.    
 Our data from mutant and morphant zebrafish demonstrate that loss of fibrillin-2 
causes early embryonic phenotypes in zebrafish (Fig. 1B, Figs. 2B, D, and Fig. 10B). 
Interestingly, morpholino knockdown of Xenopus fibrillin-2 results in gastrulation arrest 
(102), a finding that likely reflects differences in the mechanisms of axial extension 
employed by Xenopus and zebrafish embryos. Alternatively, an additional fibrillin family 
member may compensate for the loss of fibrillin-2 in zebrafish but not in Xenopus during 
gastrulation. In this regard, mice homozygous for a null allele of fibrillin-2 are viable but 
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die in utero when crossed into a fibrillin-1 deficient background, suggesting partial 
functional redundancy between fibrillin-1 and fibrillin-2 (121-123). Fibrillin-2 knockout 
mice exhibit syndactyly and congenital contractures of the forelimbs (122) but not 
notochord or vascular abnormalities, possibly due to evolutionary differences between 
mice and zebrafish.  
Microfibril signaling 
Microfibrils have recently been demonstrated to modulate critical morphogenetic 
signaling events (122, 124-127), and the phenotypes observed in pfd
gw1
 mutants may 
therefore result in part from altered signaling. While the notochord distortion observed in 
pfd
gw1
 mutants (Fig. 1B) likely results from weakness of the notochord sheath due to 
disruption of the outer sheath layer (Figs. 3B, D), the etiology of the endothelial cell 
disorganization and altered caudal vein formation in pfd
gw1
 mutants (Fig. 2B) is less 
certain. The mechanisms of venous plexus formation may be similar to those involved in 
epithelial branching morphogenesis, where signaling by bone morphogenetic protein-7 
plays a prominent role (128, 129). A genetic interaction between fibrillin-2 and bone 
morphogenetic protein-7 has been demonstrated in fibrillin-2 knockout mice (122), and 
epithelial branching morphogenesis is inhibited in embryonic lung cultures after fibrillin-
2 knockdown (130). Signaling by bone morphogenetic protein-7 or other morphogens 
may therefore be required for endothelial cell branching and venous plexus 
morphogenesis in pfd
gw1
 mutants. Since heterofibrils of fibrillin-2 and fibrillin-1 may be 
required for caudal vein formation, and mutations in fibrillin-1 lead to excessive 
transforming growth factor- activity (124-127), we considered whether increased 
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transforming growth factor- signaling could explain the caudal vein abnormalities in 
pfd
gw1
 mutants. However losartan, an inhibitor of transforming growth factor- signaling 
(126) does not rescue the vascular phenotype of pfd
gw1
 mutants (data not shown).  
Microfibrils in human disease 
Mutations in human fibrillin-2 cause congenital contractural arachnodactyly, a rare 
disease with autosomal dominant inheritance that is characterized by congenital joint 
contractures, arachnodactyly, kyphoscoliosis, malformed ear helices, and vascular 
abnormalities (131). The pathogenesis of congenital contractural arachnodactyly is 
uncertain and could result from haploinsufficiency or a gain of function mutation 
(antimorphic and/or neomorphic) in fibrillin-2. Our results demonstrate that 
heterozygosity for a null allele at the fbn2 locus in zebrafish does not cause any overt 
phenotype (Figs. 1A, C, E and data not shown) even in mature fish (data not shown), a 
finding corroborated by mice heterozygous for a null allele of fibrillin-2 (121-123). 
Furthermore, the mutations that are known to cause congenital contractural 
arachnodactyly all cluster within a well-defined region near the middle of human 
fibrillin-2, a finding that is statistically unexpected and suggests a role for this region in 
mediating interactions with other proteins (131-133). These data suggest that a gain of 
function mutation (antimorphic and/or neomorphic) in human fibrillin-2 is required to 
cause congenital contractural arachnodactyly, a hypothesis now testable through 
transgenic expression experiments in the pfd
gw1
 mutant. Taken together, the data reveal a 
genetic interaction between fibrillin-2 and the lysyl oxidases in late notochord formation, 
demonstrate the importance of fibrillin-2 in specific early developmental processes in 
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zebrafish, and provide insight into the pathogenesis of congenital contractural 
arachnodactyly. Furthermore, the pfd
gw1
 mutant described here should now permit studies 
to elucidate the cell biological mechanisms of fibrillin-2 in early development. 
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Figure legends 
Fig. 1. The pfd
gw1
 mutation disrupts notochord and vascular development. (A) The 
notochord (black arrow), caudal vein (white arrow), and fin fold (black arrowheads) form 
normally in wild-type embryos, and melanin pigmentation is present (white arrowhead). 
(B) pfd
gw1 
mutants exhibit notochord kinking (black arrow), a cavernous caudal vein with 
loss of the usual reticular venous plexus (white arrow), and fin fold attenuation (black 
arrowheads). Melanin pigmentation is present (white arrowhead). (C) Fin fold 
(arrowheads) and caudal vein (arrow) in a wild-type embryo. (D) Attenuated fin fold 
(arrowheads) and cavernous caudal vein (arrow) typical of pfd
gw1 
mutants. (E, F) Ventral 
views of a wild-type embryo (E) and a pfd
gw1
 mutant (F) demonstrating skin distention 
secondary to edema in the mutant (F, arrowheads). Red blood cells have extravasated into 
the edematous area (F, arrow). All embryos were photographed at 30 hpf. 
Fig. 2. The pfd
gw1
 mutation disrupts venous plexus and axial vessel formation. (A-D) 
pfd
gw1
 was crossed into a fli1:EGFP transgenic line to allow visualization of endothelial 
cells. (A) The caudal vein of wild-type embryos has a well-formed venous plexus 
(arrowheads). (B) The caudal vein of pfd
gw1
 mutants has lost its characteristic reticular 
pattern, and endothelial cells are disorganized (arrowheads). (C, D) Dorsal aorta (upper 
circle) and cardinal vein (lower circle) in a wild-type embryo (C) and a pfd
gw1
 mutant (D), 
demonstrating reduced axial vessel diameters in the mutant (D, circles). Embryos were 
photographed at 30 hpf (C, D) and 35 hpf (A, B). 
Fig. 3. The outer layer of the notochord sheath is disrupted in pfd
gw1
 mutants. (A-F) 
Transmission electron micrographs of truncal cross-sections from embryos at 30 hpf. (A) 
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Notochord sheath of a wild-type embryo (between arrows). The area in the white square 
is shown at higher magnification in panel C. (B) Notochord sheath of a pfd
gw1
 mutant 
(between arrows). The area in the white square is shown at higher magnification in panel 
D. (C) Notochord sheath of a wild-type embryo with inner (i), medial (m), and outer (o) 
layers. (D) Notochord sheath of a pfd
gw1
 mutant where inner (i) and medial (m) layers are 
normal, but the outer (o) layer is reduced in size. (E, F) Notochord sheaths of wild-type 
embryos treated with 10 M neocuproine (E) or 10 mM -aminopropionitrile (F). Not = 
notochord. 
Fig. 4. pfd
gw1
 mutants are sensitized to inhibition of lysyl oxidase. Clutches from 
pfd
gw1
/+ intercrosses were incubated in vehicle (A, B), the copper chelator neocuproine (2 
M) (C, D), or the lysyl oxidase inhibitor -aminopropionitrile (1 mM) (E, F). Notochord 
is normal in wild-type embryos treated with vehicle or neocuproine (A, C) and shows a 
very mild herniation event in -aminopropionitrile (E, arrowhead). Notochords of pfdgw1 
mutants in neocuproine and -aminopropionitrile (D, F, arrowheads) are substantially 
more distorted than mutants incubated in vehicle (B, arrowhead). Embryos were 
incubated in PTU to inhibit melanin pigmentation and photographed at 30 hpf. 
Fig. 5. pfd
gw1
 mutants are sensitized to notochord distortion after partial knockdown 
of loxl5b. Embryos from pfd
gw1
/+ intercrosses were injected with 5 ng control MO (A, B) 
or 5 ng loxl5b MO (C, D) and examined at 30 hpf. Neither morpholino induced 
notochord distortion in wild-type embryos (A, C). However, pfd
gw1
 mutants injected with 
lysyl oxidase morpholino developed striking notochord distortion (D, arrowheads) 
compared to mutants injected with control morpholino (B, arrowheads). (E) Wild-type 
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embryo incubated in high-dose (6 M) neocuproine, demonstrating classic sine-wave 
appearance of lysyl oxidase inhibition at 30 hpf. (F) pfd
gw1
 mutant at 30 hpf with irregular 
notochord distortion after incubation in 6 M neocuproine. Embryos were treated with 
PTU to inhibit melanin pigmentation. 
Fig. 6. The pfd
gw1
 mutation disrupts the zebrafish fbn2 gene. (A) The pfd
gw1
 lesion 
was meiotically mapped to a telomeric region bounded by markers zC124A3 and z33723 
on chromosome 22. The number of recombinants is noted for each marker; a single 
recombinant was identified at z33723. Marker, gene, and fibrillin EST locations relative 
to BACs and scaffolds (scfld) are illustrated on the physical map, which is based on Zv6. 
(B) Sequencing traces from the fibrillin on chromosome 22 revealed a nonsense mutation 
(arrow) in pfd
gw1
 mutants that abrogates an AvaII restriction enzyme site. (C) Genotyping 
of pfd
gw1
 fish by restriction digest of a PCR product encompassing the mutated sequence. 
PCR product from the wild-type allele (+) is cleaved to generate fragments of 143 bp and 
43 bp; product from the mutant allele (-) is not cleaved. (D) Structure of zebrafish 
fibrillin-2 illustrating the conserved modular domains of this 2868 amino acid protein. 
The glycine-rich domain and location of the RGD motifs (asterisks) are characteristic of 
fibrillin-2 but not fibrillin-1 or fibrillin-3 orthologues. The pfd
gw1
 mutation is predicted to 
result in a truncated protein product (arrow). (E) Structure of the three human fibrillins 
and zebrafish fibrillin-4. The percent amino acid identity with zebrafish fibrillin-2 and 
fibrillin-4 is indicated. The dashed line indicates sequence that is presumed to exist but 
has not been determined. (F) Phylogenetic tree of fibrillin DNA coding sequences from 
various vertebrate species. Latent transforming growth factor-beta binding protein 1 
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(LTBP1) is used as the outgroup. Species are identified using standard two-letter 
abbreviations with zebrafish genes in bold. The arrow indicates Xenopus laevis fibrillin, a 
predicted fibrillin-2 orthologue. The scale bar reflects expected substitutions per site, and 
partial sequences begin with “p”.  
Fig. 7. fbn2 expression is consistent with the pfd
gw1
 phenotype and dramatically 
reduced in pfd
gw1
 mutants. (A-J) Clutches from pfd
gw1
/+ intercrosses were subjected to 
whole-mount in situ hybridization at the indicated developmental stages using probes to 
fbn2. (A) Lateral view of a wild-type embryo at 9 hpf. (B) Dorsal view of a wild-type 
embryo at the 3-somite stage demonstrating fbn2 expression in the notochord (arrow) and 
paraxial mesoderm (arrowheads). (C) Dorsal view of a wild-type embryo at the 7-somite 
stage demonstrating fbn2 expression in the notochord (arrow) and somites, with foci of 
increased staining near notochord-somite boundaries (arrowheads). (D) Lateral view of a 
wild-type embryo at the 20-somite stage with fbn2 expression in the region of the 
developing caudal vein (arrowhead) and eye (arrow). (E) Lateral view of a wild-type 
embryo at 24 hpf with hypochord (arrow) and prominent fin fold expression 
(arrowheads). (F-J) fbn2 expression is dramatically reduced in pfd
gw1
 mutants at all stages 
analyzed. (K) RT-PTCR for fibrillin-2 (fbn2) or spadetail (spt) using RNA from embryos 
at the indicated developmental stages. Unfert. = unfertilized. 
Fig. 8. fbn2 expression in frozen sections (A-C), and at high-power magnification in 
a whole-mount specimen (D). (A) Cross-section through the head of a wild-type embryo 
at the 20-somite stage demonstrating fbn2 expression in the lens placodes (arrowheads). 
(B) Cross-section through the trunk of a wild-type embryo at the 20-somite stage 
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demonstrating fbn2 expression in the notochord (n), floorplate (arrow), hypochord 
(arrowhead), and paraxial mesoderm (p). (C) Cross-section through the trunk of a wild-
type embryo at 24 hpf demonstrating fbn2 expression in the hypochord (arrow) and fin 
fold (arrowheads). The plane of section is schematized for A-C. (D) Dorsal view of a 
wild-type embryo at 24 hpf demonstrating fbn2 expression in two parallel lines of fin fold 
cells.  
Fig. 9. pfd
gw1
 heterozygote embryos exhibit an intermediate level of fbn2 expression. 
(A-C) Clutches from pfd
gw1
/+ intercrosses were subjected to whole-mount in situ 
hybridization at the 20-somite stage using probes to fbn2, photographed, and then 
genotyped. fbn2 expression is robust in wild-type embryos (A), dramatically reduced in 
mutant embryos (C), and intermediate in heterozygote embryos (B). 
Fig. 10. Morpholino knockdown of fbn2 recapitulates the pfd
gw1
 phenotype. (A) 
Wild-type embryos injected with 2.4 ng of control morpholino exhibit normal notochord 
(black arrow), caudal vein (white arrow), and fin fold formation (arrowheads). (B) 
Embryos injected with 2.4 ng of a start morpholino targeting fbn2 develop notochord 
kinks (black arrows), a cavernous caudal vein with loss of the usual reticular venous 
plexus (white arrow), and fin fold attenuation (arrowheads). The caudal vein and fin fold 
abnormalities in fbn2 morphants are better appreciated at higher magnification (D vs. C). 
(E, F) Ventral views demonstrating truncal edema with skin distention in wild-type fish 
injected with fbn2 morpholino (F, arrowheads) but not control morpholino (E, 
arrowheads). (G, H) pfd
gw1
 mutants injected with control morpholino (G) or fbn2 
morpholino (H) are indistinguishable. All embryos were treated with PTU to inhibit 
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melanin pigmentation and photographed at 30 hpf. Embryos in G and H were 
photographed and then genotyped. 
Table 1. pfd
gw1
 mutants are sensitized to pharmacologic inhibition of lysyl oxidase. 
Embryos were treated as indicated and scored for notochord phenotype at 30 hpf. 
Embryos with mild notochord herniation events in -aminopropionitrile were scored as 
normal (if wild-type) or mild (if pfd). Data shown are the pooled results of four 
independent experiments. 
Table 2. Genetic interaction between loxl5b and the pfd
gw1
 locus. Embryos were 
injected with morpholino as indicated and the number of live embryos sorted to new 
dishes at 10 hpf noted; these embryos were scored for notochord phenotype at 30 hpf. 
The number of sorted embryos that were either dead or dysmorphic at 30 hpf is also 
noted. Data shown are the pooled results of three independent experiments.  
Table 3. Morpholino knockdown of fbn2 consistently recapitulates the pfd
gw1
 mutant 
phenotype. Wild-type embryos were injected with morpholino as indicated and the 
number of live embryos sorted to new dishes at 10 hpf noted; these embryos were scored 
for the pfd
gw1
 mutant phenotype at 30 hpf. The number of sorted embryos that were either 
dead or dysmorphic at 30 hpf is also noted. Data shown are the pooled results of three or 
more independent experiments.  
S. Fig. 1. Protein sequence alignment of zebrafish fibrillin-2 with human, mouse, 
and rat orthologues. Conserved elements are highlighted using colors as follows: 
predicted furin cleavage sites, purple (2); EGF-like domains (3), light gray; hybrid motifs 
(2), red; TB domains (7), blue; calcium-binding EGF-like domains (43), dark gray; 
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glycine-rich domain (1), gold; potential N-glycosylation sites (12-13), green; RGD motifs 
(2), yellow. The number of times each element is observed is in parentheses.  
S. Fig. 2. Partial sequence of zebrafish fibrillin-4. (A) Nucleotide sequence with the 
predicted translation start site highlighted in red. EST sequence from EE319589 is in 
small caps and is supported by BAC CT027715. Sequence in pink is inferred from 
Zv7_scaffold988. All other sequence was cloned, suggesting that CT027715 should be 
joined to Zv7_scaffold988 in the physical genome assembly. (B) Protein sequence 
derived from translation of the nucleotide sequence in A.  
S. Fig. 3. Protein sequence alignment of zebrafish, Xenopus laevis, and human 
fibrillins. Conserved elements are highlighted using colors as follows: predicted furin 
cleavage sites, purple; EGF-like domains, light gray; hybrid motifs, red; TB domains, 
blue; calcium-binding EGF-like domains, dark gray; internal unique domains (glycine-
rich, proline-rich, proline/glycine-rich or proline/glutamine-rich), gold; RGD motifs, 
yellow.  
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Pharmacologic treatment Observed Phenotype 
Wild-type pfd mutant 
Normal Worse Mild Severe 
None 110 (100%) 0 (0%) 33 (97%) 1 (3%) 
Neocuproine (2 M) 114 (99%) 1 (1%**) 0 (0%) 35 (100%*) 
-aminopropionitrile (1 mM) 114 (96%) 5 (4%**) 1 (3%) 31 (97%*) 
*p < 0.01 vs. no treatment by 1-way ANOVA 
**p not significant vs. no treatment by 1-way ANOVA 
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Figure 5 
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Specific 
Morphol-
ino 
Dose of 
Morphol
-ino (ng)  
Embryos 
injected 
(#) 
Embryos 
sorted/ 
scored (#) 
Dead or 
dysmorphic 
embryos (#) 
Observed Phenotype 
Wild-type pfd 
Normal Worse Mild Severe 
Control 5 280 191 13 135 
(100%) 
0 (0%) 41 
(95%) 
2 (5%) 
loxl5b 5 300 222 13 143 
(88%) 
19 
(12%*) 
3 (6%) 44 
(94%*†) 
*p < 0.01 vs. no treatment by 1-way ANOVA 
†p < 0.05 vs. wild-type by 1-way ANOVA 
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Specific 
Morpholino 
Dose of 
morpholino 
(ng)  
Embryos 
injected 
(#) 
Embryos 
sorted/ 
scored (#) 
Dead or 
dysmorphic 
embryos (#) 
Observed Phenotype 
Wild-type Mutant 
Control 7.2 533 377 39 338 (100%) 0 (0%) 
fbn2 (start) 2.4 545 406 33 8 (2%) 365 (98%*) 
fbn2 (start) 0.12 320 212 37 175 (100%) 0 (0%**) 
*p < 0.01 vs. control by 1-way ANOVA 
**p not significant vs. control by 1-way ANOVA 
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DrFbn2          MGVWK----------LANVVLWWA---------------------AVHSVQGQGDGDIQA 29 
HsFBN2          MGRRRRLCLQLYFLWLGCVVLWAQGTAGQPQPPPPKPPRPQPPPQQVRSATAGSEGGFLA 60 
MmFBN2          MGRRRRLCLQPYFVWLGCVALWAQGTDGQPQPPPPKTLRPQPPPQQVRPAVAGSEGGFMG 60 
RnFBN2          MGRRRRLCLRPYFVWLGCVALWAQGTDGQPQPPPPKTLRPQPPPQQVRPAGAS-EGGFAG 59 
                **  :          *. *.**                        *:.. .  :*.: . 
 
DrFbn2          SRFTGKPEGEVQQRVRRRGQ-ESLRGPNVCGSRFHSYCCPGWKTLPGGNQCIVPICRNSC 88 
HsFBN2          PEYREE-GAAVASRVRRRGQQDVLRGPNVCGSRFHSYCCPGWKTLPGGNQCIVPICRNSC 119 
MmFBN2          PEYRDE-GAVAASRVRRRGQQEILRGPNVCGSRFHSYCCPGWKTLPGGNQCIVPICRNSC 119 
RnFBN2          PEYRDE-GALAASRVRRRGQQEILRGPNVCGSRFHSYCCPGWKTLPGGNQCIVPICRNSC 118 
                ..:  :  . . .******* : ************************************* 
 
DrFbn2          GDGFCSRPNMCTCSSGHLAPSCGAAAVQSCSVRCMNGGMCNEDACSCQKGYTGTHCGQPV 148 
HsFBN2          GDGFCSRPNMCTCSSGQISSTCGSKSIQQCSVRCMNGGTCADDHCQCQKGYIGTYCGQPV 179 
MmFBN2          GDGFCSRPNMCTCSSGQISPTCGAKSIQQCSVRCMNGGTCADDHCQCQKGYIGTYCGQPV 179 
RnFBN2          GDGFCSRPNMCTCSSGQISPTCGGKSIQQCSVRCMNGGTCADDHCQCQKGYIGTYCGQPV 178 
                ****************:::.:**. ::*.********* * :* *.***** **:***** 
 
DrFbn2          CESGCQNGGRCIGPNRCACVYGFTGPQCERDYRTGPCFTQVNNQMCQGQLSGIVCTKTLC 208 
HsFBN2          CENGCQNGGRCIGPNRCACVYGFTGPQCERDYRTGPCFTQVNNQMCQGQLTGIVCTKTLC 239 
MmFBN2          CENGCQNGGRCIGPNRCACVYGFTGPQCERDYRTGPCFTQVNNQMCQGQLTGIVCTKTLC 239 
RnFBN2          CETGCQNGGRCIGPNRCACVYGFTGPQCERDYRTGPCFTQVNNQMCQGQLTGIVCTKTLC 238 
                **.***********************************************:********* 
 
DrFbn2          CATIGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAVPGLCAGGNCINTVGSY 268 
HsFBN2          CATIGRAWGHPCEMCPAQPQPCRRGFIPNIRTGACQDVDECQAIPGICQGGNCINTVGSF 299 
MmFBN2          CATIGRAWGHPCEMCPAQPQPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSF 299 
RnFBN2          CATIGRAWGHPCEMCPAQPQPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSF 298 
                *******************:***********************:**:* **********: 
 
DrFbn2          ECKCPAGHRQSETNQKCEDIDECATISGVCDGGECTNTAGSYVCTCPRGYITSTDGSRCV 328 
HsFBN2          ECRCPAGHKQSETTQKCEDIDECSIIPGICETGECSNTVGSYFCVCPRGYVTSTDGSRCI 359 
MmFBN2          ECRCPAGHKQSETTQKCEDIDECSVIPGVCETGDCSNTVGSYFCLCPRGFVTSTDGSRCI 359 
RnFBN2          ECRCPAGHKQSETTQKCEDIDECSVVPGICETGDCSNTVGSYFCLCPRGFVTSTDGSRCI 358 
                **:*****:****.*********: :.*:*: *:*:**.***.* ****::********: 
 
DrFbn2          DHRIGTCFSSLANGRCASELSGQYTKMQCCCDTGRCWALGHIPEMCPVRGSDEYRRLCIQ 388 
HsFBN2          DQRTGMCFSGLVNGRCAQELPGRMTKMQCCCEPGRCWGIGTIPEACPVRGSEEYRRLCMD 419 
MmFBN2          DQRAGTCFSGLVNGRCAQELPGRMAKAQCCCEPGRCWSIGTIPEACPVRGSEEYRRLCLD 419 
RnFBN2          DQRTGTCFSGLVNGRCAQELPGRMAKAQCCCEPGRCWGIGTIPEACPVRGSEEYRRLCLD 418 
                *:* * ***.*.*****.**.*: :* ****:.****.:* *** ******:******:: 
 
DrFbn2          RLPFG--TGNGGIIHDGNGGLN------IGGYGKGPS--QNGNGGGGYIYGSEHTFTNGN 438 
HsFBN2          GLPMGGIPGSAGSRPGGTGGNGFAPSGNGNGYGPGGTGFIPIPGGNGFSPGVGGAGVGAG 479 
MmFBN2          GLPMGGIPGSSVSRPGGTGST-------GNGYGPGGTGFLPIPGDNGFSPGVGGAGVGAG 472 
RnFBN2          GLPMGGIPGSSVSRPGGSGSN-------SNGYGPGGTGFLPIPGGNGFSPGVGGAGVGAG 471 
                 **:*  .*..    .*.*.         .*** * :      *..*:  *   : .... 
 
DrFbn2          GNGGQKIQISQLNETTIDVCKHFTNLCLNGRCIPTPTSYRCECNMGYRQDVRGECIDVDE 498 
HsFBN2          GQGPIITGLTILNQT-IDICKHHANLCLNGRCIPTVSSYRCECNMGYKQDANGDCIDVDE 538 
MmFBN2          GQGPIITGLTILNQT-IDICKHHANLCLNGRCIPTVSSYRCECNMGYKQDANGDCIDVDE 531 
RnFBN2          GQGPIITGLTILNQT-IDICKHHANLCLNGRCIPTVSSYRCECNMGYKQDANGDCIDVDE 530 
                *:*     :: **:* **:***.:*********** :**********:**..*:****** 
 
DrFbn2          CVSNPCVNGDCVNTQGSYHCKCHEGYQGTPTKQACIDIDECIVNGVMCRNGRCVNTDGSF 558 
HsFBN2          CTSNPCTNGDCVNTPGSYYCKCHAGFQRTPTKQACIDIDECIQNGVLCKNGRCVNTDGSF 598 
MmFBN2          CTSNPCSNGDCVNTPGSYYCKCHAGFQRTPTKQACIDIDECIQNGVLCKNGRCVNTDGSF 591 
RnFBN2          CTSNPCSHGDCVNTPGSYYCKCHAGFQRTPTKQACIDIDECIQNGVLCKNGRCVNTDGSF 590 
                *.**** :****** ***:**** *:* ************** ***:*:*********** 
 
DrFbn2          QCICNAGFEISPDGKNCIDHDECATTNMCLNGMCINEDGSFKCICKPGFALAPNGRYCTD 618 
HsFBN2          QCICNAGFELTTDGKNCVDHDECTTTNMCLNGMCINEDGSFKCICKPGFVLAPNGRYCTD 658 
MmFBN2          QCICNAGFELTTDGKNCVDHDECTTTNMCLNGMCINEDGSFKCVCKPGFILAPNGRYCTD 651 
RnFBN2          QCICNAGFELTTDGENCVGHDECTTTNMCLNGMCINEDGSFKCVCKPGFVLAPNGRCCTD 650 
                *********::.**:**:.****:*******************:***** ****** *** 
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A) 
gaggatttaggagggaattgggaatatgacagtttcggtccggggttcccgggatctttaaaacaacgtagccaatcagctaatgtaataattaaccccttttat
taattgaatattttattgcgtttacgtttcatcagtcagtcgaacaaatatgcgctattcatattattattattatctggttaaattaaagaacgatttgctatagcaatac
ccattcactcaagagtgcagagagttttgtcgcgtccagctgctagtgggtaacgttaggatagattggtgctggctggcgtcatgattttatatcgttcagtca
aacgtttaggatcctccttcattctcttcactaagtgcgctcctcctgtacttcaattcttattcttgtagctttacttttctggtcaaaaaccggatatgttatgatttcc
ctttcatctcatggactaacagactgtaaaggtacactgggttaaattgcactaggatatatcatgtcatctcagggggacctcaggtgtttatttggatttgttgct
ctgttgggaattttaacggggaaaatctctggaattcatggaaaagcaactgttcatattgatggatcacagagacgccaaaaacaagagtccctgagaggc
cctaatgtgtgtggatctcgtctGCAGTCCTTCTGTTGTCCAGGCTGGAAGACTCTGCCTGGGGGCAACCAGT
GTGTTGTGCCTATTTGCCGGAGTGACTGTGGGGATGGTTTCTGCTCCAGACCTAACATGTGCA
CATGTCCTGGTGGACAAACAGCTACAACCTGTTTTACTAAATCATCCAAACAATGCAAAATAA
GGTGTATGAATGGAGGAGTGTGTGAAGATGACTATTGTCAGTGTCCAAAGGGATATACAGGA
AGCTTTTGTGGACAACCTGTCTGTGAAAAAAACTGTCAGAATGGTGGACACTGCATTGGACCG
AACAGATGCGCGTGTGGATACGGCTTCACTGGACCACAGTGTGAGAGAGACTACCGGACAGG
CCCATGCTTCATCCAAGTGCACAGCAGGAAGTGTGCAGGTCAGAGCAGTGAATTTGTTTGCAG
TAAGGCCTTGTGCTGTGCCACAGTGGGTCAAGCGTGGGGTCACTCGTGCGAGCAGTGCCCACC
TATCAGCTCGCCCTGCACCAGAGGGTTCATCCCAAACACCCGCACAGGAGCCTGCCAAGATGT
TGATGAATGCAAGGTTGTCCCCGATCTGTGTAAAGGAGGAAGATGCATCAACACATTGGGTTC
ATATCAGTGCACGTGTCCTGTCGGTTACCAACAGCATGTGAGCATTTTGAAGTGCGAGGATGT
GGATGAATGCTCCACCATTGAACGTGCGTGTGAAGCGGGACACTGCATTAATTCGGCGGGCA
GTTTCTCCTGTGTGTGTCCTTCTGGATATGTGCTGTCTGCAGACCGGACTCGCTGTCTTGACCA
GCACACAGGGATCTGCTTTGCGTCAGTTGTGAATGGACGCTGTGCTCATGAAATCAGCGGACG
TTTCAATAAAATCCAGTGCTGCTGTGATCGTGGCCGGTGCTGGAGTCAAAGAACAACTCATGA
AATGTGTCCTGTACCAGGATCAGATGAATACTTGAGGATTTGTCTGGTAGGCTCTGCTCTGAG
TGGCTACAATGAGGAGGATCCTGAAATGAGCCCTCACCACCACAGCAGCTTCAGTGTTTCCCC
TAATGACCAGATACTTCACCCACATAATGGCAATGGACAAATAAAACCCCAGATTCGCCAAA
CACCTCAAATTCTGCAGTTTCCACAGATTCCACAGATCCCAAGGCATGACAATGGATTTAAAC
CACAACGACCTGTTGTTAGTGTGAATGAGACTGTGAACAGGTGCCGTTTGCTTCCTAATTTGT
GTCTGAATGGACGCTGTATTCCCATGGAGTCTGACTACCGATGTGACTGTAACACCGGATTCA
AAGAAGACAACAGAGGAGAGTGCTCAGATGTAGATGAGTGTGAGTTTGACCCCTGTGCTAAT
GGAAACTGCATCAACACTCCTGGTTCCTACTACTGCAGATGCCACACAGGCTTTCTTAGGGTT
ACAGGCAAACAAACCTGCATAGATATTGATGAATGTCTTCAGAATGGAGTGCTCTGTAAGAA
CGGCCGCTGTCTGAACACTGAGGGAAGCTTTCAGTGCATCTGCAACTCTGGATTTAAGCTTTC
ACCTGATGGGAGAAACTGTGTAGATCATGATGAATGTGCCGCCACAAACATGTGTCTTAACGG
CATGTGTATTAACGAAGACGGCAGCTTTAAATGTGTGTGTAAACCTGGATTCACCCTCAACTC
TAGTGGACGATACTGTACAGAAATCGATGAGTGCCGGACTCCAGGTGTGTGCATGAATGGAC
GATGTGTAAACACACAGGGCTCTTTCAGGTGTGAGTGTTTTGCAGGTCTTACTGTTGGAATAG
ACGGCCGAACATGTGTAGACACACACATGCGTAGCACCTGTTATGGGGCTGTAAAAAGAGGT
TTGTGTTTACGACCCTTCCAGCGTGCTGTCACCAAGTCACAGTGCTGCTGTGCCAACCCTGACT
ATGCCTTCGGTGAACCCTGCCATCCCTGCCCTGCCAAACACTCAGCTGAGTTTCAGGTCTTGTG
TGCGAGCGGTGTTGGATTTTCTGCTGATGGCAAAGACATTAATGAGTGCGCTCTGGATCCGGA
TATCTGCTCAAATGGAGTGTGTGAGAATCTCCGAGGAAATTTCCGCTGCATCTGTAACATTGG
CTATGAAAGTGACCAGAGCGGCAGAAACTGTTTAGATATTGATGAATGTGTGGTGAACAGTCT
CCTCTGTGATAATGGCCTGTGCCGGAATGTTCCAGGAAGCTACAGTTGCACCTGCCCGGCGGG
GTTCATCTTCAGACATGACACAGAGACATGTGAGGATGTGAATGAGTGTGTGAGCAGCCCAT
GCGTCAATGGAGTGTGTAAAAACAGTGCAGGCTCTTTCTACTGTGAATGTTCACAAGGAAGTA
AACTGGACAGCACTGGACTTTTATGTGTTGACAGTGTGAAGGGTTCATGCTGGTTAACTCTTC
AGGATGGTCGTTGTGAAGTTAACATCAACGGAGCTACACTGAGATCACAGTGCTGTGCCACAC
TAGGATTGGCGTGGGGCAGCCCATGTGAACCATGTCAAACTGATCTAGTGTGCGAACGAGGA
TTTGCTCGGTCAAGAGGGGCTTCATGTGAAGATGTGAATGAATGTGAGGTGTTTCCTGGTGTG
TGTCACAATGGACACTGTGTGAACACTAGAGGCTCATTTAAATGTCAGTGCCCAGAAAGCCTC
ACACTGGATGTCACTGGACGCCTCTGTGTTGATGTTCGTTCAGAGCCGTGCTTTCTTACTTACG
AAGAAGATGTGTGTACACAGCCGGTACCAGGACGCTTCCGCATGGACATGTGTTGCTGTACGG
TGGGTTTGGCTTGGGGCAAAGATTGTGACTTATGTCCTGAGCCTGGTACTCGGCAGTTTGACA
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CCCTGTGCCCAAGAGGACCAGGCTTCGCCAACAAAGGAGACGTGCTCACTGGCAGAGCTGTC
TATAAAGATATTAATGAGTGCAAAGTTTTCCAAAGCATTTGTGTCCATGGGAAATGTCGGAAC
ACCATTGGGAGCTTCAGATGTCGCTGTGATAGTGGATTTGCACTGGATACCAATGAGAAAAAC
TGCACAGATATTGACGAGTGCATGATCTCTCCTGATGTCTGTGGTCATGGCACATGTGTGAAC
ACTTTGGGCAGTTTCCAATGTGACTGTTTTCCTGGCTACGAAAGTGGAATCATGATGATGAAG
AACTGCATGGATATTGATGAATGTGAGCGTAACCTTTCACTGTGCAATGGAGGCACCTGTGAA
AACACTGACGGCAGCTACAAGTGTGTGTGTCCGCCTGGTCATCATCTGTCTGTGGATGGCAGT
GCCTGTGAAGACGTGAACGAGTGTGATCTGAGTAGCACACTTTGTCCTAATGGCTGGTGTGTG
AATTTGGTGGGAACCTACCAGTGCTCATGTAACTCTGGCTACCAGACGGCACCTGATTGGAAG
GGTTGCACAGATATAGATGAGTGCACAATAGAGAACGGAGGATGTGAGCTGTACTGTAGTAA
CTCAGAGGGCAGTTACTCCTGCAGCTGTGGTCAGGGTTACAGTCTCACGCCGGACCAGCGGAC
ATGTTCAGATGTGAATGAATGTGAAGAGGTTTTAGACATCTGTGAAGGTGGTCAGTGCACTAA
CGTTCCTGGAGCATATCATTGTTTGTGTTACGAAGGATTTATGGCTTCCGTGGACATGAAGAC
ATGTATTGATGTGAATGAGTGTGAACTGAACGACAACATCTGTGCATTTGGGGAGTGTGAGAA
CACCAAGGGTTCTTTCATCTGTCATTGTGACATAGGTTACGCCGTAAAAAAAGGAACCTCTGG
CTGCACTGATGTTAATGAGTGTGAGATTAACAGTCATAACTGTGACACACATGCCACCTGTGT
CAACACACCAGGACATTACCACTGCTCCTGCGGGGACGGATGGTTTGGAGATGGAGTCAAAT
GTGCTGATGTGGATGAGTGTGCTAACAGGACTAGCGTCTGCAGCGCTGATGCCGAGTGTGTGA
ACACAGCTGGCTCATACCACTGTGAATGTTCAGACGGGTTTATTGGAGACGGGGTTATCTGCT
CAGATTTGGATGAATGCGCTGAAGATGTGGATCTGTGTGAAAATGGCCAGTGTCTAAATGTTC
CTGGCAGCTATCGCTGTGAATGTGAGATGGGCTTCACACACACTTCAAACAGAAAAACCTGTC
GAGATATAGACGAGTGCTCCTTCCAGAACATCTGTGTGTTTGGCACATGTCAGAATATTCCAG
GAATGTTTCGCTGTATTTGTGATGAGGGGTATGAGCTGGACAGGACAGGTGGAAATTGCACA
GATGTGGACGAGTGTCTCGATTCCTTAAACTGTGTTAATGGTCACTGTGAGAACACAGCCGGC
TCGTACCAGTGTAACTGTCCTATTGACTTCGAGCTCAATCCTACTGGAATTGGATGCGTTGACA
CCCGGGTTGGAAACTGTTTTCTGGAGGTGGCGTACCATAGTAAGCTGGCATGTAGTGCTGAAA
TTGGATTTGGAGTCAGTCGTTCCTCATGTTGCTGTTCTCTGGGACGGGTGTGGGGTTACCCATG
TGACCACTGCCCTACACTCAACACCTCGGAATATAACACACTCTGTCCTGGAGGAGAGGGGTT
CAAACCCAACCCTGTCACCATCATCTTGGAAGATATCGATGAGTGTCAGGAGCTGCCCGGCCT
CTGTCAGGGTGGAAACTGTGTTAACACATTCGGAAGTTTCCAGTGTGAATGTCCAGCCGGATT
CTACCTTAACACACAGAGCCGCATCTGTGAAGATATCGATGAGTGTGTGCTCAGTTTGGGGGT
TTGTGGTCCAGGCACCTGCTACAACACACTGGGAAACTACACTTGTGTCTGTCCACAGGAATA
CATTCAGGTGAATGGAGGACACAGATGCATGGATATGAGGAAAAGTTTGTGCTATCGCAGCT
ACAATGGCAGTGCCTGTGAACATCAGCTCAACTTTAACATCACACACCGATTGTGTTGCTGTT
CCTACAATGTGGGAAAAGCCTGGAACAAGCCATGCCATGCCTGCCCGATACCTGGAACTGAT
GACTACAGCAGTCTTTGTGGCAGTGTGACTGGATTCTGGATCAACATTGCAACTGGAAAGCCA
AAAGATATTGACGAATGTCATGAAATCCCGGGAGTTTGTGCTCATGGTGTGTGTATAAACCAC
ATGGGCAGTTTCCACTGCGAGTGTCCCACTGGCTTCCTTTATAATGACCTGCTGCTCATCTGTG
AAGACATTGATGAATGCAGCAGCAGAGAGCCTGTGTGTCAGAGAAATGCAGACTGCATCAAC
CGTCCAGGCGGTTATCAGTGTGAATGTTCTGATGGGTATATACTCACACCTAATGGAGACTGT
AATGATCGTAATGAGTGCTTGGAGACACCCAGTGTGTGTCGTCATGGTGACTGTGTGGATATT
CCAGGAGGGTATGAGTGCATGTGCCACACCGGATTTACAGTAACACCAAACCGCAGGATGTG
TGTAGATGTCAATGAATGTTCACCTCAGCCGTGTGGGAATGGCACATGTAAAAACTCTGTTGG
ATCATTTAACTGTATCTGCCATCACGGATTTGAGCTCGCCACTAATAACTACTGTACAGATATC
GATGAGTGTGCAGTTTTTCACTCTCAGCTCTGCAGGAATGGTCGGTGTGTCAATAATGTGGGC
TCCTTCCAGTGTCTCTGTAGAGAAGGTTATGAACTCACTTTTGATGGCAAGACTTGTATGGATG
TTAATGAGTGTACAATCATTCCTGGGATATGTGCTCCTGGAACTTGTCTGAATCTGGATGGTTC
TTTCAGATGTGTCTGTCCTGATGGGTACATTGTCCAGAGTGATCACTGCGTAGATGTAAACGA
GTGTTCGGAGGAGCCTGGGATCTGCACATATGGGACCTGCTTCAACAGTCTGGGCAGCTTTGA
GTGTGTGTGTAAACCAGGATTTGTGCTGTCAGAAGATAAGCGCAGATGTTATGACACCAGAG
AGAGCTTCTGTTTCACACGCTTTGAGAACAGCAAGTGCTCTGTCCCGCAGGCGTTTAACACCA
CCAAAGCCAAGTGCTGCTGTAGTATCATGGCCAAGGAGGGCTGGGGCGACCCGTGTGAGCTG
TGCCCTAAAGAACATGATGCATTTCAGGATCTGTGCCCGTTTGGTCATGGGATCATTCCTGGT
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GTTGGGGACACACGTGTAGATTTAAACGAGTGTGTGGAGAATCCAGAGATCTGTGTAAACGG
ACGCTGCATCAACATGGATGGTTCCTTTCGCTGTGAGTGTCCAGCAGGGTACACTCTTGACTA
CACAGGAACACATTGTGATGATATCGATGAATGTTCAGTGAGAAACCCATGTGGAAACGGCA
CGTGCTCCAATGTAATCGGGGCATTTGAGTGTTTGTGTGAAGAAGGATTTGAGCCTGGACCGA
TGATGAGCTGTGAAGATGTGAACGAATGTGGTCAGAATCCTCTGCTCTGTGCATTTCGCTGCA
TCAACACTTTCGGGAGTTATGAATGCAGCTGTCCATCTGGTTACACACTGAGAGAGGATGGAC
GCATGTGTCAAGATGTAGACGAGTGTGCAGAAGATCTTCATAACTGTGACTCCAGAGGAATG
GAATGTAGCAACCTAATTGGCACATTTATGTGTGTTTGTCCGGCCGGTATGATCCGCAGGATG
AGTGATGAGGCCTGTCAAGATGAAAATGAATGCTTGACTCAGCCTGGTGTTTGTGAAAATGGC
CGTTGTGTGAACACTGTTGGCAGCTACACTTGTGAATGTGGTGTTGGGTTCAAAACGGACTCA
TCAGCCACACAATGTCTTGATTACAGGAAAGGCTTCTGTTTCACTGAAGTTCTGCACACCATG
TGTCAGATGTCGTCCAGCAGTCGTGTTCCTGTCAGCAGGTCTCAGTGCTGCTGTAATGGAGGT
CATGGGTGGGGGGATCAGTGTGAGCTCTGCCCTCTGCCTGCCACTGCCAACTACAAAAAACTC
TGTCCATATGGTCATGGATACGCCATAGACGGAACAGATATAGATGAGTGTAAACTAATTCCA
GATGTCTGTGCCAATGGCGCTTGTATCAACATGATGGGCTCTTACAGATGCCACTGCAAACCA
GGATACATAGCATCTACTGCAGGAACCGCATGTGTTGATGTCGATGAATGTGGTATGTCTCCA
AAACCCTGTAACTTCATATGTAAGAACACCGAGGGCAGCTATGCATGTTCCTGTCCCCGTGGT
TACACTCTGCAGAATGACAACAGGTCATGCAAAGATGTGGATGAATGTCAGAGCAGACGACA
CAACTGCCAGTTCTCGTGCATGAACACCATCGGTGGATTCACATGCAAGTGTCCAGCAGGTTT
CAGCCAGCATCACAGAGCTTGCAGAGATATTGATGAATGTTTGTCAGACCTAACACCGTGTGG
CCTGCAAGGAGCATGTCAGAATTCAGTGGGAAGCTTCAGCTGTGAGTGTCCCCAGGGCTTCAG
TCTGGACTCTCTCGGCCACAACTGTGATGATGTAGATGAGTGTGCACGGGATCACAGGTGTCA
GTTCGGTTGTCAGAATGTTGCTGGAGGTTTTCGCTGCAGCTGTCCACAGGGTTACACACAACA
CCAGCAGTGGAACCAGTGTGTGGATGACAATGAGTGCTTGAACGCAGACAACTGTGGTTCAG
CTTCCTGTTTCAACACTTTGGGCAGTTTCAAGTGTGGCTGCCCATCTGGCTTCACCTTTGATCC
TGCATCTACTAGCTGTGAGGATGTAGACGAGTGCGGGTCCTTCATGAACCCCTGCAGATACGG
CTGCTCTAACACACAGGGTGGATTTGCGTGCGGGTGCCCAGCTGGTTATTACAGAGCAGGACA
GGG 
 
B) 
MSSQGDLRCLFGFVALLGILTGKISGIHGKATVHIDGSQRRQKQESLRGPNVCGSRLQSFCCPGWK
TLPGGNQCVVPICRSDCGDGFCSRPNMCTCPGGQTATTCFTKSSKQCKIRCMNGGVCEDDYCQCP
KGYTGSFCGQPVCEKNCQNGGHCIGPNRCACGYGFTGPQCERDYRTGPCFIQVHSRKCAGQSSEF
VCSKALCCATVGQAWGHSCEQCPPISSPCTRGFIPNTRTGACQDVDECKVVPDLCKGGRCINTLGS
YQCTCPVGYQQHVSILKCEDVDECSTIERACEAGHCINSAGSFSCVCPSGYVLSADRTRCLDQHTG
ICFASVVNGRCAHEISGRFNKIQCCCDRGRCWSQRTTHEMCPVPGSDEYLRICLVGSALSGYNEED
PEMSPHHHSSFSVSPNDQILHPHNGNGQIKPQIRQTPQILQFPQIPQIPRHDNGFKPQRPVVSVNETV
NRCRLLPNLCLNGRCIPMESDYRCDCNTGFKEDNRGECSDVDECEFDPCANGNCINTPGSYYCRC
HTGFLRVTGKQTCIDIDECLQNGVLCKNGRCLNTEGSFQCICNSGFKLSPDGRNCVDHDECAATN
MCLNGMCINEDGSFKCVCKPGFTLNSSGRYCTEIDECRTPGVCMNGRCVNTQGSFRCECFAGLTV
GIDGRTCVDTHMRSTCYGAVKRGLCLRPFQRAVTKSQCCCANPDYAFGEPCHPCPAKHSAEFQVL
CASGVGFSADGKDINECALDPDICSNGVCENLRGNFRCICNIGYESDQSGRNCLDIDECVVNSLLC
DNGLCRNVPGSYSCTCPAGFIFRHDTETCEDVNECVSSPCVNGVCKNSAGSFYCECSQGSKLDSTG
LLCVDSVKGSCWLTLQDGRCEVNINGATLRSQCCATLGLAWGSPCEPCQTDLVCERGFARSRGAS
CEDVNECEVFPGVCHNGHCVNTRGSFKCQCPESLTLDVTGRLCVDVRSEPCFLTYEEDVCTQPVP
GRFRMDMCCCTVGLAWGKDCDLCPEPGTRQFDTLCPRGPGFANKGDVLTGRAVYKDINECKVF
QSICVHGKCRNTIGSFRCRCDSGFALDTNEKNCTDIDECMISPDVCGHGTCVNTLGSFQCDCFPGY
ESGIMMMKNCMDIDECERNLSLCNGGTCENTDGSYKCVCPPGHHLSVDGSACEDVNECDLSSTL
CPNGWCVNLVGTYQCSCNSGYQTAPDWKGCTDIDECTIENGGCELYCSNSEGSYSCSCGQGYSLT
PDQRTCSDVNECEEVLDICEGGQCTNVPGAYHCLCYEGFMASVDMKTCIDVNECELNDNICAFGE
CENTKGSFICHCDIGYAVKKGTSGCTDVNECEINSHNCDTHATCVNTPGHYHCSCGDGWFGDGV
KCADVDECANRTSVCSADAECVNTAGSYHCECSDGFIGDGVICSDLDECAEDVDLCENGQCLNVP
GSYRCECEMGFTHTSNRKTCRDIDECSFQNICVFGTCQNIPGMFRCICDEGYELDRTGGNCTDVDE
 132 
CLDSLNCVNGHCENTAGSYQCNCPIDFELNPTGIGCVDTRVGNCFLEVAYHSKLACSAEIGFGVSR
SSCCCSLGRVWGYPCDHCPTLNTSEYNTLCPGGEGFKPNPVTIILEDIDECQELPGLCQGGNCVNTF
GSFQCECPAGFYLNTQSRICEDIDECVLSLGVCGPGTCYNTLGNYTCVCPQEYIQVNGGHRCMDM
RKSLCYRSYNGSACEHQLNFNITHRLCCCSYNVGKAWNKPCHACPIPGTDDYSSLCGSVTGFWINI
ATGKPKDIDECHEIPGVCAHGVCINHMGSFHCECPTGFLYNDLLLICEDIDECSSREPVCQRNADCI
NRPGGYQCECSDGYILTPNGDCNDRNECLETPSVCRHGDCVDIPGGYECMCHTGFTVTPNRRMCV
DVNECSPQPCGNGTCKNSVGSFNCICHHGFELATNNYCTDIDECAVFHSQLCRNGRCVNNVGSFQ
CLCREGYELTFDGKTCMDVNECTIIPGICAPGTCLNLDGSFRCVCPDGYIVQSDHCVDVNECSEEP
GICTYGTCFNSLGSFECVCKPGFVLSEDKRRCYDTRESFCFTRFENSKCSVPQAFNTTKAKCCCSIM
AKEGWGDPCELCPKEHDAFQDLCPFGHGIIPGVGDTRVDLNECVENPEICVNGRCINMDGSFRCEC
PAGYTLDYTGTHCDDIDECSVRNPCGNGTCSNVIGAFECLCEEGFEPGPMMSCEDVNECGQNPLL
CAFRCINTFGSYECSCPSGYTLREDGRMCQDVDECAEDLHNCDSRGMECSNLIGTFMCVCPAGMI
RRMSDEACQDENECLTQPGVCENGRCVNTVGSYTCECGVGFKTDSSATQCLDYRKGFCFTEVLH
TMCQMSSSSRVPVSRSQCCCNGGHGWGDQCELCPLPATANYKKLCPYGHGYAIDGTDIDECKLIP
DVCANGACINMMGSYRCHCKPGYIASTAGTACVDVDECGMSPKPCNFICKNTEGSYACSCPRGY
TLQNDNRSCKDVDECQSRRHNCQFSCMNTIGGFTCKCPAGFSQHHRACRDIDECLSDLTPCGLQG
ACQNSVGSFSCECPQGFSLDSLGHNCDDVDECARDHRCQFGCQNVAGGFRCSCPQGYTQHQQW
NQCVDDNECLNADNCGSASCFNTLGSFKCGCPSGFTFDPASTSCEDVDECGSFMNPCRYGCSNTQ
GGFACGCPAGYYRAGQG 
 
 
Supplementary Figure 2 
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HsFBN1          ----------MRRGRLLEIALGFT----------------------VLLASYTSHGADAN 28 
HsFBN2          MGRRRRLCLQLYFLWLGCVVLWAQGTAGQPQPPPPKPPRPQPPPQQVRSATAGSEGGFLA 60 
DrFbn2          ----------MGVWKLANVVLWWA---------------------AVHSVQGQGDGDIQA 29 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         ---------MSSQGDLRCLFG-------------------------FVALLGILTGKISG 26 
HsFBN3          ---MTLEGLYLARGPLARLLLAWS----------------------ALLCMAGGQGRWDG 35 
                                                                             
 
HsFBN1          LEAGNVKETRASRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHS 88 
HsFBN2          PEYREEGAAVASRVRRRGQ--QDVLRGPNVCGSRFHSYCCPGWKTLPGGNQCIVPICRNS 118 
DrFbn2          SRFTGKPEGEVQQRVRRRG--QESLRGPNVCGSRFHSYCCPGWKTLPGGNQCIVPICRNS 87 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         IHGKATVHIDGSQRRQKQE----SLRGPNVCGSRLQSFCCPGWKTLPGGNQCVVPICRSD 82 
HsFBN3          ----ALEAAGPGRVRRRGS--PGILQGPNVCGSRFHAYCCPGWRTFPGRSQCVVPICRRA 89 
                                                                             
 
HsFBN1          CGDGFCSRPNMCTCPSGQIAPSCGSRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQP 148 
HsFBN2          CGDGFCSRPNMCTCSSGQISSTCGSKSIQQCSVRCMNGGTCADDHCQCQKGYIGTYCGQP 178 
DrFbn2          CGDGFCSRPNMCTCSSGHLAPSCGAAAVQSCSVRCMNGGMCNEDACSCQKGYTGTHCGQP 147 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         CGDGFCSRPNMCTCPGGQTATTCFTKSSKQCKIRCMNGGVCEDDYCQCPKGYTGSFCGQP 142 
HsFBN3          CGEGFCSQPNLCTCADGTLAPSCGVSRGSGCSVSCMNGGTCRGASCLCQKGYTGTVCGQP 149 
                                                                             
 
HsFBN1          VCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVCTKTL 208 
HsFBN2          VCENGCQNGGRCIGPNRCACVYGFTGPQCERDYRTGPCFTQVNNQMCQGQLTGIVCTKTL 238 
DrFbn2          VCESGCQNGGRCIGPNRCACVYGFTGPQCERDYRTGPCFTQVNNQMCQGQLSGIVCTKTL 207 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         VCEKNCQNGGHCIGPNRCACGYGFTGPQCERDYRTGPCFIQVHSRKCAGQSSEFVCSKAL 202 
HsFBN3          ICDRGCHNGGRCIGPNRCACVYGFMGPQCERDYRTGPCFGQVGPEGCQHQLTGLVCTKAL 209 
                                                                             
 
HsFBN1          CCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGS 268 
HsFBN2          CCATIGRAWGHPCEMCPAQPQPCRRGFIPNIRTGACQDVDECQAIPGICQGGNCINTVGS 298 
DrFbn2          CCATIGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAVPGLCAGGNCINTVGS 267 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         CCATVGQAWGHSCEQCPPISSPCTRGFIPNTRTGACQDVDECKVVPDLCKGGRCINTLGS 262 
HsFBN3          CCATVGRAWGLPCELCPAQPHPCRRGFIPNIHTGACQDVDECQAVPGLCQGGSCVNMVGS 269 
                                                                             
 
HsFBN1          FECKCPAGHKLNEVSQKCEDIDECSTIPGICEGGECTNTVSSYFCKCPPGFYTSPDGTRC 328 
HsFBN2          FECRCPAGHKQSETTQKCEDIDECSIIPGICETGECSNTVGSYFCVCPRGYVTSTDGSRC 358 
DrFbn2          YECKCPAGHRQSETNQKCEDIDECATISGVCDGGECTNTAGSYVCTCPRGYITSTDGSRC 327 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         YQCTCPVGYQQHVSILKCEDVDECSTIERACEAGHCINSAGSFSCVCPSGYVLSADRTRC 322 
HsFBN3          FHCRCPVGHRLSDS------------------------------------------SAAC 287 
                                                                             
 
HsFBN1          IDVRPGYCYTALTNGRCSNQLPQSITKMQCCCDAGRCWSPGVTVAPEMCPIRATEDFNKL 388 
HsFBN2          IDQRTGMCFSGLVNGRCAQELPGRMTKMQCCCEPGRCWGIGT--IPEACPVRGSEEYRRL 416 
DrFbn2          VDHRIGTCFSSLANGRCASELSGQYTKMQCCCDTGRCWALGH--IPEMCPVRGSDEYRRL 385 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         LDQHTGICFASVVNGRCAHEISGRFNKIQCCCDRGRCWSQRT--THEMCPVPGSDEYLRI 380 
HsFBN3          EDYRAGACFSVLFGGRCAGDLAGHYTRRQCCCDRGRCWAAGP--VPELCPPRGSNEFQQL 345 
                                                                             
 
HsFBN1          CSVPMVIPGRPEYPPPPLGPIPPVLPVPPGFPPGPQIPVPRPP----------------- 431 
HsFBN2          CMDGLPMGGIPGSAGSRPGGTGGNGFAPSGNGNGYGPGGTGFIPIPGGNGFSPGVGGAGV 476 
DrFbn2          CIQRLPFG--TGNGGIIHDGNGGLNIGGYGKGPSQNGNGGGGYIYGSEHTFTN------- 436 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         CLVGSALSGYNEEDPEMSPHHHSSFSVSPNDQILHPHNGNGQIKPQIRQTPQILQFPQIP 440 
HsFBN3          CAQRLPLLPGHPGLFPGLLGFGSNGMGPPLGPARLNPHGSDARGIPS------------- 392 
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HsFBN1          VEYLYPS---REPPRVLPVNVTDYCQLVRYLCQNGRCIPTPGSCRCECNKGFQLDLRGEC 488 
HsFBN2          GAGGQGP---IITGLTILNQTIDICKHHANLCLNGRCIPTVSSYRCECNMGYKQDANGDC 533 
DrFbn2          GNGNGGQ---KIQISQLNETTIDVCKHFTNLCLNGRCIPTPTSYRCECNMGYRQDVRGEC 493 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         QIPRHDNGFKPQRPVVSVNETVNRCRLLPNLCLNGRCIPMESDYRCDCNTGFKEDNRGEC 500 
HsFBN3          --LGPGN---SNIGTATLNQTIDICRHFTNLCLNGRCLPTPSSYRCECNVGYTQDVRGEC 447 
                                                                             
 
HsFBN1          IDVDECEKNPCAGGECINNQGSYTCQCRAGYQSTLTRTECRDIDECLQNGRICNNGRCIN 548 
HsFBN2          IDVDECTSNPCTNGDCVNTPGSYYCKCHAGFQRTPTKQACIDIDECIQNGVLCKNGRCVN 593 
DrFbn2          IDVDECVSNPCVNGDCVNTQGSYHCKCHEGYQGTPTKQACIDIDECIVNGVMCRNGRCVN 553 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         SDVDECEFDPCANGNCINTPGSYYCRCHTGFLRVTGKQTCIDIDECLQNGVLCKNGRCLN 560 
HsFBN3          IDVDECTSSPCHHGDCVNIPGTYHCRCYPGFQATPTRQACVDVDECIVSGGLCHLGRCVN 507 
                                                                             
 
HsFBN1          TDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDG 608 
HsFBN2          TDGSFQCICNAGFELTTDGKNCVDHDECTTTNMCLNGMCINEDGSFKCICKPGFVLAPNG 653 
DrFbn2          TDGSFQCICNAGFEISPDGKNCIDHDECATTNMCLNGMCINEDGSFKCICKPGFALAPNG 613 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         TEGSFQCICNSGFKLSPDGRNCVDHDECAATNMCLNGMCINEDGSFKCVCKPGFTLNSSG 620 
HsFBN3          TEGSFQCVCNAGFELSPDGKNCVDHNECATSTMCVNGVCLNEDGSFSCLCKPGFLLAPGG 567 
                                                                             
 
HsFBN1          RYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYKRG 668 
HsFBN2          RYCTDVDECQTPGICMNGHCINSEGSFRCDCPPGLAVGMDGRVCVDTHMRSTCYGGIKKG 713 
DrFbn2          RYCTDIDECHTSGICMNGRCVNTEGSFRCECPPGLAIDVDGRVCVDTHMRTTCYGAIKMG 673 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         RYCTEIDECRTPGVCMNGRCVNTQGSFRCECFAGLTVGIDGRTCVDTHMRSTCYGAVKRG 680 
HsFBN3          HYCMDIDECQTPGICVNGHCTNTEGSFRCQCLGGLAVGTDGRVCVDTHVRSTCYGAIEKG 627 
                                                                             
 
HsFBN1          QCIKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGSDINECA 728 
HsFBN2          VCVRPFPGAVTKSECCCANPDYGFGEPCQPCPAKNSAEFHGLCSSGVGITVDGRDINECA 773 
DrFbn2          VCSRPFPGAVTKSECCCANPEHGFGEPCQPCPAFNSAEFQAVCSSGPGITTDGRDINECA 733 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         LCLRPFQRAVTKSQCCCANPDYAFGEPCHPCPAKHSAEFQVLCASGVGFSADGKDINECA 740 
HsFBN3          SCARPFPGTVTKSECCCANPDHGFGEPCQLCPAKDSAEFQALCSSGLGITTDGRDINECA 687 
                                                                             
 
HsFBN1          LDPDICPNGICENLRGTYKCICNSGYEVDSTGKNCVDINECVLNSLLCDNGQCRNTPGSF 788 
HsFBN2          LDPDICANGICENLRGSYRCNCNSGYEPDASGRNCIDIDECLVNRLLCDNGLCRNTPGSY 833 
DrFbn2          LDPDICQNGICENLRGSYRCICNIGYESDASGKNCVDINECLVNRLLCDNGMCRNTPGSY 793 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         LDPDICSNGVCENLRGNFRCICNIGYESDQSGRNCLDIDECVVNSLLCDNGLCRNVPGSY 800 
HsFBN3          LDPEVCANGVCENLRGSYRCVCNLGYEAGASGKDCTDVDECALNSLLCDNGWCQNSPGSY 747 
                                                                             
 
HsFBN1          VCTCPKGFIYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSSESTLDPTKTICIET 848 
HsFBN2          SCTCPPGYVFRTETETCEDINECESNPCVNGACRNNLGSFNCECSPGSKLSSTGLICIDS 893 
DrFbn2          TCSCPKGFSFKADSETCEDINECDSNPCINGICRNIAGSFNCECSHGSKLDSTNTVCVDS 853 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         SCTCPAGFIFRHDTETCEDVNECVSSPCVNGVCKNSAGSFYCECSQGSKLDSTGLLCVDS 860 
HsFBN3          SCSCPPGFHFWQDTEICKDVDECLSSPCVSGVCRNLAGSYTCKCGPGSRLDPSGTFCLDS 807 
                                                                             
 
HsFBN1          IKGTCWQTVIDGRCEININGATLKSQCCSSLGAAWGSPCTLCQVDPICGKGYSRIKGTQC 908 
HsFBN2          LKGTCWLNIQDSRCEVNINGATLKSECCATLGAAWGSPCERCELDTACPRGLARIKGVTC 953 
DrFbn2          MKGTCWLNIQDGRCEVNINGATLKSECCSTLGAAWGSPCERCEIDPACSKGFGRMKGLVC 913 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         VKGSCWLTLQDGRCEVNINGATLRSQCCATLGLAWGSPCEPCQTDLVCERGFARSRGASC 920 
HsFBN3          TKGTCWLKIQESRCEVNLQGASLRSECCATLGAAWGSPCERCEIDPACARGFARMTGVTC 867 
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HsFBN1          EDIDECEVFPGVCKNGLCVNTRGSFKCQCPSGMTLDATGRICLDIRLETCFLRYEDEECT 968 
HsFBN2          EDVNECEVFPGVCPNGRCVNSKGSFHCECPEGLTLDGTGRVCLDIRMEQCYLKWDEDECI 1013 
DrFbn2          EDINECEVFPGVCTNGRCVNTQGSFRCECPEGLTLDGAGRTCVDVRSEQCYMKWDEDECV 973 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         EDVNECEVFPGVCHNGHCVNTRGSFKCQCPESLTLDVTGRLCVDVRSEPCFLTYEEDVCT 980 
HsFBN3          DDVNECESFPGVCPNGRCVNTAGSFRCECPEGLMLDASGRLCVDVRLEPCFLRWDEDECG 927 
                                                                             
 
HsFBN1          LPIAGRHRMDACCCSVGAAWGTEECEECPMRNTPEYEELCPRGPGFATK-EITNGKPFFK 1027 
HsFBN2          HPVPGKFRMDACCCAVGAAWG-TECEECPKPGTKEYETLCPRGAGFANRGDVLTGRPFYK 1072 
DrFbn2          EPLPGRYRVDMCCCTVGAAWG-VDCEACPKPNTNEFKTICPRGPGIANRGDILTGRPFYK 1032 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         QPVPGRFRMDMCCCTVGLAWG-KDCDLCPEPGTRQFDTLCPRGPGFANKGDVLTGRAVYK 1039 
HsFBN3          VTLPGKYRMDVCCCSIGAVWG-VECEACPDPESLEFASLCPRGLGFASR-DFLSGRPFYK 985 
                                                                             
 
HsFBN1          DINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCV 1087 
HsFBN2          DINECKAFPGMCTYGKCRNTIGSFKCRCNSGFALDMEERNCTDIDECRISPDLCGSGICV 1132 
DrFbn2          DVNECKVFRGLCTHGTCRNTIGSFKCRCDSGFALTMEERNCTDIDECTISPDLCGHGVCV 1092 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         DINECKVFQSICVHGKCRNTIGSFRCRCDSGFALDTNEKNCTDIDECMISPDVCGHGTCV 1099 
HsFBN3          DVNECKVFPGLCTHGTCRNTVGSFHCACAGGFALDAQERNCTDIDECRISPDLCGQGTCV 1045 
                                                                             
 
HsFBN1          NTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGVCHNTEGSYRCECPPGHQLS 1147 
HsFBN2          NTPGSFECECFEGYESGFMMMKNCMDIDECERNPLLCRGGTCVNTEGSFQCDCPLGHELS 1192 
DrFbn2          NTPGSFECECFDGYESGFMMMKNCMDIDECERDPLLCRGGTCLNTEGSYECDCPPGHQLS 1152 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         NTLGSFQCDCFPGYESGIMMMKNCMDIDECERNLSLCNGGTCENTDGSYKCVCPPGHHLS 1159 
HsFBN3          NTPGSFECECFPGYESGFMLMKNCMDVDECARDPLLCRGGTCTNTDGSYKCQCPPGHELT 1105 
                                                                             
 
HsFBN1          PNISACIDINECELSAHLCPNGRCVNLIGKYQCACNPGYHSTPDRLFCVDIDECSIMNGG 1207 
HsFBN2          PSREDCVDINECSLSDNLCRNGKCVNMIGTYQCSCNPGYQATPDRQGCTDIDECMIMNGG 1252 
DrFbn2          TEASACEDVNECQLSDNLCKHGQCVNMVGTYQCSCETGYQVTPDRQGCVDIDECTIMNGG 1212 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         VDGSACEDVNECDLSSTLCPNGWCVNLVGTYQCSCNSGYQTAPDWKGCTDIDECTIENGG 1219 
HsFBN3          AKGTACEDIDECSLSDGLCPHGQCVNVIGAFQCSCHAGFQSTPDRQGCVDINECRVQNGG 1165 
                                                                             
 
HsFBN1          CETFCTNSEGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYD 1267 
HsFBN2          CDTQCTNSEGSYECSCSEGYALMPDGRSCADIDECENNPDICDGGQCTNIPGEYRCLCYD 1312 
DrFbn2          CDTHCTNSEGSYECSCSEGYALMPDLRTCADIDECEDTPDICDGGQCTNIPGEYRCLCYD 1272 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         CELYCSNSEGSYSCSCGQGYSLTPDQRTCSDVNECEEVLDICEGGQCTNVPGAYHCLCYE 1279 
HsFBN3          CDVHCINTEGSYRCSCGQGYSLMPDGRACADVDECEENPRVCDQGHCTNMPGGHRCLCYD 1225 
                                                                             
 
HsFBN1          GFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECE 1327 
HsFBN2          GFMASMDMKTCIDVNECDLNSNICMFGECENTKGSFICHCQLGYSVKKGTTGCTDVDECE 1372 
DrFbn2          GFMASMDMRTCIDVNECDLNPNICLHGDCENTKGSFICHCQLGYFVKKGSTGCTDVDECE 1332 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         GFMASVDMKTCIDVNECELNDNICAFGECENTKGSFICHCDIGYAVKKGTSGCTDVNECE 1339 
HsFBN3          GFMATPDMRTCVDVDECDLNPHICLHGDCENTKGSFVCHCQLGYMVRKGATGCSDVDECE 1285 
                                                                             
 
HsFBN1          IGAHNCGKHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSY 1387 
HsFBN2          IGAHNCDMHASCLNIPGSFKCSCREGWIGNGIKCIDLDECSNGTHQCSINAQCVNTPGSY 1432 
DrFbn2          IGAHNCDLHAACVNAPGSFKCRCRDGWEGDGIKCIDVDECVTEEHNCNPNAECLNTPGSY 1392 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         INSHNCDTHATCVNTPGHYHCSCGDGWFGDGVKCADVDECANRTSVCSADAECVNTAGSY 1399 
HsFBN3          VGGHNCDSHASCLNIPGSFSCRCLPGWVGDGFECHDLDECVSQEHRCSPRGDCLNVPGSY 1345 
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HsFBN1          RCLCKEGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDI 1447 
HsFBN2          RCACSEGFTGDGFTCSDVDECAENINLCENGQCLNVPGAYRCECEMGFTPASDSRSCQDI 1492 
DrFbn2          RCSCKEGFNGDGFSCSDMDECADNVNLCENGQCLNAPGGYRCECEMGFTPTEDSKACQDI 1452 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         HCECSDGFIGDGVICSDLDECAEDVDLCENGQCLNVPGSYRCECEMGFTHTSNRKTCRDI 1459 
HsFBN3          RCTCRQGFAGDGFFCEDRDECAENVDLCDNGQCLNAPGGYRCECEMGFDPTEDHRACQDV 1405 
                                                                             
 
HsFBN1          DECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPG 1507 
HsFBN2          DECSFQNICVFGTCNNLPGMFHCICDDGYELDRTGGNCTDIDECADPINCVNGLCVNTPG 1552 
DrFbn2          DECNFQNICVFGSCQNLPGMFRCVCDYGYELDRSGGNCTDINECFDPVNCINGVCVNLPG 1512 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         DECSFQNICVFGTCQNIPGMFRCICDEGYELDRTGGNCTDVDECLDSLNCVNGHCENTAG 1519 
HsFBN3          DECAQGNLCAFGSCENLPGMFRCICNGGYELDRGGGNCTDINECADPVNCINGVCINTPG 1465 
                                                                             
 
HsFBN1          SYICDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLG 1567 
HsFBN2          RYECNCPPDFQLNPTGVGCVDNRVGNCYLKFGPRGDGS-LSCNTEIGVGVSRSSCCCSLG 1611 
DrFbn2          SYLCNCPPDFELNPSGVGCVDTRVGNCFLDTLDRGDGG-ISCSAEIGVGVTRASCCCSLG 1571 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         SYQCNCPIDFELNPTGIGCVDTRVGNCFLEVAYH---SKLACSAEIGFGVSRSSCCCSLG 1576 
HsFBN3          SYLCSCPQDFELNPSGVGCVDTRAGNCFLETHDRGDSG-ISCSAEIGVGVTRASCCCSLG 1524 
    
                                                                          
HsFBN1          KAWGTPCEMCPAVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFG 1627 
HsFBN2          KAWGNPCETCPPVNSTEYYTLCPGGEGFRPNPITIILEDIDECQELPGLCQGGNCINTFG 1671 
DrFbn2          GAWGNPCELCPFVNSTEYKTLCPGGEGFRPNPITVILEDIDECQELPGLCQGGNCVNTFG 1631 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         RVWGYPCDHCPTLNTSEYNTLCPGGEGFKPNPVTIILEDIDECQELPGLCQGGNCVNTFG 1636 
HsFBN3          RAWGNPCELCPMANTTEYRTLCPGGEGFQPNRITVILEDIDECQELPGLCQGGDCVNTFG 1584 
                                                                             
 
HsFBN1          SFQCRCPTGYYLNEDTRVCDDVNECETP-GICGPGTCYNTVGNYTCICPPDYMQVNGGNN 1686 
HsFBN2          SFQCECPQGYYLSEDTRICEDIDECFAHPGVCGPGTCYNTLGNYTCICPPEYMQVNGGHN 1731 
DrFbn2          SFQCECPAGYYLNEETRICEDIDECTAHIGICGPGTCYNTLGNYTCVCPPEYMQVNGGNN 1691 
pXlFbn          ------------------------------------------------------------ 
pDrFbn4         SFQCECPAGFYLNTQSRICEDIDECVLSLGVCGPGTCYNTLGNYTCVCPQEYIQVNGGHR 1696 
HsFBN3          SFQCECPPGYHLSEHTRICEDIDECSTHSGICGPGTCYNTLGNYTCVCPAEYLQVNGGNN 1644 
                                                                             
 
HsFBN1          CMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFAT 1746 
HsFBN2          CMDMRKSFCYRSYNG--TTCENELPFNVTKRMCCCTYNVGKAWNKPCEPCPTPGTADFKT 1789 
DrFbn2          CMDMRKSVCYRNFN---DTCENELSFNMTKKMCCCAYNVGKAWNRPCEACPTPATSEYQL 1748 
pXlFbn          ---------RRNYN---DTCENELSSNMTKKMCCCSYNIGKAWNKPCEPCPSPATPEYIF 48 
pDrFbn4         CMDMRKSLCYRSYNG--SACEHQLNFNITHRLCCCSYNVGKAWNKPCHACPIPGTDDYSS 1754 
HsFBN3          CMDMRKSVCFRHYN---GTCQNELAFNVTRKMCCCSYNIGQAWNRPCEACPTPISPDYQI 1701 
                          * :     :*: :*  *:*:::***:**:*:***:**. ** * : ::   
 
HsFBN1          LCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVC 1806 
HsFBN2          ICGN-IPGFTFDIHTGKAVDIDECKEIPGICANGVCINQIGSFRCECPTGFSYNDLLLVC 1848 
DrFbn2          LCGNQAPGFIIDIHTGKPIDIDECREIPGICANGVCINQIGSFRCECPMGFSYNNILLIC 1808 
pXlFbn          LCGNQAPGFIIDIRTGKPMDIDECSEIPAICSNGVCINQIGTFRCECPMGFSYNNILLIC 108 
pDrFbn4         LCGS-VTGFWINIATGKPKDIDECHEIPGVCAHGVCINHMGSFHCECPTGFLYNDLLLIC 1813 
HsFBN3          LCGNQAPGFLTDIHTGKPLDIDECGEIPAICANGICINQIGSFRCECPAGFNYNSILLAC 1761 
                :**.  .**  :* ** . ***** ***.:* :*:*** :*:*:**** ** **. ** * 
 
HsFBN1          EDIDECQNG-PVCQRNAECINTAGSYRCDCKPGYRFTSTGQCNDRNECQEIPNICSHGQC 1865 
HsFBN2          EDIDECSNGDNLCQRNADCINSPGSYRCECAAGFKLSPNGACVDRNECLEIPNVCSHGLC 1908 
DrFbn2          EDIDECNSGDNLCQRNANCINIPGSYRCECSAGFKLSPSGACIDRNECQEIPNVCSHGEC 1868 
pXlFbn          EDIDECSSGENLCQRNADCINIPGSYRCECSSGYKLSPSGACVGRNECQEIPNVCSHGTC 168 
pDrFbn4         EDIDECSSREPVCQRNADCINRPGGYQCECSDGYILTPNGDCNDRNECLETPSVCRHGDC 1873 
HsFBN3          EDVDECGSRESPCQQNADCINIPGSYRCKCTRGYKLSPGGACVGRNECREIPNVCSHGDC 1821 
                **:*** .    **:**:*** .*.*:*.*  *: ::. * * .**** * *.:* **  
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HsFBN1          IDTVGSFYCLCHTGFKTNDDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHN 1925 
HsFBN2          VDLQGSYQCICHNGFKASQDQTMCMDVDECERHPCGNGTCKNTVGSYNCLCYPGFELTHN 1968 
DrFbn2          IDTQGSFRCLCHNGFKTTPDQTMCMDIDECDRQPCGNGTCKNTVGSYNCLCFPGFELTHN 1928 
pXlFbn          MDTEGSYICVCHNGFKASGDQTMCMDIDECDRQPCGNGTCKNTVGSYNCLCFPGFELTHN 228 
pDrFbn4         VDIPGGYECMCHTGFTVTPNRRMCVDVNECSPQPCGNGTCKNSVGSFNCICHHGFELATN 1933 
HsFBN3          MDTEGSYMCLCHRGFQASADQTLCMDIDECDRQPCGNGTCKNIIGSYNCLCFPGFVVTHN 1881 
                :*  *.: *:** ** .. :: :*:*::**. ..******:* :**:** *  ** :: * 
 
HsFBN1          NDCIDVDECASGNGNLCRNGQCINTVGSFQCQCNEGYEVAPDGRTCVDINECLLEPRKCA 1985 
HsFBN2          NDCLDIDECSSFFGQVCRNGRCFNEIGSFKCLCNEGYELTPDGKNCIDTNECVALPGSCS 2028 
DrFbn2          NDCMDIDECSVHASQVCRNGQCINNMGSFKCLCLDGYNLTPDGKNCVDINECVTLPGACQ 1988 
pXlFbn          NDCMDIDECSSLVGQVCRNGQCINNVGSFQCLCQEGYEITPDGKNCMDINECTSLPATCS 288 
pDrFbn4         NYCTDIDECAVFHSQLCRNGRCVNNVGSFQCLCREGYELTFDGKTCMDVNECTIIPGICA 1993 
HsFBN3          GDCVDFDECTTLVGQVCRFGHCLNTAGSFHCLCQDGFELTADGKNCVDTNECLSLAGTCL 1941 
                . * *.***:   .::** *:*.*  ***:* * :*:::: **:.*:* ***   .  *  
 
HsFBN1          PGTCQNLDGSYRCICPPGYSLQNEKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFS 2045 
HsFBN2          PGTCQNLEGSFRCICPPGYEVKSENCIDINECDEDPNICLFGSCTNTPGGFQCLCPPGFV 2088 
DrFbn2          PGTCQNLDGSFRCICPPGYEVQNDKCVDINECNVEPNICQFGTCKNTPGSFQCICQPGFV 2048 
pXlFbn          PGTCQNLEGSFRCICPPGFEVQNDNCIDINECDEEPNICLFGTCTNTPGSFQCVCPPGFV 348 
pDrFbn4         PGTCLNLDGSFRCVCPDGYIVQSDHCVDVNECSEEPGICTYGTCFNSLGSFECVCKPGFV 2053 
HsFBN3          PGTCQNLEGSFRCICPPGFQVQSDHCIDIDECSEEPNLCLFGTCTNSPGSFQCLCPPGFV 2001 
                **** **:**:**:** *: ::.::* *::**  :* :*  *:* *: *.*:*:*  **  
 
HsFBN1          LSSSGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALK-GEGWGDPCELCPTE-P 2103 
HsFBN2          LSDNGRRCFDTRQSFCFTNFENGKCSVPKAFNTTKAKCCCSKMPGEGWGDPCELCPKD-D 2147 
DrFbn2          LSDNGRRCFDTRESFCFTRFEAGKCSVPKPRNTTKAKCCCSLLPGEGWGDPCELCPRDTE 2108 
pXlFbn          LSDNGRRCFDTRQSFCFTRFDNGKCSVPKAFNTTKARCCCSKMPGEGWGDPCELCPQE-G 407 
pDrFbn4         LSEDKRRCYDTRESFCFTRFENSKCSVPQAFNTTKAKCCCSIMAKEGWGDPCELCPKE-- 2111 
HsFBN3          LSDNGHRCFDTRQSFCFTRFEAGKCSVPKAFNTTKTRCCCSKRPGEGWGDPCELCPQE-G 2060 
                **.. :** * * *:*::.*: .*** *:. * :* .***:    *********** :   
 
HsFBN1          DEAFRQICPYGSGIIVGPDDSAVDMDECKE-PDVCKHGQCINTDGSYRCECPFGYILAGN 2162 
HsFBN2          EVAFQDLCPYGHGTVPSLHDTREDVNECLESPGICSNGQCINTDGSFRCECPMGYNLDYT 2207 
DrFbn2          EAAFHTLCPYGHEAVP-KPEGREDMNECVENPEICGNGLCINTDGSFRCECPFGYNLDYT 2167 
pXlFbn          SVAFQELCPYGHGSIPGMGDTREDVNECSESPGICVNGVCINTDGSFRCECPFGYNLDYT 467 
pDrFbn4         HDAFQDLCPFGHGIIPGVGDTRVDLNECVENPEICVNGRCINMDGSFRCECPAGYTLDYT 2171 
HsFBN3          SAAFQELCPFGHGAVPGPDDSREDVNECAENPGVCTNGVCVNTDGSFRCECPFGYSLDFT 2120 
                  **: :**:*   :    :   *::** * * :* :* *:* ***:***** ** *  . 
 
HsFBN1          --ECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFR 2220 
HsFBN2          GVRCVDTDECSIGNPCGNGTCTNVIGSFECNCNEGFEPGPMMNCEDINECAQNPLLCAFR 2267 
DrFbn2          GVNCVDTDECSIGNPCGNGTCSNVPGGFECSCQEGFEPGPMMTCEDINECAVNPLLCAFR 2227 
pXlFbn          GVNCVDTDECSIGNPCGNGTCSNVVGGFECACDEGFEPGPMMTCEDINECTN-PLLCAFR 526 
pDrFbn4         GTHCDDIDECSVRNPCGNGTCSNVIGAFECLCEEGFEPGPMMSCEDVNECGQNPLLCAFR 2231 
HsFBN3          GINCVDTDECSVGHPCGQGTCTNVIGGFECACADGFEPGLMMTCEDIDECSLNPLLCAFR 2180 
                  .* * ****: :***:***.** *.*** * :***** **.***::**   ******* 
 
HsFBN1          CVNTYGSYECKCPVGYVLREDRRMCKDEDECEEGKHDCTEKQMECKNLIGTYMCICGPGY 2280 
HsFBN2          CMNTFGSYECTCPIGYALREDQKMCKDLDECAEGLHDCESRGMMCKNLIGTFMCICPPGM 2327 
DrFbn2          CVNTFGSYECMCPTGYVLRDDNRMCRDQDECAEGLDDCASRGMACKNQIGTFMCICPPGM 2287 
pXlFbn          CINTYGSYECTCPSGYTLREDQRMCKDLDECAEGLHDCESRGMMCKNLIGTFMCICPPGL 586 
pDrFbn4         CINTFGSYECSCPSGYTLREDGRMCQDVDECAEDLHNCDSRGMECSNLIGTFMCVCPAGM 2291 
HsFBN3          CHNTEGSYLCTCPAGYTLREDGAMCRDVDECADGQQDCHARGMECKNLIGTFACVCPPGM 2240 
                * ** *** * ** **.**:*  **:* *** :. .:*  : * *.* ***: *:* .*  
 
HsFBN1          QRRP-DGEGCVDENECQTKPGICENGRCLNTRGSYTCECNDGFTASPNQDECLDNREGYC 2339 
HsFBN2          ARRP-DGEGCVDENECRTKPGICENGRCVNIIGSYRCECNEGFQSSSSGTECLDNRQGLC 2386 
DrFbn2          TRRP-DGEGCMDLNECRSKPGICKNGRCVNTVGSYRCECNEGFEASATGTECIDNRKGFC 2346 
pXlFbn          QRRP-DGEGCMDENECRTKPGICANGRCVNTIGSYKCDCNEGFQVSSSGTECVDTRQGFC 645 
pDrFbn4         IRRM-SDEACQDENECLTQPGVCENGRCVNTVGSYTCECGVGFKTDSSATQCLDYRKGFC 2350 
HsFBN3          RPLPGSGEGCTDDNECHAQPDLCVNGRCVNTAGSFRCDCDEGFQPSPTLTECHDIRQGPC 2300 
                     ..*.* * *** ::*.:* ****:*  **: *:*. **  ...  :* * *:* * 
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HsFBN1          FTEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFQGTVAFKKLCPHGRGFMTN 2399 
HsFBN2          FAEVLQTICQMASSSRNLVTKSECCCDGGRGWGHQCELCPLPGTAQYKKICPHGPGYTTD 2446 
DrFbn2          FTEVLQTMCQQSSTNRNTVTKSECCCNGGRGWGSLCELCPLPGTIQYKKMCPLGPGYTTD 2406 
pXlFbn          FTEVLQTMCQLSSTNRNMVTKSECCCNSGRGWGNQCEICPLPGTGAFKKMCPHGAGFSTD 705 
pDrFbn4         FTEVLHTMCQMSSSSRVPVSRSQCCCNGGHGWGDQCELCPLPATANYKKLCPYGHGYAID 2410 
HsFBN3          FAEVLQTMCRSLSSSSEAVTRAECCCGGGRGWGPRCELCPLPGTSAYRKLCPHGSGYTAE 2360 
                *:***:.:*:  *:.   *::::***..*:***  **:**: .*  ::*:** * *:  : 
 
HsFBN1          GADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTSCVDLNECNQAPKPCNFIC 2459 
HsFBN2          GRDIDECKVMPNLCTNGQCINTMGSFRCFCKVGYTTDISGTSCIDLDECSQSPKPCNYIC 2506 
DrFbn2          GRDINECEVMPNLCKNGQCINSVGSFRCHCNVGYTNDFTGTSCIDMDECSQSPKPCNFLC 2466 
pXlFbn          GRDIDECKVLPNLCKNGQCINTIGSFRCHCKLGYTTDITGTTCVDLDECAQSPKPCNFIC 765 
pDrFbn4         GTDIDECKLIPDVCANGACINMMGSYRCHCKPGYIASTAGTACVDVDECGMSPKPCNFIC 2470 
HsFBN3          GRDVDECRMLAHLCAHGECINSLGSFRCHCQAGYTPDATATTCLDMDECSQVPKPCTFLC 2420 
                * *::**.:: .:* :* *:*  **::* *: **  . :.*:*:*::**   ****.::* 
 
HsFBN1          KNTEG-SYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQH 2518 
HsFBN2          KNTEG-SYQCSCPRGYVLQEDGKTCKDLDECQTKQHNCQFLCVNTLGGFTCKCPPGFTQH 2565 
DrFbn2          KNTEG-SYLCSCPRGYILQPDGKTCKDLDECSTKQHNCQFLCVNTIGGFTCKCPSGFTQH 2525 
pXlFbn          KNTEGKSITCSCPTAYILQEDGKRCKDLDECSTKQHNCQFLCVNTIGSFTCKCPPGFTQH 825 
pDrFbn4         KNTEG-SYACSCPRGYTLQNDNRSCKDVDECQSRRHNCQFSCMNTIGGFTCKCPAGFSQH 2529 
HsFBN3          KNTKG-SFLCSCPRGYLLEEDGRTCKDLDECTSRQHNCQFLCVNTVGAFTCRCPPGFTQH 2479 
                ***:* *  **** .* *: *.: ***:*** :::***** *:**:*.***:**.**:** 
 
HsFBN1          HTSCIDNNECTSDINLCGSKGICQNTPGSFTCECQRGFSLDQTGSSCEDVDECEGNHRCQ 2578 
HsFBN2          HTACIDNNECGSQPSLCGAKGICQNTPGSFSCECQRGFSLDATGLNCEDVDECDGNHRCQ 2625 
DrFbn2          QTACIDNNECSNQPNICGSRASCLNSPGSFNCECQKGFSLDATGLNCDDVDECGGNHRCQ 2585 
pXlFbn          QSSCIDNNECNAQPNLCGSRGTCQNNPGSFTCECQKGFSLDNSGSNCEDVDECDGNHRCQ 885 
pDrFbn4         HRACRDIDECLSDLTPCGLQGACQNSVGSFSCECPQGFSLDSLGHNCDDVDECARDHRCQ 2589 
HsFBN3          HQACFDNDECSAQPGPCGAHGHCHNTPGSFRCECHQGFTLVSSGHGCEDVNECDGPHRCQ 2539 
                : :* * :**  :   ** :. * *. *** *** :**:*   * .*:**:**   **** 
 
HsFBN1          HGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECL-SAHICGGASCHNTLGSYKCMCPAGF 2637 
HsFBN2          HGCQNILGGYRCGCPQGYIQHYQWNQCVDENECS-NPNACGSASCYNTLGSYKCACPSGF 2684 
DrFbn2          HGCQNMMGGYRCGCPQGYVQHYQWNQCVDENECT-GNQVCGSASCYNTLGSYKCVCPSGF 2644 
pXlFbn          HGCQNVLGGFRCGCPQRYVQHYQWNQCVDENECA-SQSACGSASCYNTLGSFKCVCPSGF 944 
pDrFbn4         FGCQNVAGGFRCSCPQGYTQHQQWNQCVDDNECL-NADNCGSASCFNTLGSFKCGCPSGF 2648 
HsFBN3          HGCQNQLGGYRCSCPQGFTQHSQWAQCVDENECALSPPTCGSASCRNTLGGFRCVCPSGF 2599 
                .****  **:**.*** : ** ** ****:***  .   **.*** ****.::* **:** 
 
HsFBN1          QYEQFSGGCQDINECGSAQ-APCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGN 2696 
HsFBN2          SFDQFSSACHDVNECSSSK-NPCNYGCSNTEGGYLCGCPPGYYRVGQGHCVSGMGFNKGQ 2743 
DrFbn2          DFEATAGGCQDVNECSMGN-NPCSYGCSNTDGGYLCGCPGGFYRAGQGHCINGVGF-QGQ 2702 
pXlFbn          DFDQSFGGCQDVDECSSGGGNPCSYGCSNTDGGYLCGCPGGYFRAGQGHCVSGMGFGKGS 1004 
pDrFbn4         TFDPASTSCEDVDECGSFM-NPCRYGCSNTQGGFACGCPAGYYRAGQG------------ 2695 
HsFBN3          DFDQALGGCQEVDECAGRR-GPCSYSCANTPGGFLCGCPQGYFRAGQGHCVSGLGFSPGP 2658 
                 ::    .*.:::**.     ** *.*:** **: **** *::* ***             
 
HsFBN1          PEPPVSGEMDDNSLSPEACYECKINGYPKR-GRKRRSTNETDASNIEDQSETEANVSLAS 2755 
HsFBN2          YLSLDTEVDEENALSPEACYECKINGYSKKDSRQKRSIHEPDPT-------AVEQISLES 2796 
DrFbn2          FGSEGG--DDEESLSPEACYECKINGDLGKKGRHRRNADDNE---------LKETVSMAS 2751 
pXlFbn          YLQAPVEEDEENVLSPESCYECKINGYPKR-GRQRRNADDINGN-------EIQNVSLAS 1056 
pDrFbn4         ------------------------------------------------------------ 
HsFBN3          Q----DTPDKEELLSSEACYECKINGLSPR-DRPRRSAHRDH------------QVNLAT 2701 
                                                                             
 
HsFBN1          WDVEKTAIFAFNISHVSNKVRILELLPALTTLTNHNRYLIESGNEDGFFKINQK-EGISY 2814 
HsFBN2          VDMDSPVNMKFNLSHLGSKEHILELRPAIQPLNNHIRYVISQGNDDSVFRIHQR-NGLSY 2855 
DrFbn2          MDIQTSIPMNLSLAQLLNKEPLLELLPALEPLEHHVRYVITHGNQGEHFRILERRDGKSV 2811 
pXlFbn          VDIDAPLNMTLNISDLANKQHIFEFIPALESLENRVRYIISHGNEGGIFHIHQR-DGISY 1115 
pDrFbn4         ------------------------------------------------------------ 
HsFBN3          LDSEALLTLGLNLSHLGRAERILELRPALEGLEGRIRYVIVRGNEQGFFRMHHL-RGVSS 2760 
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HsFBN1          LHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDKYDKDYLSGELGDNLKMKIQVLLH 2871 
HsFBN2          LHTAKKKLMPGTYTLEITSIPLYKKKELKKLEESNEDDYLLGELGEALRMRLQIQLY 2912 
DrFbn2          LRLGRRPPAPGLYRLEIASLRLFGPRKLQQMEDQHDSDYLLGEIGDALRIKLHIHLH 2868 
pXlFbn          LHLGHKKVATGIYNLEIASVSLYRKKELQKLEDEKDHNYLSGEVGQTLKMKLHIHLY 1172 
pDrFbn4         --------------------------------------------------------- 
HsFBN3          LQLGRRRPGPGTYRLEVVSH-MAGPWGVQPEGQP-------GPWGQALRLKVQLQLL 2809 
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Abstract 
A number of zebrafish mutants identified in large-scale forward genetic screens exhibit 
notochord distortion. We now report the cloning and further characterization of one such 
mutant, gulliver
m208 
(gul
m208
). The notochord defect in gul
m208 
mutants is exacerbated 
under conditions of copper depletion or lysyl oxidase cuproenzyme inhibition that are 
without a notochord effect on wild-type embryos. The gul
m208 
phenotype results from a 
missense mutation in the gene encoding Col8a1, a lysyl oxidase substrate, and 
morpholino knockdown of col8a1 recapitulates the notochord distortion observed in 
gul
m208 
mutants. Interestingly, the amino acid mutated in gul
m208 
Col8a1 is highly 
conserved, and the equivalent substitution in a closely related human protein, COL10A1, 
causes Schmid metaphyseal chondrodysplasia. Taken together, the data identify a new 
protein essential for notochord morphogenesis, extend our understanding of gene-nutrient 
interactions in early development, and suggest that human mutations in COL8A1 may 
cause structural birth defects. 
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Introduction 
The notochord is a midline structure that functions both as an axial skeleton and as an 
important signaling center to other tissues during embryogenesis (31). It is one of the 
defining structures of the chordate phylum, and is the first organ to fully differentiate in 
vertebrates (31). The notochord arises from the dorsal organiser and likely represents a 
primitive form of cartilage, as indicated by its expression of type II collagen, type IX 
collagen, sox9, aggrecan, and chondromodulin (16). In higher chordates, the notochord 
plays a critical role in vertebral column formation and persists post-embryonically as the 
nucleus pulposus of intervertebral discs (16).  
 In zebrafish, studies of notochord morphogenesis are facilitated by the genetic 
tractability of this model organism and by the ease with which its notochord is visualized 
throughout early development (16, 19, 20). During late notochord morphogenesis, 
chordamesoderm differentiates into mature notochord, a transition that involves the 
downregulation of specific marker genes and the inflation of notochord cell vacuoles 
which exert turgor pressure on an extracellular matrix sheath (31). If sheath formation is 
impaired, this turgor pressure results in notochord abnormalities that are readily 
observed, permitting insight into the mechanisms of both notochord morphogenesis and 
extracellular matrix formation. Indeed, a number of zebrafish notochord mutants have 
already been identified during large-scale forward genetic screens (17, 18), and early 
studies of these mutants established the importance of laminins and coatomer proteins in 
notochord differentiation and sheath formation (19, 20). Since notochord abnormalities 
and extracellular matrix defects have both been implicated in the development of 
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structural birth defects (11, 15, 134), elucidating the mechanisms of notochord formation 
will not only permit a greater understanding of the biology of this important organ, but 
may also allow for the therapeutic intervention or prevention of structural birth defects, 
which are a major cause of morbidity and mortality in children (135). 
Previous work in our laboratory has demonstrated that copper deficiency causes 
notochord distortion in zebrafish embryos and that this distortion results from the 
inhibition of specific lysyl oxidase cuproenzymes, which crosslink collagens in the 
notochord sheath (14, 80). In addition, we have recently conducted a forward genetic 
screen for zebrafish mutants that exhibit increased notochord distortion after partial lysyl 
oxidase inhibition, identifying one such mutant (136). These studies raised the intriguing 
possibility that notochord mutants previously identified in large-scale forward genetic 
screens (17, 18) could provide insight into the molecular mechanisms of copper-
dependent notochord formation. We now report the mapping and further characterization 
of one such recessive lethal mutant, gulliver
m208 
(17). The analysis presented here 
demonstrates a role for the alpha 1 chain of type VIII collagen in zebrafish notochord 
formation and an interaction with lysyl oxidase cuproenzymes. 
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Materials and methods 
Zebrafish maintenance 
Gulliver
m208
 was obtained from the Zebrafish International Resource Center (Eugene, 
OR). Zebrafish were reared under standard conditions at 28.5C (33) and staged as 
described (34). Synchronous, in vitro fertilized embryos were obtained for all 
experiments, which were carried out in accordance with Washington University‟s 
Division of Comparative Medicine guidelines. In Figs. 1, 2, and the first two lanes of 5B, 
“wild-type” refers to either +/+ or +/- embryos. 
Microscopy 
Live embryos were anesthetized in tricaine, mounted in 2% methylcellulose, and imaged 
using an Olympus SZX12 zoom stereomicroscope fitted with an Olympus DP70 camera. 
Electron microscopy was carried out as previously described (80) except that negatives 
were directly scanned using a Canon Canoscan 8400F. For the electron microscopy, 
sections from two wild-type and two mutant embryos were examined. 
Pharmacologic treatment and yolk sac extension measurements 
Pharmacologic compounds were purchased from Sigma (St. Louis, MO).-
aminopropionitrile (A3134) and neocuproine (N1501) were prepared as 100 mM stocks 
in egg water (33) and dimethyl sulfoxide, respectively, and diluted in egg water. 
Tunicamycin (T7765) was prepared as a 1 mg/mL stock in DMSO and used at a 
concentration of 2 g/mL. 4-Phenylbutyric acid (P21005) was prepared as a 2 M stock in 
DMSO and used at a concentration of 5 mM in buffered egg water adjusted to a pH of 6.9 
(137). In all cases, embryos were placed in compound between 6 and 10 hpf. Lengths of 
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individual yolk sac extensions were measured from photographs of 10 mutant and 10 
wild-type embryos per pharmacologic treatment using ImageJ software (47). Values are 
reported in arbitrary units, with standard deviations noted. 
Meiotic mapping 
Gulliver
m208
 was mapcrossed to the polymorphic WIK strain and the progeny (AB*/WIK) 
raised to adulthood. The gul
m208 
mutation was assigned to chromosome 9 by centromeric 
linkage analysis (26, 93) using simple sequence length polymorphism (SSLP) markers 
(94) and DNA from early pressure gynogenetic diploids. For fine mapping, 1295 mutant 
embryos from AB*/WIK females crossed to AB*/AB males were collected and assessed 
for recombination along chromosome 9 by SSLP analysis. Embryos were incubated in 2 
M neocuproine to accentuate the mutant phenotype and facilitate rapid mutant 
identification. When necessary, candidate marker primer pairs for BAC sequences were 
generated using the Zebrafish SSR search website of the Massachusetts General Hospital 
(http://danio.mgh.harvard.edu/markers/ssr.html). Primers for the BAC markers used in 
Fig. 3 are: zC81J7 – forward 5‟-TTGTTCTGCAAATTTTGTTGG-3‟ and reverse 5‟-
GGGGCAACCCCTCTAAAGT-3‟; zK46K9 – forward 5‟-
AACACAAGCTGGGACTGGAC-3‟ and reverse 5‟-
GATGTCTAACACAAACACATTGG-3‟; zC206L17 – forward 5‟-
GAGTATCACCTCTGACAGATGGG-3‟ and reverse 5‟-
GCAGCATTGACGGTGAAGGTCAC-3‟; zK229B18 – forward 5‟-
TGATTAATACAACATGGGCA-3‟ and reverse 5‟-CGCACTGTGAAATAACATGA-
3‟; zC184M13 – forward 5‟-GGAAGTGTGTGTGTGCGTTT-3‟ and reverse 5‟-
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GGCCACAAGAACCATGACA-3‟ (descendents of one WIK grandparent) and also 
forward 5‟-TGGTGTAGGGGGCTAACAAG-3‟ and reverse 5‟-
TGAACTGAACTGGCATGAACA-3‟ (descendents of the other WIK grandparent). 
DNA from wild-type and heterozygote embryos as well as WIK and AB grandparents 
was used to ensure polymorphism between AB and WIK.  
Cloning and annotation 
Full-length col8a1 was amplified from wild-type and mutant cDNA and cloned into pCR-
XL-TOPO (Invitrogen). cDNA for these reactions was generated with Superscript III 
reverse transcriptase (Invitrogen) and PCR carried out using Phusion DNA polymerase 
and high-fidelity buffer (Finnzymes). The primers used for PCR were: forward primer 5‟-
GAGTGAGCCCACCAATCCTTG-3‟ and reverse primer 5‟-
CCTTCAAATTCTTACTTATTCTTGC-3‟. The full-length zebrafish col8a1 coding 
sequence is available at Genbank (accession number EU781032). The protein sequence 
alignment of zebrafish Col8a1 with orthologues from other species was created using 
ClustalW2 (96). Signal peptides were predicted using SignalP 3.0 (39).   
Trimerization assay 
Wild-type and mutant col8a1 sequences were subcloned into pCS2+ and in vitro 
transcribed and translated in the presence of TRAN35S-LABEL (MP Biomedicals) using 
the SP6 TNT Coupled Reticulocyte Lysate System (Promega) essentially as described 
(138, 139). 5 µl of each 25 µl reaction was mixed with an equal volume of 2X sample 
buffer containing 250 mM Tris pH 6.8, 4 M urea, 4% sodium dodecyl sulfate (SDS), 24 
mM dithiothreitol, and a small amount of bromophenol blue. Samples were heated at 
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50C for 5 minutes and subjected to SDS-PAGE on a 1 mm gel with 3.5% stacking and 
7.5% resolving layers. The gel was fixed for 30 minutes in a mixture of 20% methanol 
and 10% glacial acetic acid, washed in water for 5 minutes, and vacuum dried at 80 C 
for 2 hours before exposure of a low-energy phosphor screen (Amersham) and image 
acquisition using a Storm imaging system (Amersham). 
Whole-mount in situ hybridization and frozen sections 
Embryos were manually dechorionated at the indicated developmental stages, fixed in 
4% paraformaldehyde-PBS overnight at 4C, and dehydrated by methanol series. The 
probe construct was generated by cloning the 5‟ end of zebrafish col8a1 into pCRII 
(Invitrogen). The primers used for the PCR amplification reaction were: forward primer 
5‟-GAGTGAGCCCACCAATCCTTG-3‟ and reverse primer 5‟-
CTCCTGGACTTCCAATACCC-3‟. DIG-labeled antisense RNA probes were 
synthesized using a DIG-labeling kit (Roche), and whole-mount in situ hybridization was 
performed as previously described (14, 45).  
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
RNA was obtained from pooled embryos or unfertilized eggs using Trizol reagent 
(Invitrogen). For Figs. 4J and 5B, cDNA was prepared from 500 ng of RNA using an 
oligo dT primer and Superscript III reverse transcriptase (Invitrogen). PCR amplification 
over 35 cycles was subsequently performed using 1 L of cDNA and GoTaq polymerase 
(Promega) in a final volume 25 L. The annealing temperature was 57C and the 
extension time 1 minute. Primers to col8a1 were: forward primer 5‟-
GAGTGAGCCCACCAATCCTTG-3‟ and reverse primer 5‟-
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CCTCTGGGAATGGTCTCACC-3‟. Primers to xbp1 were: forward primer 5‟- 
GTTCAGGTACTGGAGTCCGC-„3 (140) and reverse primer 5‟- 
GGATGTCCAGAATACCAAGCAGG-3‟. Primers to ampka1 and spt (also known as 
tbx16) have been reported previously (141). For Fig. 6C, cDNA was prepared from 1 g 
of RNA and the annealing temperature was 55C. The forward primer to col8a1 was as 
noted above, but the reverse primer was 5‟- GACATTCCTGGCTTACCAATTCC-3‟. 
Band quantitation was performed using ImageJ software (47). For Fig. 4J, band 
quantitation of col8a1 was calculated using a different exposure of the same gel where 
the bands were not saturated. 
Morpholino and mRNA injections  
Morpholino oligonucleotides (27) targeting start and splice sites in col8a1 were 
resuspended in Danieau buffer (start MO) or water (splice MO), diluted to include 0.05% 
phenol red, and injected into 1-cell embryos. Standard control morpholino (Gene Tools, 
LLC) was resuspended in Danieau buffer and likewise injected. Morpholino sequences 
were: 5‟-CCGTAGGAGAAGATAATCTCAAGGA-3‟ (start MO) and 5‟-
TAAAGTGTATCTCCTTACCTTTCCT-3‟ (splice MO). The start MO was used at doses 
of 2.4 ng and 7.2 ng. Capped, polyadenylated mRNA for rescue experiments was 
generated from wild-type or mutant full-length clones of zebrafish col8a1 using the 
mMESSAGE mMACHINE kit (Ambion). Individual embryos from gul
m208
/+ intercrosses 
were injected with either 200 or 800 pg of mRNA. 
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Results 
gul
m208
 mutants are sensitized to lysyl oxidase inhibition 
Gulliver
m208 
(gul
m208
) mutants exhibit notochord distortion similar to what is obtained 
under conditions of copper deficiency or direct pharmacologic lysyl oxidase 
cuproenzyme inhibition (14, 17, 74, 80). However, the distortion observed in gul
m208
 
mutants is less robust, and we therefore tested these mutants for sensitivity to lysyl 
oxidase inhibition (Fig. 1). Clutches from gul
m208
/+ intercrosses were incubated in vehicle 
(Fig. 1A, B) or in a dose of the copper chelator neocuproine (Fig. 1C, D) that does not 
cause notochord distortion in wild-type embryos (Fig. 1C and Gansner et. al, 2007). 
Under such copper-limiting conditions, gul
m208
 mutants exhibited increased notochord 
distortion (Fig. 1D vs. Fig. 1B, arrowheads), presumably due to the partial inhibition of 
lysyl oxidase activity (80). This hypothesis was confirmed by incubating clutches from 
gul
m208
/+ intercrosses in a dose of the irreversible lysyl oxidase inhibitor -
aminopropionitrile that does not cause notochord distortion in wild-type embryos (Fig. 
1E). Under these conditions, increased notochord distortion in gul
m208
 mutants was again 
observed (Fig. 1F vs. Fig. 1B, arrowheads).  
 Interestingly, the notochord distortion observed in gul
m208
 mutants is accompanied 
by a decrease in the length of the yolk sac extension (wild-type length = 3.23 0.09 vs. 
mutant length = 2.64 0.18 in vehicle), and the increased notochord distortion observed 
after neocuproine or -aminopropionitrile treatment is associated with a further 
shortening of this structure in mutant but not wild-type embryos (wild-type length = 3.33 
0.15 vs. mutant length = 2.31 0.09 in neocuproine; wild-type length = 3.22  0.12 vs. 
 150 
mutant length = 2.13  0.16 in-aminopropionitrile) (Fig. 1). These data suggest that 
force generation in the notochord is impaired in gul
m208
 mutants and confirms a synergy 
between the gul
m208
 locus and both copper chelation and lysyl oxidase inhibition.  
Electron microscopy reveals notochord abnormalities in gul
m208
 mutants 
To determine if a defect in notochord sheath formation could explain the notochord 
phenotype of gul
m208
 mutants, we imaged truncal cross-sections from gul
m208
 mutant and 
wild-type embryos by transmission electron microscopy. This revealed abnormalities in 
both the vacuolated notochord cells and notochord sheath of gul
m208
 mutants at 24 hpf 
(Fig. 2). In the vacuolated notochord cells of gul
m208
 mutants, the rough endoplasmic 
reticulum exhibits striking areas of engorgement compared to wild-type embryos, 
presumably due to retention of protein that fails to be secreted and instead forms large 
circular aggregates (Fig. 2B vs. Fig. 2A, arrows). These aggregates are also observed in 
the hypochord, which is closely apposed to the ventral aspect of the notochord (Fig. 2C, 
red arrows) and plays a critical role in the formation of the dorsal aorta (57, 58). While 
the inner (i), medial (m), and outer (o) layers of the notochord sheath are present in both 
wild-type embryos and gul
m208
 mutants, the fibrillar medial layer appears disordered in 
gul
m208
 mutants (Fig. 2E vs. Fig. 2D). 
The gul
m208
 mutation disrupts the zebrafish col8a1 gene 
To determine the molecular basis of the gul
m208
 phenotype, we meiotically mapped the 
gul
m208
 locus to a centromeric region of chromosome 9 (Fig. 3A). This region contains 
twenty-six genes (S. Fig. 1) one of which encodes the alpha 1 chain of type VIII collagen 
(Col8a1), a known lysyl oxidase substrate (67). Cloning and sequencing of zebrafish 
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col8a1 revealed a missense mutation in gul
m208
 mutants that is absent in wild-type 
embryos (Fig. 3B). This mutation results in the substitution of histidine for tyrosine in the 
C1q-like domain of Col8a1 (Y628H) (Fig. 3C). Protein sequence alignment demonstrates 
that the tyrosine mutated in gul
m208
 fish is highly conserved (Fig. 3D; see also the 
Discussion), and that zebrafish Col8a1 is similar to homologues in other species (S. Fig. 
2). Sequencing of other genes located in the region between our flanking markers did not 
identify any additional mutations capable of causing the gul
m208
 phenotype (S. Fig. 1). 
The expression of col8a1 is consistent with the gul
m208
 phenotype 
To determine the spatio-temporal expression of zebrafish col8a1, we performed whole-
mount in situ hybridization on wild-type embryos at various stages of development (Fig. 
4). Consistent with the hypothesis that the Y628H substitution disrupts notochord 
morphogenesis, col8a1 is robustly expressed in the notochord at the 5-, 10-, 15-, and 20-
somite stages (Fig. 4A-D, arrows). Starting at the 10-somite stage and continuing through 
24-30 hpf, expression is also observed in the prechordal plate region (Fig. 4B-E, asterix), 
floorplate (Fig. 4B-E, G, black arrowhead), and hypochord (Fig. 4B-E, G, white 
arrowhead). At 24 hpf, notochord staining is diminished (Fig. 4E) and col8a1 is 
expressed in the caudal somites (Fig. 4F, arrowheads). By 48 hpf, col8a1 expression is 
restricted to the forming jaw cartilages (Fig. 4H, I, arrows). A difference in staining 
intensity was not detected between gul
m208
 mutant and wild-type embryos processed in 
the same basket (data not shown), suggesting that mutant col8a1 transcripts are not 
degraded or overexpressed.  
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 To precisely map the onset of col8a1 expression, we employed a more sensitive 
method for transcript detection, reverse transcriptase-polymerase chain reaction (RT-
PCR). This revealed that col8a1 is expressed at very low levels maternally and is 
upregulated between 9 hpf and the 3-somite stage (Fig. 4J). Importantly, a PCR product 
was not obtained if the reactions were performed in the absence of cDNA (Fig. 4J).  
The Y628H substitution prevents Col8a1 trimerization but does not activate the 
unfolded protein response 
Since C1q-like domains are important for oligomerization (142), we tested whether the 
Y628H substitution impairs zebrafish Col8a1 trimer formation using an in vitro assay 
previously validated in studies of a closely-related collagen, collagen X (138, 139, 143). 
While transcription and translation from either wild-type or mutant plasmid contructs 
results in the production of Col8a1 monomers (Fig. 5A, lanes 1 and 2), only wild-type 
zebrafish Col8a1 is able to trimerize (Fig. 5A, lane 1). Co-transcription and translation of 
half the amounts of wild-type and mutant Col8a1 together did not prevent trimerization 
(Fig. 5A, lane 3), consistent with loss of function of mutant Col8a1. Bands migrating 
faster than monomer may represent late initiation products, as they were not present in a 
negative control lane and were not cleaved in reactions supplemented with canine 
pancreatic microsomes, which facilitate proteolytic processing of the Col8a1 signal 
peptide (data not shown).  
 We also considered whether the gul
m208
 phenotype could result from a toxic effect 
of mutant Col8a1 aggregates, which are observed in the endoplasmic reticulum of gul
m208
 
mutants at 24 hpf (Fig. 2B, E). These aggregates could lead to endoplasmic reticulum 
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stress, which results in the processing of x-box binding protein-1 (xbp1) mRNA to a 
splice form encoding an activator of the unfolded protein response (144). However, xbp1 
splicing is not observed in wild-type embryos or gul
m208
 mutants at 24 hpf (Fig. 5B). 
Furthermore, incubation of wild-type embryos in tunicamycin, an inhibitor of N-
glycosylation that causes endoplasmic reticulum stress, results in xbp1 splicing (Fig. 5B) 
but does not cause the gul
m208
 phenotype (data not shown). Finally, 4-phenylbutyric acid, 
a chemical chaperone that reduces endoplasmic reticulum stress (145, 146), does not 
rescue the gul
m208
 phenotype (data not shown). These data suggest that the Y628H 
substitution causes notochord distortion through insufficient Col8a1 deposition in the 
notochord sheath rather than through activation of the unfolded protein response.  
Morpholino knockdown of col8a1 recapitulates the gul
m208
 phenotype 
To determine if loss of col8a1 recapitulates the notochord phenotype observed in gul
m208
 
mutants, we designed morpholinos to knock down col8a1 in zebrafish. While injection of 
standard control morpholino into wild-type embryos did not result in any visible 
phenotypic effect (Fig. 6A and Table 1), injection of a splice morpholino targeting col8a1 
caused notochord distortion indistinguishable from what is observed in gul
m208
 mutants 
(Fig. 6B and Table 1). Importantly, this splice morpholino also caused a dose-dependent 
reduction in col8a1 transcript, as detected by RT-PCR (Fig. 6C). Injection of a second, 
distinct morpholino targeting the start site of col8a1 gave identical phenotypic results 
when used at a dose of 2.4 ng (data not shown), confirming that the gul
m208
 phenotype 
results from loss of Col8a1. Interestingly, injection of either the start or splice 
morpholinos at higher doses resulted in more robust notochord distortion (Fig. 6D and 
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data not shown). Neither morpholino altered melanin pigment formation (data not 
shown).  
Injection of 200 pg of mRNA encoding full-length col8a1 into clutches from 
gul
m208
/+ intercrosses did not rescue the gul
m208
 phenotype (data not shown), whereas 
injection of 800 pg of mRNA caused dysmorphism during epiboly and at 26 hpf (data not 
shown). This suggests that col8a1 expression must be restricted to specific cell types 
during early development in order for rescue to be successful. 
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Discussion 
These data reveal a previously unappreciated role for the alpha 1 chain of type VIII 
collagen (Col8a1) in zebrafish notochord formation. Type VIII collagen is formed 
through homopolymerization of either alpha 1 or alpha 2 polypeptide chains (147) and is 
a member of the short-chain collagen family that includes type X collagen. The 
experiments with neocuproine (Fig. 1C, D) reveal a gene-nutrient interaction between 
copper and col8a1 that significantly alters notochord morphogenesis. The notochord 
sensitivity of gul
m208
 mutants to lysyl oxidase inhibition (Fig. 1D, F) suggests that some 
mutant Col8a1 may be able to fold in vivo, and residual Col8a1 function could explain 
the enhanced notochord distortion observed with higher doses of col8a1 morpholino (Fig. 
6D). Importantly, the mechanism by which morpholinos decrease specific gene 
transcription precludes the accumulation of protein aggregates in the rough endoplasmic 
reticulum, arguing that mutant Col8a1 aggregates do not cause the gul
m208
 phenotype. In 
addition, no mutant Col8a1 is present in the morpholino-injected wild-type embryos, and 
thus mutant protein cannot be interfering with normal collagen assembly in the 
extracellular space. Taken together, the data presented here strongly suggest that the 
Y628H substitution causes notochord distortion through insufficient Col8a1 deposition in 
the notochord sheath. 
Implications for other notochord mutants 
Our results advance the possibility that published late notochord mutants such as crash 
test dummy, zickzack, wavy tail, quasimodo, and kinks (17, 18) may encode mutations in 
lysyl oxidases, proteins required for lysyl oxidase activity, or lysyl oxidase substrates. In 
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some cases, additional phenotypes may help to identify the mutant gene. For instance, 
quasimodo exhibits defects in both notochord and melanin pigment formation (18), 
suggesting a mutation in a protein required for global copper homeostasis. The lesion in 
quasimodo has been mapped to a region near the atp7a locus (148), and may thus be 
allelic to calamity (14).  
 Our data also suggest that force generation in the notochord can be indirectly 
measured by quantitating the length of the yolk sac extension, which is simple to do and 
could prove useful in studies of other notochord mutants. Since col8a1 is not expressed in 
the yolk sac extension (Fig. 4), the reduction in the length of this structure in gul
m208
 
mutants, both before and after pharmacologic treatment (Fig. 1), provides evidence for 
impaired force generation in the notochord, and implicates Col8a1, copper, and lysyl 
oxidases in this force generation process. 
Conservation of amino acid Y628  
The Y628H substitution identified in gul
m208
 mutants is located within the C1q-like 
domain of Col8a1 (Fig. 3C). This domain is present in a number of other proteins, 
including the structurally similar collagen paralogues COL8A2 and COL10A1 (Fig. 3D) 
(143, 149, 150). Alignment of all 31 human C1q-like domain-containing proteins reveals 
only eight invariant residues, including the tyrosine corresponding to Y628 in zebrafish 
Col8a1 (151). Furthermore, this tyrosine is conserved in all predicted 52 zebrafish C1q-
like domain-containing proteins (152). In view of such notable evolutionary conservation, 
it is not surprising that the Y628H substitution present in gul
m208
 mutants could be 
deleterious. Indeed, an identical substitution at the equivalent position in human 
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COL10A1 (Y597H) causes Schmid metaphyseal chondrodysplasia, an autosomal 
dominant skeletal disorder (153). The Y597H mutation is predicted to prevent proper 
folding of the COL10A1 C-terminal noncollagenous domain (NC1) in the endoplasmic 
reticulum and to cause disease by haploinsufficiency (149). This mechanism may also 
account for the gul
m208 
phenotype since the crystal structures of the COL10A1 and 
COL8A1 NC1 domains are very similar and in each case the histidine would destabilise 
the hydrophobic core of the protein (149, 150).  
Our data support the hypothesis that the Y628H substitution inhibits proper 
folding of individual Col8a1 chains. First, the large circular aggregates visualized by 
electron microscopy are consistent with unfolded Col8a1 monomer that is retained in the 
rough endoplasmic reticulum (Fig. 2B, E, arrows). Similar aggregates resulting from 
protein retention in the endoplasmic reticulum are observed in three zebrafish coatomer 
mutants, although the cause of retention is different in these mutants and leads to a more 
severe phenotype (19). Second, the in vitro trimerization assay directly demonstrates a 
defect in mutant Col8a1 trimerization (Fig. 5A, lane 2 vs. lane 1). This presumably 
results from a primary defect in NC1 domain folding rather than a defect in inter-chain 
assembly because the mutated tyrosine is buried in the NC1 domain (150). We propose 
that the Y628H substitution in Col8a1 inhibits monomer folding in gul
m208 
mutants. Since 
the NC1 domain nucleates trimer formation (154-156), this unfolded Col8a1 monomer 
would subsequently fail to trimerize and form higher-order assemblies (Fig. 7). 
Comparative expression of type VIII collagen 
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Zebrafish col8a1 expression is restricted to a few tissues during early development (Fig. 
4), and the absence of col8a1 expression in zebrafish eye was initially puzzling because 
Type VIII collagen is a major component of Descemet‟s membrane in other vertebrates 
(157-160). However, zebrafish encode a paralogue of col8a1 located on chromosome 22 
(BAC CR956626), and an EST encoding part of this paralogue (DN898414) has been 
isolated from zebrafish eye, specifically from the anterior segment where Descemet‟s 
membrane is located. Thus, it appears that partitioning of tissue-specific patterns of 
expression has occurred (56), and type VIII collagen distribution in zebrafish is expected 
to be broader than what is predicted from the expression data presented here (Fig.4).     
 Previous work demonstrates that type VIII collagen is distributed in the cartilage 
matrix and perichondrium of fetal calf tissues (161). The zebrafish notochord is most 
closely related to cartilage as a tissue (16), and expression of col8a1 in notochord and jaw 
cartilages (Fig. 4A-D, H, I) suggests an association between cartilage and type VIII 
collagen deposition that is evolutionarily conserved during early development. This 
association is supported by the similar spatio-temporal expression profiles of col8a1 and 
cartilage-expressed col2a1 in zebrafish embryos (compare Fig. 4 with Fig. 3 of Yan et al., 
1995) (44). Importantly, loss of wild-type col8a1 expression in jaw cartilages likely 
causes the severe head malformation noted in gul
m208 
mutants by 72 hpf (17) and thus the 
two principal phenotypes of gul
m208 
mutants (notochord distortion and head 
malformation) involve the major cartilage and cartilage-related tissues of zebrafish during 
early embryogenesis. Mice lacking both alpha 1 and alpha 2 chains of type VIII collagen 
exhibit anterior segment abnormalities in the eye but are not noted to have notochord or 
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jaw malformations (162). The reasons for these differences are presently unknown, 
though Col8a1 is expressed in at least some cartilages of newborn mice (163). 
Short-chain collagens in human disease 
Col8a1 belongs to a small group of highly-related short-chain collagens, and the gul
m208
 
mutant zebrafish may provide insight into the mechanism by which specific types of 
point mutations in these collagens cause disease. Indeed, our findings may be relevant to 
the molecular pathogenesis of Schmid metaphyseal chondrodysplasia, which is currently 
debated. Schmid metaphyseal chondrodysplasia results from mutations at multiple sites 
in COL10A1, and functional haploinsufficiency due to nonsense-mediated decay of 
mutant message appears to cause this disorder (164, 165). However, an effect of 
misfolded protein on chondrocyte differentiation secondary to activation of the unfolded 
protein response has also been invoked (166, 167). The determination of whether a 
missense mutation causes disease through loss of function or endoplasmic reticulum 
stress is potentially critical because treatment options may differ. 4-Phenylbutyric acid 
has been shown to reduce endoplasmic reticulum stress and restore glucose homeostasis 
in a mouse model of type 2 diabetes (145) and is already approved by the U.S. Food and 
Drug Administration for the chronic management of certain urea-cycle disorders (168). 
Thus, a disease caused by endoplasmic reticulum stress may be amenable to treatment 
with this chemical chaperone. Our data suggest that mutations affecting monomer folding 
(Fig. 7) cannot be rescued by 4-phenylbutyric acid (Fig. 5B and data not shown).  
 To date, no human disease has been shown to result from mutations in COL8A1. 
While COL8A1 has been evaluated as a candidate gene for certain eye disorders due to 
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the presence of type VIII collagen in Descemet‟s membrane and to the fact that mutations 
in COL8A2 cause corneal dystrophies (169-171), the data presented here suggest that a 
role for COL8A1 in cartilage development should now be considered. Indeed, the 
expression pattern of col8a1 in zebrafish (Fig. 4) and the notochord and head phenotypes 
of gul
m208
 mutants (17) suggest that mutations in COL8A1 could result in 
chondrodysplasias. A number of different mutations in COL10A1 cause Schmid 
metaphyseal chondrodysplasia (172), but not all patients with this disease have an 
identifiable mutation in COL10A1 and additional unknown loci are implicated in its 
pathogenesis (153, 173-175). COL8A1 may thus be a candidate gene for Schmid 
metaphyseal chondrodysplasia or another chondrodysplasia.  
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Figure legends 
Fig. 1. gul
m208 
mutants are sensitized to lysyl oxidase inhibition. Clutches from 
gul
m208
/+ intercrosses were incubated in vehicle (A, B), the copper chelator neocuproine 
(2 M) (C, D), or the lysyl oxidase inhibitor -aminopropionitrile (1 mM) (E, F). The 
notochord is normal in wild-type embryos treated with vehicle, neocuproine, or -
aminopropionitrile (A, C, E). Notochords of gul
m208
 mutants incubated in neocuproine 
and -aminopropionitrile (D, F, arrowheads) are substantially more distorted than 
mutants incubated in vehicle (B, arrowheads). Insets show notochord at higher 
magnification. Embryos were treated with PTU to inhibit melanin pigmentation and 
photographed at 30 hpf. 
Fig. 2. Electron microscopy reveals notochord abnormalities in gul
m208 
mutants. (A-
E) Transmission electron micrographs of truncal cross-sections from embryos at 24 hpf. 
(A) Notochord sheath and vacuolated notochord cell of a wild-type embryo, with small 
areas of protein accumulation visible in the rough endoplasmic reticulum (arrow). (B) 
Notochord sheath and vacuolated notochord cell of a gul
m208
 mutant with large circular 
aggregates of protein in the rough endoplasmic reticulum (arrow). (C) Notochord and 
hypochord of a gul
m208
 mutant with large circular aggregrates of protein in the hypochord 
(red arrows) and notochord (yellow arrow). (D) Notochord sheath of a wild-type embryo 
with inner (i), medial (m), and outer (o) layers indicated. Small areas of protein 
accumulation are visible in the rough endoplasmic reticulum (red arrow). (E) Notochord 
sheath of a gul
m208
 mutant where the collagen fibrils in the medial (m) layer appear 
 163 
disorganized. A large circular aggregate of protein is visible in the rough endoplasmic 
reticulum (red arrow). Not = vacuolated notochord cell; Hyp = hypochord. 
Fig. 3. The gul
m208
 mutation disrupts the col8a1 gene. (A) The gul
m208
 lesion was 
meiotically mapped to a centromeric region of chromosome 9 bounded by markers 
zK46K9 and zK229B18. The number of recombinants at each marker is noted. According 
to the physical genome assembly (Zv7), 26 genes are located within the critical region, 
including the alpha 1 chain of type VIII collagen (col8a1). (B) Sequencing of wild-type 
and gul
m208
 mutant cDNAs revealed a missense mutation in gul
m208
 mutant col8a1 that 
changes a tyrosine to a histidine. (C) Structure of the predicted 711-amino acid zebrafish 
Col8a1 protein. NC1 and NC2 are two non-collagenous domains. The Y628H 
substitution present in gul
m208
 mutants (arrow) is located within the C1q-like domain 
(grey) of NC1. (D) Protein sequence alignment of N-terminal portions of select C1q-like 
domains. Conserved residues, including Y628 (arrow), are shaded yellow. Sequence 
numbering refers to the zebrafish Col8a1 sequence (DrCol8a1). 
Fig. 4. col8a1 expression is consistent with the gul
m208
 phenotype. 
(A-I) Whole-mount in situ hybridization for col8a1 was performed on wild-type embryos 
at various developmental stages. (A) Lateral view of a 5-somite embryo with col8a1 
expression in the vacuolated notochord cells (arrow). (B-D) Lateral views of 10- (B), 15- 
(C), or 20- (D) somite embryos with col8a1 expression in the notochord (arrow), 
floorplate (black arrowhead), hypochord (white arrowhead), and prechordal plate region 
(asterix). (E) Lateral view of an embryo at 24 hpf with col8a1 expression in the floorplate 
(black arrowhead), hypochord (white arrowhead), and prechordal plate region (asterix). 
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(F) Dorsal view of an embryo at 24 hpf with col8a1 expression in the caudal somites 
(arrowheads). (G) Lateral view of an embryo at 30 hpf with col8a1 expression in the 
floorplate (black arrowhead) and hypochord (white arrowhead). (H) Dorsal view of an 
embryo at 48 hpf with col8a1 expression in jaw cartilages (arrows). (I) Lateral view of an 
embryo at 48 hpf with col8a1 expression in jaw cartilages (arrows). (J) RT-PCR for 
col8a1 at the indicated developmental stages. As controls, maternally-expressed 5'-AMP-
activated protein kinase catalytic subunit alpha-1 (ampka1) and zygotically-expressed 
spadetail (spt) were amplified in parallel (104, 176). The fold induction of col8a1 relative 
to ampka1 is noted. Unfert. = unfertilized; NA = not applicable. 
Fig. 5. The Y628H substitution prevents Col8a1 trimerization. (A) Constructs 
encoding wild-type (lane 1) or gul
m208
 mutant (lane 2) Col8a1 were transcribed and 
translated in the presence of radiolabelled methionine, and the products analyzed as 
described under Experimental Procedures. Col8a1 monomers and trimers are indicated. 
Co-transcription and translation of half the amounts of wild-type and mutant construct 
together does not prevent trimerization (lane 3). The approximate location of molecular 
weight markers (kDa) is noted. (B) RT-PCR to assess the splice status of xbp1 in wild-
type embryos and gul
m208
 mutants at 24 hpf. Splicing of xbp1 is not observed in gul
m208
 
mutants but occurs after incubation of wild-type embryos in tunicamycin. U = unspliced; 
S = spliced. Amplification of the gene spt was performed in parallel to confirm that equal 
amounts of cDNA were used for each condition. 
Fig. 6. Morpholino knockdown of col8a1 recapitulates the gul
m208
 phenotype. 
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(A) Wild-type embryos injected with 12 ng of control morpholino exhibit normal 
morphology. (B) Embryos injected with 2.4 ng of a splice morpholino targeting col8a1 
develop notochord distortion (arrowheads) characteristic of gul
m208
 mutants. (C) RT-PCR 
at 24 hpf demonstrating a dose-dependent reduction in col8a1 transcript after morpholino 
injection. (D) Embryos injected with 12 ng of a splice morpholino targeting col8a1 
develop notochord distortion (arrowheads) that is worse than in gul
m208
 mutants. Insets 
show notochord at higher magnification. All embryos were treated with PTU to inhibit 
melanin pigmentation and photographed at 30 hpf. 
Fig. 7. Model of Col8a1 assembly in wild-type and gul
m208
 mutant embryos. Col8a1 
monomer containing the Y628H mutation is unable to fold, preventing trimer formation 
and higher-order assembly that occurs in the absence of the mutation. The Y628H 
mutation is located within the NC1 domain of Col8a1 (asterisk).  
Table 1. Morpholino knockdown of col8a1 recapitulates the notochord distortion 
observed in gul
m208
 mutants. Wild-type embryos were injected with morpholino and 
live embryos sorted to new dishes at 10 hpf; these embryos were scored for notochord 
distortion at 30 hpf. Data shown are the pooled results of three independent experiments. 
S. Fig. 1. (A) Ordered list of the genes located between markers zK46K9 and 
zK229B18. Marker zC206L17 is included for reference. A single asterisk indicates the 
gene where most of the coding sequence was cloned from gulliver mutant cDNA. Double 
asterisks indicate genes where the entire coding sequence was cloned from gulliver 
mutant cDNA. (B) Nucleotide coding sequence of genes cloned from gulliver mutant 
cDNA. Primers used for PCR are indicated. Notes are included detailing why any 
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alterations to the predicted amino acid sequence are not expected to cause the gul
m208
 
phenotype. 
S. Fig. 2. Protein sequence alignment of zebrafish Col8a1 with orthologues from 
other species. Predicted signal peptides are in bold and the conserved tyrosine at position 
628 is in blue. The C1q-like domain is in grey. 
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Specific 
Morpholino 
Dose of 
morpholino (ng)  
Embryos 
scored (#) 
Dead or dysmorphic 
embryos (#) 
Notochord distortion 
- + 
Control 12 186 10 172 (98%) 4 (2%) 
col8a1 (splice) 2.4 170 2 2 (1%) 166 (99%) 
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A) 
Marker zK46K9 (1 recombinant) 
Q6GML5_DANRE = PHD finger protein 11 (PHF11) 
c13orf1 = Chronic lymphocytic leukemia deletion region gene 6 protein 
zgc:56602 = Ribonuclease H2 subunit B (RNASEH2B)  
zgc:152866 = X-linked interleukin-1 receptor accessory protein-like 1 precursor 
(IL1RAPL1) 
Marker zKC206L17 (0 recombinants) 
**zgc:101814 = C3orf26 
**zgc:63472 = transmembrane protein 30A (TMEM30A) 
*zgc:158743 = Discoidin, CUB and LCCL domain-containing protein 2 precursor 
(DCBLD2) 
col8a1– annotated only on BAC (BX322575) 
zgc:101070 = jagunal homolog 1 (JAGN1)  
**tfg = TRK-fused gene  
LOC100006853 = Target of Nesh-SH3 precursor (ABI3BP)  
LOC558093 = interphotoreceptor matrix proteoglycan 2 (IMPG2)  
tlr20f = Toll-like receptor 20f 
A3KPA1_DANRE = Sentrin-specific protease 7 (SENP7) 
g12 = Mid1-interacting protein 1 (MID1IP1)  
LOC794667 = Ornithine carbamoyltransferase (OTC) 
RPGR = X-linked retinitis pigmentosa GTPase regulator 
zgc:110822 = Sushi repeat-containing protein SRPX precursor (SRPX)  
SYTL5 = Synaptotagmin-like protein 5 
asb11 = Ankyrin repeat and SOCS box protein 11 
zgc:56589 = Phosphatidylinositol N-acetylglucosaminyltransferase subunit A (PIGA) 
zgc:113314 (novel protein) 
LOC795718 = Gap junction alpha-8 protein (GJA8) 
cx45.6 = Gap junction alpha-5 protein (GJA5) 
LOC558758 = Lysophosphatidic acid phosphatase type 6 precursor (ACP6) 
chaf1b = Chromatin assembly factor 1 subunit B 
Marker zK229B18 (1 recombinant) 
 
B) 
>Sequence for zgc:101814. Forward 5‟-GCGATTGCGGTTTGAGACATG-3‟ and 
reverse 5‟-GGCATTAAAGTACACAACAATCTCTC-3‟. 
ATGGCTGATGATTTAGGAGACGAGTGGTGGACCCAGGGCGATAATTCAGATG
TGCCTGAGGTAGAGGAGGAAACAGAGCCTGCAGAAGAAAAACAACCGATTA
AATCTACACCTAAGAAAAGGAAGGTTGAAAAACAGATTCCAGATGCCACAA
AGAAAAAGAAGAAGGCAACAGTTAAGAAAGAATGTTTCATCACGCAAGAGA
GATCAGAGGAAAAGCCTGATAACGAGTCTAACAAAAACAAGAAAAGAAGAA
AGAAGAAGAAAACCATCACAGATGTCCTGACAAGCTCTAAGCCTGTGCCCGG
CTCTCCAGTTGACCTTGTGAGCCTTCTGAAGACTTACCACAGCCAGACCCGCT
CTGTTATTGAGCAGGAGGAACTGACGTTACAAGATTCTTGTTTCCTCAGCTGT
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AATGACCTCACACACAGCTTGTCTTCCTACCTCAAAGAAGTTTGTCCAAAGTG
GGCTAAAATGCAGAAACAGCACACCCAGACCAGCTCAGTGGTTTTGCTAATT
GTTTGTGGATCTGCTTTAAGAACCATTGATCTCATTAAGCAGCTGGTGACATT
CAAAGGACAAGCTAAAGTGCTGAAGCTGTTTGCAAAACACATCAAAGTGGA
AGAACAGATAAAGTCATTGAGTAAAGGTGTGACCCATATTGCTGTTGGAACT
CCTGGGAGAATTTGCGCGCTGTTAGAGAAAGAGGGATTGACTGTGCAAGGAC
TACGTTATCTGGTGCTGGACTGGAACTACAGAGACCAGAAGCAAAGGAGGAT
GGTGGATGTACCAGAGGTGAAAGGAGACTTACTAAAAATGATGGACCAAGG
TCTAATCCAGAGCTGCAGAGAAGGAACGGTTAAAATAGGACTCTTCTGA 
NOTES: H27P and insertion of K before ATVKKEC vs. zgc:101814 (BC083291), but 
BAC BX957250 agrees in both cases with the above sequence. 
 
>Sequence for zgc:63472. Forward 5‟- GAAAACTTCCTTCGGTGGCAG-3‟ and 
reverse 5‟- GCTTGTTTTCAGTGATTCTGGG-3‟. 
ATGGCCAAGAAGGCAGTAGGTTTAGGGCCACTGTCGAGGCGTCCAGATAACT
CGGCGTTTAAACAGCAGAGATTACCAGCCTGGTCTCCATCTCTCACGGCACA
GACCGTCCTGCCAATCTTCTACATCCTAGCTGTCGTGTGCCTGCTGCTGGGCA
TCTGGCTCCTCATCACTGTCCAGAACACACACCAACTGAAGGTGGACTACAC
CGATGCTGGAACATGTGAACAGTGCTTCGAGCTTCATGCCAACAACACCAGA
ACGGTCTGCACATGTTCAGTCAACTTCTACGTTCCAAGACCCTTTCCGGGCGA
CGTGTTCTTCTACTACGGTCTGAGGAACTTTCATCAGAACCTGCGGAGGTACA
TGGACTCCCGCGATGATGCACAGATGGTGGGGAGGAAGAACAACCTGAAGG
CACCGAGTTCATACTGCGCTCCGTTTCATTACGATGCAAACGGGGTACCCATC
GCCCCCTGCGGTGCCGTGGCCAACAGCATGTTCAACGACTCATTTACACTGAT
GTATCATCAAGCTAATGGGGCAGAAGTGCAAGTTCCTCTCTATAGGAAGGGC
ATTGCTTGGTACACAGACAAAAATGTCAAGTTCCGCAACCCTCCGACCAACA
ACACATTTTCCCTTCGACAAGCCTTTGAAGGCACGACTCGGCCCTTATACTGG
CAGCACTCGGTTTATGAGCTGGATGACACAGACTCCAACAACAATGGTTTCA
TAAATGACGACCTGATTGTCTGGATGAGAGAGGCAGCCTTCCCTAATTTCAA
AAAGCTTTATGGGGTTCTCAATCGTGCTCAAGAGCCTTTCACTGAAGGCCTGC
CCGCCGGCAACTACAACATCTCTATAGATTACAATTTTCCTGTTGAGCCCTTC
AGAGGTCGAAAGGAGCTGGTGATCTCAATGGTGACCTGGTTTGGTGGGCAGA
ATTACTTTCTGCCCATTGCGTATCTGGTGACCAGTGGGCTAATCCTGGTGACT
GCTGTCGTTCTCACAACAGTGTTTGTCAAATTTGGCAAAAATGGCAAGAACA
TGGAGGAATAA 
Notes: 1) R77Q vs. zgc:63472 (NM_200596) but EST EB861052 agrees with the above 
sequence. 2) K136N, but EST AL920832 agrees with the above sequence. 3) P268L, but 
EST CR929675 agrees with the above sequence. 
 
>Sequence for tfg. Forward 5‟-GATTGACACGTCCAAAACACCAGC-3‟ and reverse 
5‟-GAGGGAAGTTATAGTGAGGTGCTG-3‟. 
ATGAATGGACAGCTGGACCTGAGTGGGAAGCTGATCATCAAAGCTCAGCTGG
GTGATGATATTCGTCGTATTCCTATCCACAATGAAGACATCACCTACGACGAG
CTCCTGCTGATGATGCAGAGAGTTTTTCGTGGCCAGTTACAGAGCAGCGATG
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AAGTCACCATCAAATACAAGGACGAAGATGACGACCTTATCACCATCTTTGA
CAGTTCTGATTTGTCCTTTGCGATCCAGTGCAGTAGAATATTAAAGCTCACTC
TTTTTGTGAATGGGCAGCCTCGGCCACTGGAGTCATCTCAGGTGAAGCACCTG
CGCAGAGAACTGATCCATTTGAGGAATAAAGTCAACAGCCTGCTGGACAGCC
TGGAGCCACCCTTAGAGTCTGTCCCAGAAAGCACCAACCCAGAAACTGAATG
TGTAAATGATGCAGTAGACTCCACAATGAGGCATGCTCCTCCTGTCAGTGCTG
CCAGCATGTCTGCTTTTGACCCACTGAAGAACCAGGAAGAGGTCAACAAGAA
TGTCATTTCTGCATTTGGTTTAACTGAGGAACCTGCCCCAGTTCCAGCTGTAG
CTGCCACCGCTGCTGCAGAGGAGCGCTCTGCTACTCCAGACAGTATTGCCTCT
TCATCCTCTGCAGCGCCCCCTGCTGCTGTGGCTCCACAGGCCCCCCCACCTTA
TTCAGGGGTCCAGCAACCCCCCTCTACTACTATGGATGGTCAGATGTATCAGC
AGTATCAGGCTCCAGGTGGATATCCTCCACCAGCTGGACCGCAGCAGCAGTA
TGGCATGCAGTACCCTGCTGGTTATACTCCTCAATCTGGTGTTCCTCAGGCTC
CGCCTCCTCAACAGCAGTTCCAGAATTACCCCACCCCTACTTCTCAGGCTGCT
GGCGCTCCTGGCTCCGCCCCTGGCTTTTCTGGCCAATCACAGCCTCCTGCTCC
CCAAGCACCTGCTCAGTATCCACCCGGAGCCTTTCCGCCTCAAAACTACACAT
CCCAGGCCTCTCAGCAGCCCGCAAACTACAGCCTGCCTCCAACCTCGCAGGC
CACAGCCGGTTACCAGCCCCGTCCCGGATACACCCCACCACCAGGTGCCACC
CCTCCACCCGGGGGTGCCAATCCCTATGCCCGAAACCGCCCGCCTTACGGCC
AGGGCTACACCCAACCAGGTCCTGGCTATCGGTAA 
NOTES: 100% nucleotide agreement with CT726943 and CT700332 (full coverage 
when both are aligned). 
 
>Sequence for zgc:158743. Forward 5‟-CGGCTGATCGGGACACTTTAGC-3‟ and 
reverse 5‟-AGGCTCGGGGAGAGATTTCC-3‟. 
ATGGACGCGTCGGTAATGGTGGGCAGAGGAACCGGAGGGGCTGCGCTCTTCA
TCCTGATCGTCTTCATCGTACTACTAGGTGCCAGAAGCTCACGGGCGCAGAA
GGGGGACGGCTGTGGACACACAGTGCTAGGTGTGGGCAGCGGGAGCCTGGC
GTCTCTGGGTTATCCTCAGTCTTATCCTTCACAGTCTGTGTGTGAGTGGGAGA
TCAGCGTGACCGCTGGGCACAAAGTCCTTGTGCGCATCGCAGATCTTGACATT
GATACAAACAATTGCCAGGTGTCTTACCTGCGACTCTATAATGGGATCGGAC
CGGGACGAACAGAAATTGTGAAGTTTTGTGGCAGTAAAGAATGGAAAGAATT
GGTTATAAAGTCTGAGGGCCATCAGGTCACAGTGCAGTTCATGAGTGGACCA
CACCACAACGGCCGTGGCCTTTTCCTCTCCTACACCAACAGTCAGCACACTGA
CCTCATCACCTGTCTGGAGAAAGGAGAGCACTTCAGTGAAGCAGAGTTCAGT
AAATTCTGTCCTGCTGGATGCCTGATTGATTTCGGAGAGGTTTCGGGAACCAT
ACCGCATGGATACAGAGATTCTTCTCCTCTGTGCCTGGCCGGCATTCATGCGG
GTGTGCTGTCCAACACTCTGGGGGGGCAGATCAGTGTGGTCAGCAGCAAAGG
CATCCCACACTACGAAAGCTCACTGGCTAACAATGTGACATCTGTGCCTGGA
AATCTCTCCCCGAGCCT 
NOTES: Fragment. D28A (in signal peptide) vs. zgc:158743 (NM_001080171) but this 
change is present in CO922572. Larger fragment was also cloned – sequence below. 
>Additional sequence for zgc:158743. Forward 5‟-GGGACACTTTAGCATTATGC-3‟ 
and reverse 5‟-GAGTGCCTCCTGATAGGTGG-3‟. 
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GGGACACTTTAGCATTATGCATTCGGACTGCAGGCTGCTGGGATGGACGCGT
CGGTAATGGTGGGCAGAGGAACCGGAGGGGCTGCGCTCTTCATCCTGATCGT
CTTCATCGTACTACTAGGTGCCAGAAGCTCACGGGCGCAGAAGGGGGACGGC
TGTGGACACACAGTGCTAGGTGTGGGCAGCGGGAGCCTGGCGTCTCTGGGTT
ATCCTCAGTCTTATCCTTCACAGTCTGTGTGTGAGTGGGAGATCAGCGTGACC
GCTGGGCACAAAGTCCTTGTGCGCATCGCAGATCTTGACATTGATACAAACA
ATTGCCAGGTGTCTTACCTGCGACTCTATAATGGGATCGGACCGGGACGAAC
AGAAATTGTGAAGTTTTGTGGCAGTAAAGAATGGAAAGAATTGGTTATAAAG
TCTGAGGGCCATCAGGTCACAGTGCAGTTCATGAGTGGACCACACCACAACG
GCCGTGGCCTTTTCCTCTCCTACACCAACAGTCAGCACACTGACCTCATCACC
TGTCTGGAGAAAGGAGAGCACTTCAGTGAAGCAGAGTTCAGTAAATTCTGTC
CTGCTGGATGCCTGATTGATTTCGGAGAGGTTTCGGGAACCATACCGCATGG
ATACAGAGATTCTTCTCCTCTGTGCCTGGCCGGCATTCATGCGGGTGTGCTGT
CCAACACTCTGGGGGGGCAGATCAGTGTGGTCAGCAGCAAAGGCATCCCACA
CTACGAAAGCTCACTGGCTAACAATGTGACATCTGTGCCTGGAAATCTCTCCC
CGAGCCTTTTTACTTTCAAGACCAGCGGTTGCTATGGTACTTTGGGTTTGGAG
TCGGGGGTGGTGAGCGACTCTCAGATCACGGCCTCGTCCGAGTGGGAATGGG
GCGGTCATGGAAAACAGCCCACCGTCTGGGGCCCTACGGGGGCCCGCCTCAA
AACTCCAGGACGTCCGTGGGCTGCAGCCAACAGCGACACCAAAGAATGGATT
CAAGTGGACCTAAAGAAAGAGAAAAAAATAACAGGCATTACCACCACTGGC
TCCACACTCCCAGAGTATCAGTTTTACGTTTCAGCCTATGAGGTGTTATATAG
CCATGATGGACAGCAGTGGAAAACCTATCAAGAAGTGGGATCAGATAAAAA
CAAGATTTTCCAAGGTAACACCCACTATCTGCAGGAGGTGCGAAACAACTTT
ATTCCTCCAATTGAGGCACGCTTTCTCCGAATATGTCCCTTACAGTGGCACCA
GAGGATCGCCCTTAAAATGGAACTGCTGGGCTGCCAACCACATGCAGCGAGG
CCCAGAATCTTCCACCCAGGCCCTGCACCTCCTCGCAGGAAGAGCACAACAC
CGCCAGCGCAGGACAGGACCACACACACACCCAACATCCGAAACTCCACCAT
GCCTCCACACTCCCATGACGAGGTGGCTCTGGTAGCAGTGTTGGTTCCTGTAT
TGGTGGTGGTTCTGACGACACCAGTTCTGGTGATGGTGTGCTCATGGCTGTGG
AAGAACAGAAAAAGCCCTGAGGTGACGTATGACCTTCCACACTGGGAGCGC
ACGGTGTGGTGGAAGAGTATGAAACAGTTGTTGCCCTCTAAGCTGGATGGAG
AAGACTGTGTTCGCTATAGCTCTACGGCGCGAGTGGACCACCAGAGACCCCG
GGTGGAGCCTGCAGAATACGCCCAACCGCTGGTCACAGGAAACATGGCCTCT
CTTGGACAACGGTCGACATTTAAACCCGAAGAGGCCGATGTTCCCGAATACG
ATGCACCTATTCCTCCAGAACATTACCATGCTTATGCTGAGCCCCTTCCTGCT
TCTGGCACTGAATACGCCATGCCGATCATGATTGACAGGGCTAACCACCTAT
CAGGAGGCACTC 
NOTES: Longer than zgc:158743 (NM_001080171). Compare with cds for CAQ14992 
– agrees for all amino acids except E121D and L122V, both of which are conservative 
changes. Missing sequence for the terminal 45 amino acids compared to cds for 
CAQ14992. Smaller fragment was also cloned – see above.  
 
 
Supplementary Figure 1 
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BtCOL8A1        MAGPPSPLQLLGVLLTLSVGSIRLIHAGAYYGIKPLPPQIPAQIPPQIPQYQPLGQQVPH 60 
GgCOL8A1        MAVQPGPPQLLQVLLTISLGSIRLIQAGAYYGIKPLPPQIPPQMPPQIPQYQPLGQQVPH 60 
OcCOL8A1        MAVPPGPPQLLQVLLTISLGSIRLIQAGAYYGIKPLPPQIPPQMPPQIPQYQPLGQQVPH 60 
MmCOL8A1        MAVPPRPLQLLGILFIISLNSVRLIQAGAYYGIKPLPPQIPPQIPPQIPQYQPLGQQVPH 60 
HsCOL8A1        MAVLPGPLQLLGVLLTISLSSIRLIQAGAYYGIKPLPPQIPPQMPPQIPQYQPLGQQVPH 60 
DrCol8a1        MAMAAFLVALVQLTFLP------LAFGGGYYPHKSHP-----------QQHQPL----PQ 39 
                **  .    *: : :        *  .*.**  *. *            *:***    *: 
 
BtCOL8A1        MPLGKDGLNVGKELPHMQYGKEYPHLPQYRKEVQPAPRMGKEAAPKKGK-EIPLASLRGE 119 
GgCOL8A1        MPLAKDGLTMGKEMPHAQYGKEYPHLPQYMKEVQPVPRMGKEAVPKKGK-EIPLASLRGE 119 
OcCOL8A1        MPLAKDGLTMGKEMPHAQYGKEYPHLPQYMKEVQPVPRMGKEAVPKKGK-EIPLASLRGE 119 
MmCOL8A1        MPLGKDGLSMGKEMPHMQYGKEYPHLPQYMKEIPPVPRMGKEVVPKKGKGEVPLASLRGE 120 
HsCOL8A1        MPLAKDGLAMGKEMPHLQYGKEYPHLPQYMKEIQPAPRMGKEAVPKKGK-EIPLASLRGE 119 
DrCol8a1        MHMG-----MGKEMPHMPYPHYRKDLPMHLNKGKDNK---GETIPRGEQ---GVQGQPGA 88 
                * :.     :***:**  * :   .** : ::         *. *:  :    : .  *  
 
BtCOL8A1        QGPRGEPGPRGPPGPPGLPGQGIPGVKGKPGPQGYPGIGKPGMPGMPGKPGAMGMPGAKG 179 
GgCOL8A1        QGPRGEPGPRGPPGPPGLPGQGIPGIKGKPGPQGYPGVGKPGMPGMPGKPGAMGMPGAKG 179 
OcCOL8A1        QGPRGEPGPRGPPGPPGLPGQGIPGIKGKPGPQGYPGVGKPGMPGMPGKPGAMGMPGAKG 179 
MmCOL8A1        QGPRGEPGPRGPPGPPGLPGHGMPGIKGKPGPQGYPGIGKPGMPGMPGKPGAMGMPGAKG 180 
HsCOL8A1        QGPRGEPGPRGPPGPPGLPGHGIPGIKGKPGPQGYPGVGKPGMPGMPGKPGAMGMPGAKG 179 
DrCol8a1        QGPVGPPGPQGPPGPQGNGIQGPPGKPGPPGPPGYPGIGKPGMSGMPGKAGDPGQPGQPG 148 
                *** * ***:***** *   :* **  * *** ****:*****.*****.*  * **  * 
 
BtCOL8A1        EIGPKGEIGPMGIPGPQGPPGPHGLPGIGKPGGPGLPGQPGAKGERGPKGPPGPPGLQGP 239 
GgCOL8A1        EIGPKGEIGPMGIPGPQGPPGPHGLPGIGKPGGPGLPGQPGAKGDRGPKGPPGPPGLQGP 239 
OcCOL8A1        EIGPKGEIGPMGIPGPQGPPGPHGLPGIGKPGGPGLPGQPGAKGDRGPKGPPGPPGLQGP 239 
MmCOL8A1        EIGPKGEIGPMGIPGPQGPPGPHGLPGIGKPGGPGLPGQPGAKGERGPKGPPGPPGLQGP 240 
HsCOL8A1        EIGQKGEIGPMGIPGPQGPPGPHGLPGIGKPGGPGLPGQPGPKGDRGPKGLPGPQGLRGP 239 
DrCol8a1        EQGPRGEDGQPGIAGPPGPPGPSGLPGIGKPGGQGLPGQPGNKGEPGHKGFPGLPGLPGP 208 
                * * :** *  **.** ***** ********** ******* **: * ** **  ** ** 
 
BtCOL8A1        KGEKGFGMPGLPGLKGPPGMHGPPGPVGLPGVGKPGVTGFPGPQGPLGKPGPPGEPGPQG 299 
GgCOL8A1        KGEKGFGMPGLPGLKGPPGMHGPPGPVGLPGVGKPGVTGFPGPQGPLGKPGPPGEPGPQG 299 
OcCOL8A1        KGEKGFGMPGLPGLKGPPGMHGPPGPVGLPGVGKPGVTGFPGPQGPLGKPGPPGEPGPQG 299 
MmCOL8A1        KGEKGFGMPGLPGLKGPPGMHGPPGPVGLPGVGKPGVTGFPGPQGPLGKPGPPGEPGPQG 300 
HsCOL8A1        KGDKGFGMPGAPGVKGPPGMHGPPGPVGLPGVGKPGVTGFPGPQGPLGKPGAPGEPGPQG 299 
DrCol8a1        KGDRGIGLPGPQGPKGPVGPPGLRGPAGLPGVGKTGLPGIPGPAGVPGKPGEPGEPGPEG 268 
                **::*:*:**  * *** *  *  **.*******.*:.*:*** *  **** ******:* 
 
BtCOL8A1        PIGVPGVQGPPGIPGIGKPGQDGIPGQPGFPGGKGEQGLPGLPGPPGLPGVGKPGFPGPK 359 
GgCOL8A1        PIGVPGVQGPPGLPGVGKPGQDGIPGQPGFPGGKGEQGLPGLPGPPGLPGVGKPGFPGPK 359 
OcCOL8A1        PIGVPGVQGPPGLPGVGKPGQDGIPGQPGFPGGKGEQGLPGLPGPPGLPGVGKPGFPGPK 359 
MmCOL8A1        LIGVPGVQGPPGMPGVGKPGQDGIPGQPGFPGGKGEQGLPGLPGPPGLPGVGKPGFPGPK 360 
HsCOL8A1        PIGVPGVQGPPGIPGIGKPGQDGIPGQPGFPGGKGEQGLPGLPGPPGLPGIGKPGFPGPK 359 
DrCol8a1        PPGEKGPQGPQGAPGIGSPGEKGLPGQPGTPGHKGLHGPPGLPGKPGLPGFGKPGYPGPK 328 
                  *  * *** * **:*.**:.*:***** ** ** :* ***** *****.****:**** 
 
BtCOL8A1        GDRGVGGLPGPLGPRGEKGPVGAPGLGGPPGEPGLPGIPGPMGPPGAIGFPGPKGEGGVV 419 
GgCOL8A1        GDRGIGGVPGALGPRGEKGPVGAPGMGGPPGEPGLPGIPGPMGPPGAIGFPGPKGEGGIV 419 
OcCOL8A1        GDRGIGGVPGALGPRGEKGPVGAPGMGGPPGEPGLPGIPGPMGPPGAIGFPGPKGEGGIV 419 
MmCOL8A1        GDRGIGGVPGVLGPRGEKGPIGAPGMGGPPGEPGLPGIPGPMGPPGAIGFPGPKGEGGVV 420 
HsCOL8A1        GDRGMGGVPGALGPRGEKGPIGAPGIGGPPGEPGLPGIPGPMGPPGAIGFPGPKGEGGIV 419 
DrCol8a1        GDRGMGGLPGPQGPKGEKGHMGQPGMMGPPGQTGLPGPSGPIGAPGEVGSPGLKGEGGAG 388 
                ****:**:**  **:**** :* **: ****:.**** .**:*.** :* ** *****   
 
BtCOL8A1        GPQGPPGPKGEPGLQGFPGKPGFLGEVGPPGMRGLPGPIGPKGEAGLKGLPGLPGAPGLL 479 
GgCOL8A1        GPQGPPGPKGEPGLQGFPGKPGFLGEVGPPGIRGLPGPIGPKGEAGHKGLPGLPGVPGLL 479 
OcCOL8A1        GPQGPPGPKGEPGLQGFPGKPGFLGEVGPPGIRGLPGPIGPKGEAGHKGLPGLPGVPGLL 479 
MmCOL8A1        GPQGPPGPKGEPGLQGFPGKPGFLGEVGPPGMRGLPGPIGPKGEGGHKGLPGLPGVPGLL 480 
HsCOL8A1        GPQGPPGPKGEPGLQGFPGKPGFLGEVGPPGMRGLPGPIGPKGEAGQKGVPGLPGVPGLL 479 
DrCol8a1        GAKGDPGPIGLTGPPGIPGQPGQPGEDGEPGPRGPQGPIGPKGEGGSNGLPGPPGQSGLP 448 
                *.:* *** * .*  *:**:**  ** * ** **  ********.* :*:** ** .**  
 
 
 
 
 180 
BtCOL8A1        GPKGEPGIPGEQGLQGPPGIPGISGPSGPIGPPGIPGPKGEPGLPGPPGFPGVGKPGVAG 539 
GgCOL8A1        GPKGEPGIPGDQGLQGPPGIPGITGPSGPIGPPGIPGPKGEPGLPGPPGFPGVGKPGVAG 539 
OcCOL8A1        GPKGEPGIPGDQGLQGPPGIPGITGPSGPIGPPGIPGPKGEPGLPGPPGFPGVGKPGVAG 539 
MmCOL8A1        GPKGEPGIPGDQGLQGPPGIPGIVGPSGPIGPPGIPGPKGEPGLPGPPGFPGVGKPGVAG 540 
HsCOL8A1        GPKGEPGIPGDQGLQGPPGIPGIGGPSGPIGPPGIPGPKGEPGLPGPPGFPGIGKPGVAG 539 
DrCol8a1        GLKGETGPPGPEGPRGPTGIPGLAGPGGLLGPPGPPGPKGEVGPPGQAGQPGEGSPGIQG 508 
                * ***.* ** :* :**.****: **.* :**** ****** * ** .* ** *.**: * 
 
BtCOL8A1        LHGPPGKPGALGPQGQPGLPGPPGPPGPPGPPAVMPPTPPPHGEYLPDMGLGIEGAKPPH 599 
GgCOL8A1        LHGPPGKPGALGPQGQPGLPGPPGPPGPPGPPAVMPPTPAPQGEYLPDMGLGIDGVKTPH 599 
OcCOL8A1        LHGPPGKPGALGPQGQPGLPGPPGPPGPPGPPAVMPPTPAPQGEYLPDMGLGIDGVKTPH 599 
MmCOL8A1        LHGPPGKPGALGPQGQPGLPGPPGPPGPPGPPAVMP-TPSPQGEYLPDMGLGIDGVKPPH 599 
HsCOL8A1        LHGPPGKPGALGPQGQPGLPGPPGPPGPPGPPAVMPPTPPPQGEYLPDMGLGIDGVKPPH 599 
DrCol8a1        PVGPPGPPGPNGSPGQPGIQGPPGPPGPPGP----APSPDLMG-VLPEMGPALDGVKAGY 563 
                  **** **. *. ****: ***********    . :*   *  **:** .::*.*. : 
 
BtCOL8A1        AYG--AKKGKNGGGPAYEMPAFTAELTAPFPPVGAPVKFDKLLYNGRQNYNPQTGIFTCE 657 
GgCOL8A1        AYA--AKKGKNGG-PAYEMPAFTAELTAPFPPVGAPIKFDRLLYNGRQNYNPQTGIFTCE 656 
OcCOL8A1        AYA--AKKGKNGG-PAYEMPAFTAELTAPFPPVGAPIKFDRLLYNGRQNYNPQTGIFTCE 656 
MmCOL8A1        AYA--GKKGKHGG-PAYEMPAFTAELTVPFPPVGAPVKFDKLLYNGRQNYNPQTGIFTCE 656 
HsCOL8A1        AYG--AKKGKNGG-PAYEMPAFTAELTAPFPPVGAPVKFNKLLYNGRQNYNPQTGIFTCE 656 
DrCol8a1        KKGKYAGEGDMMGANGLEMPAFTAKLTAPFPPVGTPIVLDKLLYNGRQNYNPQTGVFTCD 623 
                  .  . :*.  *  . *******:**.******:*: :::**************:***: 
 
BtCOL8A1        VPGVYYFVYHVHCKGGNVWVALFKNNEPVMYTYDEYKKGFLDQASGSAVLLLRPGDRVFL 717 
GgCOL8A1        VPGVYYFAYHVHCKGGNVWVALFKNNEPVMYTYDEYKKGFLDQASGSAVLLLRPGDRVFL 716 
OcCOL8A1        VPGVYYFAYHVHCKGGNVWVALFKNNEPVMYTYDEYKKGFLDQASGSAVLLLRPGDRVFL 716 
MmCOL8A1        VPGVYYFAYHVHCKGGNVWVALFKNNEPMMYTYDEYKKGFLDQASGSAVLLLRPGDQVFL 716 
HsCOL8A1        VPGVYYFAYHVHCKGGNVWVALFKNNEPVMYTYDEYKKGFLDQASGSAVLLLRPGDRVFL 716 
DrCol8a1        LPGVYYFAYHVHCKGANVWVGLYRNGEPVMYTYDEYKKGFLDQASGSAVIPLQPGDTVYL 683 
                :******.*******.****.*::*.**:********************: *:*** *:* 
 
BtCOL8A1        QMPSEQAAGLYAGQYVHSSFSGYLLYPM 745 
GgCOL8A1        QNPSEQAAGLYAGQYVHSSFSGYLLYPM 744 
OcCOL8A1        QMPSEQAAGLYAGQYVHSSFSGYLLYPM 744 
MmCOL8A1        QMPSEQAAGLYAGQYVHSSFSGYLLYPM 744 
HsCOL8A1        QMPSEQAAGLYAGQYVHSSFSGYLLYPM 744 
DrCol8a1        QLPSDQAAGFYAGQFVHSSFSGFLLYPM 711 
                * **:****:****:*******:***** 
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Discussion: Summary and Future Directions 
This thesis originated in the observation that the pleiotropic phenotype of copper 
deficiency in zebrafish embryos includes a strikingly distorted notochord. The work that 
followed has elucidated a number of genes essential for notochord morphogenesis in 
zebrafish and has contributed to an understanding of the gene-nutrient interactions critical 
for notochord development. Importantly, though our studies focused on a single nutrient 
involved in the formation of a single organ system, the results are broadly generalizable 
to other nutrients and organ systems.  
 Cloning of the lysyl oxidase gene family in zebrafish (Chapter 2) sets the stage for 
more detailed study of the role of individual family members in early development. Our 
work concentrated on the notochord-expressed lysyl oxidases, revealing overlapping 
roles for loxl1 and loxl5b in notochord formation as well as interactions between these 
genes, the gene encoding collagen II, and copper. However, the embryonic functions of 
other lysyl oxidase family members, including Lox, Loxl2a, Loxl3a, and Loxl5a are yet 
to be determined. Studies of these family members will be facilitated by the optical 
clarity and genetic tractability of the zebrafish. 
 Our data suggest that studies of notochord formation may be relevant to 
understanding the etiology of congenital birth defects of the axial skeleton (Chapters 2, 4, 
and 5). For instance, mutations in human lysyl oxidases may contribute to the 
development of idiopathic scoliosis, a hypothesis now testable using a candidate gene 
approach based on our findings in zebrafish. The data may also have implications for 
certain diseases prevalent in adults. Single nucleotide polymorphisms in the human 
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LOXL1 gene have recently been associated with pseudoexfoliation syndrome, a late-onset 
systemic disorder of altered extracellular matrix homeostasis that can lead to glaucoma 
and blindness (177-186). Interestingly, many carriers of the high-risk polymorphisms do 
not develop pseudoexfoliation syndrome, and therefore additional environmental or 
genetic factors must strongly influence the phenotypic expression of the syndrome (180-
182). The gene-nutrient interaction demonstrated between copper and zebrafish loxl1 in 
notochord formation (Chapter 2) suggests that suboptimal copper nutrition or 
polymorphisms in genes affecting the delivery of copper to LOXL1 may play a role in 
the pathogenesis of this disorder.  
The identification of a novel lysyl oxidase inhibitor, 2-mercaptopyridine-N-oxide, 
provided an important tool for use in our forward genetic sensitivity screen. 2-
mercaptopyridine-N-oxide reduces amine oxidase activity in adult zebrafish extracts 
(Chapter 3), and the kinetics of lysyl oxidase inhibition by 2-mercaptopyridine-N-oxide 
should now be determined using precise radioactive assays and recombinant or purified 
lysyl oxidases. This potent compound may provide a basis for pharmacologic 
optimization by medicinal chemists with the goal of creating an inhibitor that is family-
member specific. In light of the role of LOX in hypoxia-dependent cancer metastasis 
(54), such a drug could be important as a chemotherapeutic agent. It would also facilitate 
studies aimed at delineating the function of individual lysyl oxidases in early 
development.  
 Using 2-mercaptopyridine-N-oxide, we conducted a forward genetic screen for 
mutants that exhibit increased notochord distortion after partial lysyl oxidase inhibition. 
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This screen yielded a mutant in fibrillin-2 with defects in notochord and vascular 
morphogenesis and provided insight into the pathogenesis of congenital contractural 
arachnodactyly (Chapter 4). Future screens should focus on mutants that appear wild-type 
before pharmacologic inhibition and manifest a mutant phenotype only after exposure to 
2-mercaptopyridine-N-oxide. This approach will identify “nonessential” genes that are 
actually essential under stress, as elegant work has recently demonstrated in yeast (107). 
It will also identify hypomorphic alleles of “essential” genes that may not be lethal, 
permitting studies into the role of these genes in adult fish. Cloning of each mutant locus 
will provide structure-function information about the affected protein and will further 
elucidate the molecular mechanisms of notochord formation.  
Studies of the notochord mutant gulliver demonstrated a gene-nutrient interaction 
between copper and the gene encoding the alpha 1 chain of type VIII collagen (Chapter 
5). This finding reiterates the need to interpret the nutritional status of an organism within 
the context of its specific genotype. The biological relevance of COL8A1 is poorly 
defined, and the gulliver mutant zebrafish may permit important studies into various 
aspects of COL8A1 function in the extracellular matrix. The observation that inhibition 
of lysyl oxidases (Chapter 2), disruption of fibrillin-2 (Chapter 4), or disruption of 
collagen VIII (Chapter 5) results in notochord distortion underscores the utility of the 
notochord as a model for understanding extracellular matrix formation. 
The gene-gene and gene-nutrient interactions elucidated in this thesis (Chapters 2, 
4, and 5) are particularly relevant in the era of personalized medicine that is now upon us. 
Sequencing individual human genomes has become a reality, with dramatic reductions in 
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cost and increases in speed (187). Indeed, the sequencing of James Watson‟s genome was 
recently completed in less than 2 months at a cost of under $1 million (188, 189). While 
the goal of the $1000 genome (190) is still out of reach, it will soon become a reality. 
Even today, single nucleotide polymorphism typing is being commercially exploited to 
provide interested parties with information regarding their putative health risks, 
determined mainly on the basis of genome-wide association studies. However, the 
interpretation of the polymorphisms and other quirks of individual genomes remains a 
largely unsolved challenge. For the full potential of this information to be realized, the 
functions and interactions of genetic and environmental networks involved in 
development and disease must be clarified. This represents one of the greatest challenges 
now facing science.  
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